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1.1 Cystic fibrosls disease 
Cystic fibrosis (CF) is an autosomal recessive disease caused by genetic 
lesions in the cystic fibrosis transmembrane conductance regulator (CFTR) 
gene. This CFTR gene was cloned in 1989,1-3 and located to the long arm of 
chromosome 7 (7q3L2). lt encodes the CFTR protein that functions as a 
adenosine 3',5'-cyclic monophosphate (cAMP)-regulated chloride channe1 in 
the apical rnembrane of exocrine epithelia, 4,5 like the sweat gland, 
subrnandibular glands, and the pulmonary, gastrointestinal, hepatobiliaty, 
and urogenital tracts. In individuals with CF the defective chloride transport 
leads to abnormal ion and water transport,6 whieh causes dehydration of 
secretions and malfunctioning of the obstructed exocrine glands, whieh 
typically results in chronic airway obsttuction, pancreatie insufficiency (PI), 
and intestinal malabsorption. The sunrival of CF patients has immensely 
improved throughout the last century: while in 1938, 70% of babies died 
within the first year of life, 7 the median survival is now reported to be 
towards 30 years of age,8,9 most probably due to the introduction of new 
therapeutic regimes, like physiotherapy, aggressive antibiotic treatment, 
pancreatic enzyme replacement, and proper nutrition. 
CF is the most common, lethal, inherited disease in the Caucasian 
population. lO There have been many reports on the incidence in Europe 
vmying from 1 in 2000 live bitths in Ireland 11 to 1 in 40000 live bit-ths in 
Finland. 12 In the Netherlands the incidence was estimated around 1 in 3600 
life births,13 CF is found to be rare in persons from non-Caucasian origin. 
The most common CFTR gene mutation in the Caucasian population is the 
ó.F508 rnutation, a deletion of the amino acid phenylalanine at position 508, 
which occurs in approximately 70% of CF al1eles and 90% of CF patients. 
Vet, presently over 870 different CFTR mutations have been identified,14 
which give rise to the cystic fibrosis phenotype. 
Historicaioverview1S 
As far back as the 17 th century, reports have been found on children with 
symptoms as meconium ileus, pancreatic and lung disease and salt 10SS.16 
However, first in 1938 cystic fibrosis was recognized and described as a 
separate disease syndrome.7 Chronic lung infection was recognized early as 
one of the major symptoms, and consequently antibiotics were introduced in 
the treatment of CF in the 1940s. When investigations revealed that salt loss 
occurred via the sweat gland and that children with CF exhibited elevated 
chloride and sodium concentrations in their sweat,17 Gibson and Cooke l8 
instigated the use of the diagnostic pilocarpine sweat test in 1959. In the 
1980s more knowledge was galned about the molecular basis of the disease 
by Knowies and Boucher,19 who described a disturbed chloride and sodium 
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transport in respiratOly epithelia, and by Quinton and Bijman6 who 
described chloride impermeability of the CF sweat gland. 
After the c10ning of the CFTR gene in 1989,1-3 the basic defect in CF was 
firmly established as a dysfunctioning or mislocalization of the cAMP-
mediated CFTR Cl- channe1.4 ,s Present research is addressing a large number 
of different aspects of the disease. With respect to the influence of the 
genetic background, it is interesting to investigate the effect of specific CFTR 
gene mutations on the disease phenotype, and the impact of genetic factors 
outside the CFTR gene. Gther investigations focus on the possible 
contribution of different ion channels to disease severity, whereby the 
alternative chloride channels are of major interest. Additionally, it is reported 
that the apical sodium channel, expressed in ainvay and intestinal 
epithelium, might be hyperactive in CF and contributes importantly to the 
CF phenotype. 20,21 Moreover, the question arises if these channels are 
defective itself or if its regulation by the CFTR chloride channel might be 
disrupted. At the molecular and cellular level, researchers are aiming to 
circumvent the basic CF defect. Most fundamental, is the introduction of the 
normal CFTR gene into the affected cell by gene therapy. Other approaches 
are the pharmacotherapy to correct the CFTR processing and trafficking 
defect, or to compensate for the CFTR defect by exploiting alternative 
chloride channels. 
1.2 Clinical descrlptlon of CF15,22-24 
CF is considered to be a monogenic disease, implicating that it is caused by 
mutations within a single gene. However, the clinical phenotype that is 
associated with this disease shows a considerable variability. Both the 
number of affected organs and the extent of the disease within aspecific 
organ vary substantially between CF patients. The factors producing this 
variability are not weIl recognized, which complicates prognosis and 
treatment. Moreover, patients rnay present with little or atypical symptoms 
and these patients are diagnosed at adolescent or even adult age. It is 
assumed that at least the following factors are influencing CF disease 
phenotype: environmental factors (e.g., recurrent pulmonary infections, 
therapy, nutrition), gene tic factors outside the CFTR gene itself, and the 
presence of residual chloride secretion either by the CFTR channel or by 
alternative chloride channels. 
Clinically, typical CF is characterized by the accumulation of viscous mucus 
in the ainvays resulting in chronic obstructions, fibrosis, and finally 
destruction of the lung tissue.22 The most prominent symptoms in the 
respiratOly tract are cough, tachypnea and wheezing due to recurrent and 
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chronic bronchopulmonruy infections. The intestinal tract shows 
malabsorption and pancreatie insufficiency, which causes steatorrhea and 
failure to thrive. Sweat glands are most eonsistently affected in CF and 
produce sweat with elevated chloride and sodium levels. 
The information on the development of CF pathology is derived mostly from 
autopsy studies, which ouIy report about the terminal stage of the disease. 
Additionally, sinee life expeetaney has inereased, organs might be affeeted 
more severely22 and patients may present with new complications like 
diabetes and amyloidosis. 
Respirat01Y tract 
At birth, the macroscopie and microscopie appearance of the ainvays is 
normal, indicating that ainvay disease develops postnatally.25 Over the first 
months of life, pathology starts in the small alrways and bronehioles beeome 
plugged with mucus and bronchiolar mucosa becomes inflamed.26,27 This 
mucus is vel}' viscous with an abnormal thickness and accumulates in the 
ainvays, thus impairing mucociliruy clearance. 
With progressive disease this causes bronchiolitis and bronchitis, and 
eventually bronchiolectasis and bronchiectasis. The submucosal glands 
located in the proximal airways are normal at birth as well, but also become 
obstructed with mucus resulting in dilations and hypertrophy. Moreover, in 
the bronchial and bronchiolru' epithelium of CF patients more mucus-
containing goblet cells are found, contributing to the mucus accumulation. 
The naso- and oropharyngeal mucosa are also inflamed and erythematous. 
The onset of inflammation may occur before chronic infection is present, 
implying a major disease-causing role for inflammation and mucus 
accumulation rather than infection. In advanced lung disease, the 
deformations in the lung structure lead to chronic hypoxia and pulmonary 
ru-terial vasoconstriction with irreversible changes in vessel walis. This might 
develop into secondary pulmonruy hypertension, contributing to respiratOly 
failure. Since there are good therapies to alleviate the intestinal symptoms, 
respiratOly failure is presently the major cause of morbidity and mortality in 
CF. 
Usually, the first clinical symptom following from these respiratOly 
abnormalities is intermittent coughing which becomes persistent and 
productive with tenacious, pUlulent sputum. Wheezing may occur due to the 
chronic inflammation of the small airways. Hyperinflation of the lungs starts 
eru'ly in the disease process and results in an increased thoracic index 
(antero-posterior diameter/transverse ehest wall).22 Most CF patients have 
chronic rhinitis with inflammation and irritation of the nasopharyngeal 
mueosa. This eauses the development of nasal polyps in 15 to 20% of 
patients, most frequently between 5 and 14 years of age. The enlargement of 
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the terminal phalanges of fingers and toes, i.e. dubbing, occurs in almost all 
CF patients and is generally considered indicative for extensive ainvay 
disease. In addition, a recently discovered intrinsic defect in purinergic 
signaling in CF erythrocytes, associated with a loss of CFTR control of 
vascular resistance, might also contribute to a reduced oxygen supply of 
peripheral tissues.28 
The progression of lung disease is associated with chronic lung infection 
with typical pathogens for CF disease. Typically, Staphylococcus au reus and 
Haemophilus injluenzae are first detected,29 and infeetion with Pseudomonas 
aeruginosa establishes afterwards. In advanced lung disease, P. aeruginosa 
is usually the only organism found. Unfortunately, infection with 
Burkholderia cepacia, an organism resistant to most antibiotic drugs, is 
increasing in CF patients. 30 
Many different origins for the chronic respiratOly infection in CF have been 
postulated.31 The hypothesis that mucociliary clearance in the lung would be 
abnormal, was proven incorrect, since the rate of mucus dearance in the 
centra1 ainvays is normal,32 and morphology and movement of cilia are not 
different from that in healthy individuals. 33,34 Another influencing factor 
might be the composition of the mueus itself. CF mucus contains more 
sulphated glycoproteins than the mucus of non-CF persons,3S,36 whieh 
makes the mucus viscous and difficuit to dear. Subsequently, it was 
suggested that the high salt content in the airway surface liquid of the CF 
lung, impairs the ability to kill bacteria.37,38 Other investigators claim that 
the presence of airway eeUs expressing CFTR increase the adherence of P. 
aeruginosa to the cells.39,4o Thereby the organisms become internalized into 
the cells and removed from the mucosal surface. CF cells fail to internalize P. 
aeruginosa, giving the organism the opportunity to colonize the epithelium. 
In contrast, an increased adherenee of P. aeruginosa to the CF epithelium 
has also been reported, owing to the up-regulation in CF ceUs of asialo-
ganglioside (GMt) receptors that bind P. aenlginosa.41 
Although the exact meehanism of lung infection is not elucidated to date, it 
is dear that the accumulation of thick mueus creates a convenient 
environment for pathogens. 
Gastrointestinal tract 
Pathologieal changes of the mucosa of the gastrointestinal tract are minimal 
and consist of the dilation of ducts and acinar lumens of the Brunner glands 
in the duodenum due to mucus accumulation. Moreover, there is goblet eeIl 
hyperplasia, especially in the appendix, together with an increase of mucous 
material within the Clypts and lumen of the gastrointestinal tract.42 
Clinically, abnormalities of the gastrointestinal tract consisting of thick 
meconium plugs in the lumen, have been observed as eady as 17 weeks of 
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gestation22,43,44 both from autopsy material and in utero ultrasound 
examinations. These gastrointestinal changes are usually the first 
abnormalities in CF45 and can occur without any changes in the other 
organs. The accumulation of meconium plugs can progress into meconium 
ileus (MI), the total obstruction of the dis tal ileum with meconium, which 
occurs in 10-15% ofnewborns with CF.46 It results in failure to pass 
meconium, abdominal distension, and emesis. Meconium ileus is highly 
indicative of CF and over 90% of infants with MI have CF.23 Mostly, it 
presents within 48 h after birth, or earlier when complications arise, like 
volvulus, intestinal wall perforation or meconium peritonitis. 23 
The pathogenesis of meconium ileus has been attributed to pancreatic 
insufficiencyand the consequent indigestion of intraluminal material.23,44 
Other investigators ascribe the obstluction mainly to abnormal intestinal 
transport and dehydration ofintestinal contents.47,48 MI is strongly 
associated with pancreatie insufficieney and the presence of the D.F508 
mutation,49 and is only rarely observed in pancreatic suffïcient (PS) 
patients23 (definition of pancreatic (in)sufficiency: see 'Pancreas' section 
below). 
Some newborns are detected with meconium plug syndrome, whieh is 
obsttuction by meconium in the large intestine, and is less specific for CF.5o 
Later in life the terminal ileum can become obstructed as well, with 
voluminous intestinal contents. This occurs in about 20% of CF patients and 
is named 'meconium ileus equivalent' or 'distal intestinal obstruction 
syndrome'.42,51 Mostly, this is provoked by large fatty meals, noncompliance 
with pancreatic enzyme replacement therapy, or due to intussusception or 
adhesions following abdominal surgely.15 
In the duodenum, HC03- secretion is necessary as a protection against the 
acidic secretions from the stomach. However, it has been shown that the CF 
condition results in defective duodenal HC03- secretion. Functional CFTR is 
required for the cAMP-stimulated electrogenic HC03- secretion, i.e. byan 
anion channel, as well as for the cAMP-stimulated e1ectroneutral secretion, 
i.e. by the CI-/HC03- exchanger.S2 This impairment might contribute to the 
gastrointestinal complaints of the CF patient. 
Pancreas 
Pathological changes in the pancreas may be deteeted in intrauterine life,44 
and exocrine panereatic insufficiency is present from birth in the majority of 
CF patients. 53 Nonetheless, functional pancreatie tissue is present at birth, 
capable of producing pancreatie enzymes since high levels of 
immunoreactive trypsin-like activity (IRT) are found in the neonatal blood, 
implying obstruction of the secretion of pancreatic hypsinogen.54 The 
pathological changes consist of dilated ducts and acini owing to thick and 
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inspissated pancreatic secretions. The ductal obsttuction leads to 
desttuction and 10ss of aeinar ceUs and these areas are replaced by fibrous 
tissue and fat. Only later in the disease progress, the islets of Langerhans 
are affected with deformation by fibrous tissue and destruction of beta cells, 
which impair the endocrine pancreatic function of insulin secretion. 
The obstructions in the exocrine pancreas cause deereased enzyme and 
bicarbonate release into the duodenum, whieh results in exoerine pancreatic 
insuf!ïcient in about 85% of CF patients. The severity of the pancreatic 
disorder is variabie, yet it inereases with age. 26,46,55 These patients seerete 
insuffïcient proteolytic and lipolytic enzymes to digest and absorb fat and 
protein. The subsequent steatorrhea correlates with less than 10% of normal 
pancreatie enzyme output, and only at this stage the pan creatie function 
tests become abnormal. These patients are classified as pan creatie 
insufficient (PI). Alternatively, about 10-15% ofpatients have less severe 
panereatic changes with functional pan creatie tissue left, who are named 
pancreatic sufficient (PS). With age PS patients may develop pancreatic 
insufficiency, whieh appears to be genetically determined. 56 PS seems to 
correlate with mild CFTR gene mutations, while the PI condition is 
assoeiated with more severe genetie lesions like i1F508. 
The pancreatic enzyme defieieney causes fat and protein maldigestion, with 
a distended abdomen and frequent, greasy, smelling stools. Fat loss in stools 
may be as high as 50-70% of intake, with deficiencies in (fat-soluble) 
vitamins in untreated patients. The enterohepatic circulation of bile acids is 
intenupted, since the feealloss of bile acids is increased due to steatorrhea 
and binding to undigested food substances. This process aggravates the fat 
rnalabsorption, and uneorrected maldigestion results in failure to thrive. 
Modern therapy consists of pancreatie enzyme supplements57 and a high 
calorie diet. 58 This therapy ameliorates gastrointestinal symptoms 
significantly, and although intestinal abnormalities still contribute 
substantially to CF morbidity, they are rarely life threatening. Numerous 
methods exist to evaluate the pancreatie function in CF patients.23 For 
instanee, the measurement of fecal fat excretion in 3-days-stool eollection 
(increased with PI), the level of immunoreactive ttypsin or fat-soluble 
vitamins in the blood (decreased with PI), or the prothrombin time (prolonged 
with PI). Though, the most reliable tests are the measurement of bicru'bonate 
in pancreatie secretions aftel' stimulation with secretin-choleeystokinin,59,6o 
or the amount ofelastase-1 in the stoo1,61 both ofwhieh are decreased in CF 
patients. 
The decreased secretion of insulin by the endocrine pancreas results in 
impaired glucose toleranee or even diabetes mellitus. The prevalenee of 
impaired glucose toleranee is about 15% in CF patients, while diabetes 




Abnormalities in the liver are observed in up to 50% of autopsies,63,64 
althaugh anly 2 ta 5% of CF patients present with symptamatic liver disease. 
Pathological changes in the liver structure occur in the large bile ducts, 
where CFTR is normally expressed, and consist of inspissated secretions, 
biliruy duet proliferation, periportal inflammation and fibrosis. 63 These 
fibrotic areas surround patches of normal liver parenchyma, resulting in a 
labular aspect of the liver. Symptomatic biliary cirrhasis demanstrates with 
hyperbilimbinemia, ascites, peripheral edema, or hematemesis due to 
esophageal varices.65 The exact progression of liver disease is not known, 
althaugh the high number of adults with liver disease as retrieved from past-
mortem studies might point to a progression of liver disease with age. In 
contrast to the pancreatic involvement in CF disease, there is na association 
of chronic liver disease with a specific CF genotype. 66 
Althaugh gaUbladder emptying in response ta meals is normal in CF, 
gallbladder abnarmalities at autapsy are seen in a large part of the CF 
cases.67 They include hypoplasia of the gallbladder, stones containing 
calcium and protein, and a thick, white, rnucous content. 
Genital traet 
Anatomically the female genita! tract is normal and women with CF can 
became pregnant. Reduced fertility might exist through reduced water 
content of the cervical mucus, which hinders sperm passage. 68 Other 
disturbing factors are chronic pulmonary sepsis initiating menstrual 
irregularities, and possible cysts in the ovaries. 69 Male CF patients develop 
the secondary sexual characteristics and sexual function is normal, yet the 
majority possesses abnormalities in the genital tract, and only 2 to 3% of CF 
males are fertile. Abnormalities include atrophic or absent vasa deferentia, 
and the body and tai! of the epididymis, and the seminal vesicles are di!ated, 
fibrotic, or absent as weIl. 70 Consequently, no spermatozoa are present in 
the ejaculate due to the obstruction, whereas testicular biopsies show that 
spermatogenesis is not affected. Male infertility originating from congenital 
bi!ateral absence of the vas deferens (CBAVD) might be the anly presenting 
feature of CF in mild or atypical forms of CF, associated with specific 
mutations.71 
Sweat glands 
There are na structural abnormalities of the eccrine sweat glands 72 and 
production of sweat -is normal upon stimulation with cholinergic drugs. 
However, the composition of this sweat is altered with increased chloride and 
sodium levels, resulting from disturbed electrolyte transport in the sweat 
14 
gland duct. 6 Moreover, the sweat production upon beta-adrenergie 
stimulation is absent. 73 
1.3 Eleclrolyte transport in non-CF and CF 
Introduction 
The obselvation of exeessive salt 10ss in sweat17,18 and the abnormalities in 
exocrine seeretions of CF patients74 have led to extensive investigation of the 
bioelectrical properties of different epithelial tissues like the sweat glands. 
the respiratory tract and the gastrointestinal tract. 
Sweat glands 
The sweat gland consists of a secretory coil and a reabsorptive duet. In the 
sweat secretory coil of non-CF individuals, at least two different celI types 
are involved in sweat production. 75,76 One cell type is responding ta p-
adrenergic stimulation, which causes an intracellular increase in the second 
messenger cAMP, thereby activating CFfR. The other cen type is triggered by 
eholinergic stimulation, which inereases the intracellular Ca2+ concentration 
and initiates Ca2+-dependent CI- secretion. In this way, adrenergic and/or 
cholinergic agonists induce CI- secretion in the secretory coil, whieh drives 
the electrolyte and fluid secretion to produce sweat that is iso tonic with 
plasma. In CF individuals, sweat produetion in response to p-adrenergic 
agonists is impaired due to the absence of CFfR, although the elevation of 
intracenular cAMP by adrenergic stimulation is not different between CF and 
non-CF.73 The cholinergic pathway is not disturbed in CF patients, which 
explains the normal CI- seeretion and produetion of isotonie sweat in the 
secretory eoi177 in response to pilocarpine, and the normal volume and rate 
of sweat production. 6 
In the reabsorptive duct, the electrolyte and fluid transport is driven by the 
basolaterally orientated Na+,K' -ATPase by pumping Na+ out of the cen,78 
thus ereating a luw intraeellular Na+ eoncentration (Figure 1.1). This initiates 
passive Na+ movement into the eell aeross the apieal membrane inta the cello 
In non-CF individuals this Na+ absorption is accompanied by Cl- diffusion to 
maintain eledrieal neutrality, and sinee the sweat duet is impermeable to 
water, sweat beeomes hypotonie at the end of the sweat duet. In persons 
with CF, however, the lack of CFTR impairs diffusion of CI- together with Na+ 
absorption, thereby preventing NaCI reabsorption that results in increased 
CI-, and to alesser degree, inereased Na+ eoneentrations in the sweat of CF 
patients. No other CI- channels are present in the sweat duet cells ta 
compensate for the lack of the CFfR channels. 
These abnormalities in electrolyte transport in CF could be assessed by 
measurement of the potential dilference across the epithelium that is created 
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by the differenee in charge between the apieal and basolateral eell sUl"faees. 
Hence, when potential differences across the epithelium were measured, 
which are mainly created by CI- conductance and less by Na+ conductance in 
normal sweat duet cells,79 differences were observed between normal and CF 
sweat duets. The PD in CF duets was more negative (-66 m V lumen negative) 
than that in non-CF sweat duets (-30 mV).6.78 Moreover, when luminal CI-
concentration was reduced, the PD became more negative in normal sweat 
duets pointing to the ability to seerete CI- into the duet lumen, while the 
transepithelial voltage became more positive in CF sweat ducts indicating 
the impermeability to CI-, but the partial preservation of Na' absorption.80 
Measurements of CI- transport in sweat duet epithelium, demonstrated that 
Cl' permeability of both the apical and basolateral eell membranes is 
reduced.81 ,82 The Na+ transport in the sweat gland was also investigated and 
was not primarily affected, though the abnormalities existed secondmy to 
the impaired CI- transport. 78,81 
BASOLATERAL 
Figure 1. 1 The NaCI absorption in the reabsorptive duet of the sweat gland. Na' is 
absorbed across the apical membrane down ifs electrochemical gradient, end 
transported actively aeross the basolateral membrane by the Na'. K'-A TPase pump. 
Cl- fol/ows passively aeross the luminal and basolaterol membrane in healthy 
individuals, whieh is impaired in CF patients. 
Respirat01Y tract 
The apical surface of the epithelial eells of the alrways eontaln eilia that are 
covered with mucus, in which pathogenie and inhaled material is 
16 
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aeeumulated and moved out by the ciliar movement, which process is named 
the mucociliaty clearance. The mucus is produced by the submucosal 
glands and goblet eells, while its hydration is controlled by transepithelial 
electrolyte transport. As in the sweat gland duct, fluid absorption is driven 
by the basolateral Na+,K+-ATPase83 and the consequent low intracellular Na+ 
concentration causes Na+ ions to enter the eell across the apical membrane. 
Water diffusion across the epithelium follows by osmosis. When the airway 
surfaee liquid is dehydrated, apieal Cl- ehannels ean be opened by the 
second messengers cAMP and/or Ca2 + (Figure 1.2).84,85 
MUCOSA SEROSA 
Na+ 
Figure 1.2 The proeess af Cl- seerelian in Ihe airway epithelium Na', K' and Cl- en Ier 
Ihe eell basalalerally by Ihe Na'-K'-2C1- ealransparler. K' exils Ihe eell Ihrough 
baso/atera/ channels, which creates a driving force for Cl- fo exit the cefl via apica/ 
channels and for Na+ to enter the cell apically. A low intracellular Na+ concen/ration 
is erealed by Ihe basalaleral Na', K'-ATPase pump, and produces Ihe 
electrochemica/ gradienf for Na+, which is needed by the Na+-K+-2CI- cotransporter. 
In additian la CFTR CI- ehannels, Ca"-medialed Cl- ehannels exisl in airway epilhelial 
eells, 
Chloride then exits the cell through these apical chloride channels down its 
electroehemical gradient followed by water to rehydrate the surface liquid. 
Na+,K+-ATPase preserves the low intracellulat' Na+ concentration that is 
needed by the basolateral Na'-K+-2Cl- cotransporter to let chloride enter the 
cell basolaterally against its electrochemical gradient. In the distal airways 
the net re sult of salt and water transport by the surface epithelial cells 
results in secretion, like in the cells of the submucosal glands, while in the 
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proximal airways predominantly salt and fluid absorption takes place. 
When the bioelectrical properties of airway epithelium were measured in the 
basal condition, Na+ absorption preclominated. 86 In analogy ta the sweat 
duet, the bas al potential differences across the airway epithelium, as 
assessed by the nasal potential difference rneasurement, were higher in CF 
patients (-56 mV lumen negative) than in controls (-26 mV) (Chapter 2 & refs 
19,86,87). Since the nasal epithelium is easily accessible and representative 
for proximal ainvay epithelium, the nasal potential difference measurement 
has developed as one of the diagnostic tests for CF disease. 
Sodium transport in the airway also se ems abnormal as ean be measured by 
the change in potential difference upon the addition of amiloride (Chapter 2 
& ref 19), which inhibits the apical epithelial Na+ channel (ENaC). However, 
as was demonstrated for the sweat gland duet, this transport might be 
disturbed secondarily to the anion transport irregularity.78 ,81 
Intesthwi tract 
The mechanism of fluid absOl'ption and secretion in the intestinal tissue 
functions as in the airway epithelium. Apical CI- efflux down Us 
electrochemical gradient causes osmotic fluid secretion into the gut lumen, 
whereas active Na+ absOl'ption through the basolateral Na+,K+-ATPase drives 
the fluid absorption. The function ofthe small intestine is predominantly to 
secrete fluid, while in the colon mainly fluid absorption occurs. 
The basal potential difference in the intestine was observed to be normal in 
some studies,88,89 while others demonstrated reduced baseline PD values.90 
However, defective cAMP-mediated Cl- conductance was shown in different 
regions of the intestinal tract like the jejunum, colon and rectum.91 -94 
The amiloride-sensitive Na+ transport in human rectal biopsies, as measured 
in our laboratory94 and by Hardcastle et al,95 was similar in CF and controls. 
However, other groups found enhanced Na+ transport like in the airway 
epithelium. 21 ,96 
The Na+ -glucose co transport in small intestine was increased in most 
previous studies.97,98 In contrast, more recent studies injejunal tissues of 
CF mice show no enhanced Na+-coupled glucose transport.99,lOO In our own 
laboratories, we investigated the glucose transport in cftr knockout mîce and 
their controllittermates by distinguishing between the transcellular, active 
Na+ -glucose cotransport and the paracellular, passive glucose transport. We 
demonstrated that in CF the transcellular Na+-glucose absorption is reduced 
by 25-30%, while the passive paracellular glucose absorption is twice as 
high compared to contral mice. 101 
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1.4 Identification of the CFTR gene 
Since no molecular entity ar any specific chromosomal region, deletions or 
translocations were known to be associated with cystic fibrosis disease, 
searching for the chrOlnosomallocalization of the disease locus only became 
possible with the introduction of DNA markers to perform positional or 
reverse genetics. This technique uses DNA markers to identify restrictian 
fragment length polymorphisms (RFLP) 102 and variabie number of tandem 
repeats (VNTR).103 This was performed in families with one or more 
individuals affected with CF, in which crossover events behveen CF anel 
other flanking DNA markers had been detected. By consequent linkage 
analysis of the results, DNA markers were sought that were linked to CF 
disease. The first important DNA markers that showed linkages with CF were 
D7S15,104,105 the met oncogene (MET)106 and D7S8,107 the last two flanking 
the CF locus, 108 and localized the CF gene to chromosome 7. However, the 
size of the region between MET and D7S8 was large (estimated around 
5000kb). Restriction maps of the CF region with respect to the linked 
markers were made with the use of additional DNA markers and the 
associated RFLPs, obselvation of recombination events near the CF locus, 
and analysis of linkage disequilibrium.109-111 In order to clone and sequence 
the large DNA region, novel techniques that analyze large DNA fragments 
were introduced. Chromosome walking, whieh us es the end of one clone to 
re-screen a DNA library, clones DNA fragments as large as 100 kb, 
Chromosome jumping analyzes Pal·ts of around 500 kb, by partially 
digesting the DNA and circularizing it so that distant fragments of DNA are 
brought closer together. Pulse-field gel electrophoresis in combination with 
restriction enzymes can separate DNA fragments of 100-1000 kb. With these 
methods, the loci of the markers that were linked to CF were taken as 
starting points to sequence the region of interest and scan for candidate 
sequences. The candidate co ding sequences in this cloned DNA were 
identified by loaking at conselved stretches among different species, since 
these might indicate potential co ding sequences. In addition, regions that 
contain many non-methylated dinucleotide epG stretches may precedes 
human genes. 1,112 The DNA fragments that were thus selected were then 
used in hybridization experiments to screen cDNA libraries of various 
tissues. A single cDNA clone was first isolated from sweat gland of a non-CF 
individual. This clone was used as a probe in hybridization experiments with 
other epithelial celllines. Hence, transcripts were obtalned about 6.5 kb long 
from the T84 intestinal colonic cell line that normally expresses chloride 
conductance. 2 Subsequently, transcripts were also isolated from lung tissue, 
pancreas, nasal polyps, sweat gland, liver, parotid and placenta. Initially, no 
hybridization signals were found in brain adrenal gland, skin fibroblast, and 
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lymphoblasts. 2 This expression of the CF candidate gene was in accordance 
with the tissues that are mainly affected in CF disease.' The cDNA 
sequences of this gene, derived from normal and CF individuals were 
compared.' A 3 base-pair deletion was identified in the cDNA from CF 
individuaIs, but not in that of normal individuals,'·3 implying that this would 
be the disease causing lesion. Thus, the CF gene ,vas finally mapped to 
position 7q31.2,l-3 
1.5 Structure of fhe CFTR gene & protein 
The cloned gene is approximately 230 kb long and consists of 27 exons. The 
encoded mRNA is about 6.5 kb long and is translated into a protein product 
of 1480 amino acids,l,1l3 There seem to be multiple transcription initiation 
sites, but the bas al promotor region lies behveen nucleotide positions -228 
and +48,114 The encoded protein was named cystic fibrosis transmembrane 
conductance regulator (CFTR).' On the basis of the DNA sequence of the 
gene, a potential protein stmctnre was postulated (Figure 1.3). 
The amino acid sequence of the CFTR protein shows significant homology to 
the family of ATP-binding cassette (ABC) transporters, anel specifically to P-
glycoprotein, 1 15 The predicted protein sttucture contains 2 repeated motifs, 
each consisting of a membrane-spanning domain with six hydrophobic 
transmembrane segments anel a nucleotide-binding domain (NBD) that 
interacts with ATP.2 Ten of the 12 transmembrane segments contain one or 
more charged amino acids, and between TMS 7 en 8 are two potential 
glycosylation sites. A regulatory domain, the R-elomain, separates the two 
symmetrical motifs of the putative protein. This R-domain is unique for 
CFTR and is not present in the other members of the ABC transporter 
family. This R-domain contains 9 of the 10 consensus sequences for 
phosphOlylation by protein kinase A (PKA) and 7 of the phosphorylation sites 
for protein kinase C (PKC). In aelelition this R-domain contains many charged 
amino acids.2 
1.6 mRNA and CFTR iocalization 
Investigations with antibodies against CFTR or against specific regions of the 
protein, have demonstrateel that CFTR is located within the ceH 
membrane,l16 and that the R-domain and C-terminus are located 
intracellularly, while some of the loops between transmembrane segments 
are localized on the extracellular side. 117 
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Figure 1.3 The CFTR protein consisfs of two membrane spanning domains (MSD 1 and 
MSD2), each containing 6 fransmembrane segments. Subsequenf to MSD 1 and 
MSD2 the protein confains two nucleotide binding domains (NBD 1 and NBD2). 
Befween NBD 1 and MSD2 lies the cyfoplasmic R domain. which is fhe reg ulo tory part 
of fhe protein. It contains 9 potential sites for phosphorylation by PKA (0) and 7 for 
PKC (t). Between fransmembrane segments 7 and 8 are two potential glycosylation 
sites. The most comman CFTR mufation, dF508, is located in NBD 1 (il). 
The expression pattern of CFTR mRNA and CFTR protein in different organs 
of non-CF individuals was investigated with in situ hybridization and 
irnrnunohistochemistry. The CFfR expression in organs that are rnainly 
affected in CF are given in Table l.I. Furthermore, CFTR was detected in 
parotid,2 placenta,1l8 vas deferens, 1 19 brain 120 and in the stornach. 120 In non-
epithelial eell-lines CFTR was detected in lyrnphocytes,121,122 monocytes, 123 
heart eells,124 and human endothelial eells,125 In addition, the protein was 
shown on intraeellular vesicles, where it may fulfill a role in regulated 
trafficking andjor intravesicular pH regulation.126-130 
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1.7 CFTR gene expression 
CFTR gene transcription is increased by elevations of cAMP for more than 8 
h, pointing to cAMP responsive elements in the CFTR gene promotor,139 
However, CFTR is already present in the apical membrane before cAMP 
elevation. 117 In sorne cell types expression is regulated byeeU 
differentiation, 121,140 and therefore maybe important in the life-cyc1e, while in 
other cells CFTR mRNA is present throughout cellular development. 141 
Down-regulation of CFTR gene expression is observed through phorbol 
esters 142 or an increase in intracellular calcium levels. 143 
Tabfe 1 1 Expression of CFTR mRNA ond/or protein in epitheliof tissues 
exocrine pancreatie duet 
Pancreas2,131-134 opieal membrane 
not in acinar ceUs 
serous ducfs of submucosal glands 
Respirafory tract2.135 cilialed and colleeting duets Iittle in surfoee epithelium 
opieal membrane and cytoplasm 
(base of) erypts 
Smal! & large infesfine2,132-134.136J37 villus high expressing ce lts 
apical membrane 
not in surface epithelium of colon 
reabsorptive duct 
Sweat gland2.131.l32 very liftle in seeretory eoil 
apical and baso!atera! membranes 
Liver l38 bile duel 
Salivary gland '32 intralobular duel 
apical membrane 
Kidney118.133 Tubules 
1.8 The chloride channel lunction ol CFTR 
Before the discovery of the CF gene, functional studies were executed to 
determine the exact site for the abnormal electrolyte transport and to 
identify molecular entities responsible for the electrophysiological defect. By 
application of Cl- ehannel bloekers, Bijman et al showed that CI- transport in 
the sweat gland duct is through channels rather than paraeellularly,l44 The 
identification of different chloride channels in the epithelial tissues of the 
sweat gland 145,146 and airways147-150 supported these findings. 
After the discovery of the CF gene and the resulting gene product, several 
studies confirmed CFTR as the affected gene in CF disease, and its protein 
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product as an epithelial cAMP-regulated chloride channel. Transfection of 
the CFTR eoding sequenee into eultured CF ail"way and pancreatic epithelial 
celllines corrected the chloride permeability defect. 151,152 Normal CFTR cDNA 
transfection into non-epithelial celllines resulted in plasma membrane 
chloride conductance that was stimulated by cAMP.4,153,154 Since these eells 
normally do not show chloride conductance or express CFTR, CFTR was 
identified as a chloride channel itself rather than a regulator of chloride 
transport. Moreover, by inserting antisense DNA to CFfR into normal cells, 
cAMP-mediated chloride secretion was inhibited, 155 Conc1usive evidence was 
given by Bear et al5 by fusing purified CFTR with lipid bilayers, which 
resulted in the appearance of chloride channels with the eharacteristic 
properties of CFTR-associated conductances. 
These properties of CFTR are a low unitruy conductance (6-10 pS) and 
channel gating through protein kinase A mediated phosphorylation of the R-
domaln, In intact cells, PKA is activated by cAMP and cAMP-agonists like 13-
adrenergic stimuli,156,157 CFfR shows a linear current-voltage (I-V) 
relationship, and does not display voltage-dependent activation or 
inactivation. The anion permeability sequence is Br>CI->I- > F-. The open 
probability of the channel is not influenced by stilbene derivatives like 4,4'-
diisothiocyanostilbene-2,2'-disulfonic acid (DIDS), but influenced by 5-nitro-
2-(3-phenylpropylrunino)-benzoate (NPPB), diphenylarnine carboxylic acid 
(DPC), or glibenclamide. 
1,9 Regulalion and aclivallon of CFTR 
The CFTR chloride channel is regulated by kinases, phosphatases, 
intracellular ATP concentration, and hydrolysis of ATP. Activation of the 
channel is effected by the direct action of nucleoside triphosphates on 
phosphorylated CFTR.I58-160 
As mentioned above, the R domain contains 9 (8 serines, 1 threonine) of the 
10 (1 more serine just before NBDl) consensus sequences for potential 
phosphorylation by PKA, and 7 of the binding sites for PKC,2 
Phosphorylation of these putative binding sites by PKA andlor PKC is 
needed to activate CFTR.161,162 It is not the phosphorylation of just one of 
these binding sites that can activate CFTR, as mutagenesis of single 
phosphOlylation sites did not alter channel activity, 159 In vivo, the addition of 
cAMP agonists mainly phosphorylates the serines 8660, 8737, 8795, 8813, 
and most of the decrease in open probability of the channel occurred with 
the rnutation of these serines. 163 ,164 Therefore, it is suggested that these 
phosphorylation sites are most important for channel activity, PKC, which 
can be activated by the combination of inereased Ca2+ and diacylglycerol 
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concentrations, is able to stimulate CFTR as weIl, however only up to 15% of 
the activation observed by PKA. When PKC was first applied to the channel 
with subsequent addition of PKA, the substances worked synergistic in 
stimulating CFTR, 165,166 In addition, cyc1ic-GMP-dependent protein kinases 
might be involved in phosphOlylation and activation of CFTR in the 
intestine,167,168 Both the isoenzymes cG kinase land II can phosphorylate 
CFTR in uitro at similar sites as PKA.168 However, only the cG kinase II 
isoform was able to activate CFTR in excised patches of intestinal ceIls,167 
To activate CFTR the presence of PKA alone is not sufficient, as ATP is 
required to act as P042· donor to phosphotylate the R domain. This ATP does 
not necessarily have to be hydrolysable. As CFTR shows homology with the 
ABC transporters, it was predicted and subsequently demonstrated that ATP 
binds to the NBDs.158,169 In this case, to activate the channel and keep it 
open, hydrolysable ATP is required. IS8 Non-hydrolysable ATP analogs, like 5-
adenylylimidodiphosphate (AMP-PNP), are unable to induce channel activity 
or are much less efficient. 158 This requirement for ATP hydrolysis is not fully 
understood, as Cl- is transported down its concentration gradient and no 
energy is needed to build up an electrochemical gradient. It is hypothesized, 
however, that ATP hydrolysis at NBDI might be essential to transform the 
protein to, or maintain it in the open conformation, 160 PhosphOlylation of the 
R domain is not needed for ATP to bind to the NBDs,158 However, once CFTR 
is phosphotylated by PKA, ATP alone can initiate channel function. 
The 2 NBDs do not have a similar function, as it was demonstrated by 
mutagenesis of NBD2 and deletion of the R domain, that NBD2 could 
inactivate CFTR through interaction with the R domain. 170 
The unphosphotylated R domain of CFTR seems to regulate the channel by 
keeping it in the closed conformation, since deletion of part of the R domain 
produced Cl' channels that are constitutively open. 170 The opening and 
closing by the R domain is most likely influenced by its electrical charge, 
given that substituting serine residues for negatively charged aspartic acid 
generated constitutively active channels. 164 Substitution of 6-8 
phosphOlylation sites was necessary to cause a similar effect, 163,164 
The membrane-spanning domains are thought to represent the pore of the 
channel, as mutations of specific charged amino acids in these domains 
resulted in changes in anion permeability,171 
The CFTR channel is closed through dephosphotylation by certain protein 
phosphatases, i.e. protein phosphatase 2A, but not 1 or 2B.162 
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1.10 Mulalions in Ihe CFTR gene 
Sinee the CFTR gene has been cloned, many different mutations have been 
identified, whieh ean be grouped into pathologieal mutations and benign 
sequenee variations. Pathologieal mutations can be separated into missense, 
nonsense, frameshift and mRNA splicing mutations. Missense mutations, in 
whieh a DNA nucleotide change eauses an amino acid substitution in the 
encoded protein, represent the largest part of mutations. Deletions in the 
CFTR gene are rare, no mutations have been discovered yet in the promoter 
region and there is only one example of a de nova mutation, i.e. R851X 
(mutations are named by using the single lelter code for the normal and the 
substituted amino acid, with the codon position of the eDNA in the 
middle).172 The majority ofthe missense mutations affect the regions coding 
for the NB Os ofthe putative protein, mainly NB01. 173 ,174 The most frequent 
missense mutation is a3-hp deletion that results in the loss of the amino 
acid phenylalanine at position 508 in the CFfR protein product,3 which is 
present on about 70% of CF ehromosomes. 175 However, there is large 
variation in frequency hetween different populations, with the highest 
frequency of 82% in Denmark and 32% in Turkey.n5 The overall frequency of 
non-ó.FS08 mutations is 10w, except for some rare alleles that segregate with 
aspecifie ethnic group. For instance, the W1282X accounts for 48% of CF 
chromosomes in Ashkenazi Jews 176 and 23% of French Canadian CF 
chromosomes carty the nucleotide transition 621 + lG_>T,177,178 Gther 
mutations with a high incidence in certain populations are A45SE,179 
G542X,179 G5510,174 R553X,174 and N1303K.180 Since the frequency of most 
non-ó.FS08 mutations in populations that are not from European origin is 
similar as in Caueasian CF patients, the high incidenee of CF in European 
populations is mainly due to the presence of the ó.F508 mutation. 181 Besides, 
there is complete association between one specific haplotype of closely linked 
DNA markers,3 or the "haplotype B" for the polymorphic markers XV-2c and 
KM,19,182 and the f<F508 mutation, indicating that f<F508 originated from a 
single mutational event. This background of the f<F508 mutation and its 
high frequency in the Caucasian population suggest a heterozygote 
advantage for the mutation itself or for another gene closely linked to the CF 
gene. 183 
Effect of mutations in the CFTR gene 
Wild-type CFfR is glycasylated in the ER and in the Golgi, and thereafter 
transported ta the plasma membrane, 116 The different CFTR gene mutations 
that cause CF disease are proposed to cause loss of CFfR CI- function by 
different molecular mechanisms.184-186 
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Frameshift, nonsense and splice site rnutations result in defective protein 
production. Unstable rnRNA is produced, and either a truncated, unstable 
protein is formed or no protein is detectable at al!.!87 CFTR chloride channel 
function is supposed ta be absent in these CF eeUs. 
The majority of CFTR missense mutations, and deletions of an amino acid 
cause defective protein processing, like the 3-base palr deletion ilF508. In 
this class of mutations, aberrant mRNA is formed but the mutant CFTR 
protein is unable ta aclopt a fully glycosylated, mature conformation. 188 
Consequently, it is not exported from the ER but subsequently degraded. 
Therefore, most of the AFS08 does not succeed ta reach the plasma 
membrane. 132,188-190 However, recent immunohistochemical studies have 
shown ilF508 protein localized at the apical surface membrane of epithelial 
tissues. I9I-!94 Moreover, in vitra (Chapter 4 & refs 195-197) and in vivo 
(Chapter 5 & ref 198) electrophysialagical experiments have demanstrated 
that ilF508 can exert subnormal chloride channel function, although the 
channel appears to remaln closed longer than wild-type CFTR and its 
regulation by cAMP is changed. 196,197 
In the remaining CFTR missense mutations that do not result in partial or 
tatal defective protein processing, the protein is inserted into the apical cell 
membrane and can function as chloride channel, though the regulation 
and/or conduction of these altered proteins is abnormal. For instance, 
mutations in the NBDs (as G551D) cause less chloride channel activity by 
affecting the direct interaction between ATP and the NBD, which norrnally 
stirnulates CFTR activity.197.199 The knOWll missense mutations that cause 
defective conduction of the chloride channel, e.g. Rl17H, are located in the 
membrane spanning domains that are assumed to form the channel pore. 
These mutations are associated with chloride currents that are regulated by 
cAMP and ATP similar to wild-type CFTR, but the amount of currents 
through these channels is reduced,197.200 
One additional c1ass of mutations causes reduced synthesis of normal, 
functianal CFTR, like nucleotide alterations that result in alternatively 
spliced mRNA, e.g. 3849+ lOkbC->T, or mutations in the promoter region 
that reduce transcription,186 In these cases, small amounts of normal mRNA 
or normally functioning protein are produced ensuing a mild phenotype. 
A recent study by Moyer et al20! suggests that the COOH-terminal amina 
acids of CFTR contaln matifs that localize CFTR ta the apical membrane. 
Therefore, C-terminal mutations in CFTR will result in defective apical 
polarization of the protein, and thus defective apical chloride transport. 
Sequence variations 
Nonpathological sequence variations were found within the coding region of 
the gene or within introns, and mayor may not lead to amino acid 
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substitutions. For sorne of these polymorphisms the interpretation is 
difficult, e.g. F508C and R75Q. These sequence alterations have been found 
in CF patients but also in compound heterozygotes without symptoms. 
Another example is the polymorphic Tn locus in the splice acceptor site of 
intron 8 of the CFTR gene, of which three different alleles (1'5, 1'7, 1'9) can be 
found. 202 The amount of thymidine residues at this locus determines the 
splicing process at the intron 8 ~ exon 9 junction. Alternative splicing is 
dependent on the length of this thymidine stretch, and the shorter the 
thymidine stretch the more alternative splicing occurs, resulting in CFTR 
mRNA transcripts without exon 9.202,203 Transcripts that lack exon 9 are 
translated in CFTR proteins that do not mature, and do not result in 
chloride channel activity.204,205 Individuals homozygous for the T5 alleie, or 
compound heterozygotes for a CF mutation and the 1'5 allele can be observed 
with CBAVD, however these individuals can also be without any symptoms. 
Therefore, 1'5 is c1assified as CBAVD disease mutation with partial 
penetranee. 206 In addition, the Tn locus ean influenee the phenotype of the 
RI17H CFTR gene mutation. The Rl17H mutation together with the 1'5 allele 
on one chromosome is responsible for CF, while Rl17H with 1'7 can either 
cause CF or CBAVD.207 Besides the Tn locus, two other polymorphic loci 
have been identified to influence the quantity and quality of CFTR 
transcripts, i.e. (TG)m and M470V.20S.209 The number of TG repeats can vruy 
between 9 and 13, and on a 1'5 or 1'7 background this number of TG repeats 
also influenees the amount of transcripts without exon 9: the higher the 
number of TG repeats the more transcripts without exon 9. CFTR proteins 
with either a methionine or valine at amino acid position 470 matured 
differently and exhibited different electrophysiological properties. The M470 
protein matured more slowly, but its open probability was about 1.7 times 
higher than that of the V470 protein. With the same (TG)13T5 haplotype, the 
M470V loci was observed to affect the phenotype being CBAVD or CF, 
suggesting an influence on the penetrance of the 1'5 alleie. 
These results illustrate that different polymorphisms at various loci 
themselves may not be disease causing, but the combination of different 
alle1es at these loci ean result in less functional or even insufficient CFTR 
protein.210 
1.11 Genolype-phenolype associalions 
1'he most stl'aightforward associations found between genetics and disease 
symptoms are the inherited CF mutations that determine pancreatic status 
of the patient. CF mutations are classified into lnild and severe mutations, 
and CF patients carrying 2 severe mutations confer the pancreatie 
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insufficient phenotype, while at least one copy of a mild mutation leads to 
pan creatie sufficiency as mild mutations are phenotypically dominant over 
severe mutations,3,179 The DNA alterations c1assified as nonsense, 
frameshift, splice-site, amino acid deletions, and most missense mutations 
are considered as severe mutations. Mutations found in patients wUh 
pancreatie sufficiency are G85E, G91R, E92K, R117H, R334W, R347H, 
R347P, A455E, G551S, P547H, S549N, and 3849+lOkbC->T, 15,2ll,2l2 In 
these individuals the anomalous protein is presumed ta reach the apical 
membrane and generate chloride conductanee, which would confer the 
normal pancreatie function,132,135,197,200 Only rarely is PS seen with ö.FS08 
homozygosity, and these individuals may show reduction in their pancreatic 
function with age, as may be observed in patients initially diagnosed as 
PS,2l3 
Meconium ileus is not associated with any specific genotype, but it has only 
been recognized in pancreatic insuffïcient patients. The risk to develop liver 
disease is suggested to cOlTelate with pancreatic insufficiency as weIl. In 
addition, a higher incidence was detected in patients with genotypes 
conferring severe or variabie dîsease phenotype, while no liver disease was 
observed in patients with mutations related to a mild phenotype,2l4 
Associations between genotype and severity of pulmonary disease were 
difficult to determine. The only correlation found, was a better lung function 
in PS patients, e,g, PS patients with the A455E mutation,2l5 though it is 
uncertain if this is a result of the better nutritional status that is observed in 
PS patients when compared to the PI group.56,216 Patients homozygous for 
"F508 have highly variabIe pulmonary phenotypes, and homozygosity or 
compound heterozygosity for mild mutations or stop-codon mutations are 
also not associated with better lung function. 56,217,218 The large variability in 
lung disease among patients with the same CFTR genotypes indicates the 
importance of other genetic factors outside the CFTR gene, or of 
environmental factors. 
Abnormal sweat chloride concentrations were seen in virtually all CF 
patients. Patients homozygous or compound heterozygous for 8.F508, or \Vith 
two non-8.F508 mutant alleles, were observed \Vith similar sweat chloride 
levels.219 However, sorne investigators found less e1evated sweat chloride 
levels in compound heterozygotes, 186 or in individuals with the 2789+5G->A 
or 3849+10kbC->T sequence alteration.220 In addition, sweat test results 
more towards normal values are also seen in the pancreatic sufficient CF 
patient group.56,221 
Another phenotypic feature that was found to correlate with the A455E 




In parallel with a specifïc genotype that is eonnected with a certain 
phenotype, the clinical presentation ofCBAVD seems to predispose for 
canying CFTR gene mutations. About 60% of males with CBAVD carry at 
least one CFTR mutation and 10% harbor two known mutations.223,224 
Especially the T5 allele in intron 8 occurs more often in CBA VD patients 
compared to normal or CF populations.225,226 (see also the above section: 
f8equence variationsj 
1.12 Gene Iherapy 
The most essential elements of the CF therapeutic regime concern the 
patient's nutrition, antibiotics, and the physiotherapy. However, 
identification and cloning of the CF gene has created a ncw possibility for 
therapeutic intervention, i.e. introducing normal CFTR DNA into the affeeted 
eelIs. In vitro experiments demonstrated that transferring CFTR into celIs 
canying the CF defect restores the cAMP-clependent chloride 
conductance. 152 The fundamental issues determining the success of this 
technique, are i) tm'geting of the cell type that is important in pathogenesis, 
ii) the mechanism of bringing DNA into the cell, iii) the efficiency of the gene 
transfer, and iv) the expres sion of the normal proteins in these cells. 
At present, various vehicles for gene delivery are being examined, using 
adenoviral vectors, adeno-associated viral vectors, DNA-liposome complexes, 
or receptor-mediated endocytosis. Experiments of gene delivelY in CF are 
mainly focused on the airway epithelium, since this is the most readily 
accessible organ affected. For safety, the objective is to target the 
differentiated ainvay epithelial celIs rather than the stem celIs, since any 
adverse effects of the intervention will consequently be temporary. On the 
other hand, this will imply repeatecl treatment of the affected cells. 
Early in vitro experiments already showed the possibility to use viruses as 
vehicle for gene transport into the target cells. l5 ! The most frequently 
exploited viral vectors that are used to investigate possible therapeutic 
intervention by gene transduction in CF, are the adenoviral and adeno-
associated viral vectors. For this purpose viruses are made replication 
deficient and the advantage of these specific viruses is that they naturally 
infect respiratory epithelium, hence they are assumed to target many of the 
different types of airway cells. However, all viraI vectors have the 
disadvantage of inducing an immune response in the host, causing 
inflammation of the epithelium at first application. Moreover, it can trigger 
anti body formation, thereby reducing the safety to use repeated doses. 
Therefore, one of the issues being anaIyzed at present is the immune 
response initiated by the different types ofvinlses,227,228 and the possibility 
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to administer viral vectors to the lungs with simultaneous transfeetion of 
anti-inflammatory substances. 229,23o A trial in CF volunteers to accomplish 
CFTR gene transfer by adenoviral vectors, showed a low efficiency with 
undetectable levels of gene expres sion around 40 days af ter 
administration.231 It appeared that the human coxsackie and adenovirus 
receptor (hCAR) is located basolaterally. Thus, to increase the amount of 
transfected cells and make adenovirus-mediated gene delivery successful, 
researchers suggest the use of agents that create a more permeable 
epithelium by opening light junctions,232.233 and/or by causing the cel! to 
express hCAR apically as well.234 
Liposomes, vesic1es composed of a lipid bilayer, can be engaged to cany DNA 
and deliver it to the cell by fusion with the cel! membrane. These Iiposomes 
are preferably positive in charge, cationic liposomes, to facilitate interaction 
with negatively charged DNA and enhance the merge with eell membranes, 
which hold a negative charge as weil. In CF mice liposome-complexes have 
been shown to correct the CF defect. 235 The advantage of liposomes is its 
non-viral nature, inducing a smaller immunological reaction. However, 
liposome-mediated gene transduction apperu's less efficient than transfer by 
viral vectors.229 Biological barriers that hinder delivery of the DNA into the 
eell by liposomes or adenoviruses are for instanee the sputum layer covering 
the epithelium, and the plasma membrane of the airway ceUs itself since it 
does not readily bind or incorporate the different vectors. 236 In addition, it 
was demonstrated that lipid-mediated transfeetion is reduced wîth 
polarization and differentiation of CF murine airway cells.237 The application 
of higher doses does not improve efficiency, since it increases inflammation 
and toxicity.238,239 
Another nonviral vector system is the use of receptor-mediated endocytosis. 
This strategy uses receptor-specific ligands that bind to reeeptors on the eeU 
rnembrane, to bring the desÎl'ed genetic material into the cello Obviously, a 
great advantage of this method, apart from its nonviral nature, is the 
opportunity to develop receptor-ligand combinations that target specific cel! 
types. Studies have combined this technique with the two other 
abovementioned vector systems: the coupling of a receptor-targeted ligand to 
either a virus vector or a eationic liposome proved suceessful in delivering 
genetic material to human airway epithelial cells.240,241 
1.13 Mouse models lor CF disease 
After the c10ning and characterization of the mouse gene equivalent to the 
human CFTR gene,242 mouse models eould be generated to assist CF 
research. These murine models are of great importanee to further investigate 
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the basic pathophysiology of CF disease and evaluate novel therapies. 
Co ding regions of the mause cftr gene shawed significant sequence hamolagy 
to human CFTR cDNA, particularly in the NBDs, the R domain and the 
potential PKA and PKC phosphorylation sites. This suggests that these sites 
are functianally important in bath species and that cftr function in mice may 
be similar to its functian in humans. The fiTst mouse made1s were generated 
by disrupting the eft,. gene in embryonic stem cells, either by creating an in-
frame stop-codon in exon 10, i.e. targeted disruptian,243,244 or by introducing 
a duplication of part of the DNA sequence in the eftr gene, i.e. targeted 
insertianal mutagenesis.245,246 The first two madels are ttue cftr knockout 
mice in which no cftr mRNA or pratein is produced. These mice show failure 
to thrive, intestinal obstruction similar to meconium ileus, alterations in 
mucus and serous glands in the bowel, and gall bladder disease. In contrast, 
the mouse model created by insertional mutagenesis thrives norrnally and 
shows no clinical disease symptorns. This is presumably due to same 
alternative splicing producing wild-type cftr mRNA. Indeed, low levels of RNA 
(~1O% of wild-type levels) were found by PCR experiments, resulting in a Cl-
channel rest function around 40% of controls, thereby illustrating that low 
levels of wild-type eftr can influence the phenotype prominently.245 
Gross macroscopic and microscopic pathological changes are seen in the 
intestinal tract of the cftr -J- mice. 243,244 Obsttuctions were found in both 
small and large intestine with distended areas proxirnal to obsttuction. In 
the small intestine crypts and villi are completely destroyed in many cases, 
and in the colon the mucous glands are dilated with consequent flattening of 
the epithelial surface.243 Potential difference measurements in intestinal 
tissues sho\Ved reduced baseline values in all areas investigated, like 
jejunum, caecum, and colon, and impaired responses to agonists of the 
cAMP-mediated chloride secretory pathway.24S,247 
Only little pathological changes were se en in eft,. -j- ainvays, namely 
dilatation of ducts of the serous glands in the nasal mucosa and an 
increased number of goblet ceUs in the proximal ainvays of the eft,. -j- rnice. 
However, no microscopic pathologicallesions were evident,24B pathological 
accumulation of mucus or pulmonaly inflammation and infection \Vere not 
obsenred in the CF mice,243,244 and their pulmonruy functions and 
mechanica! properties of their lungs were normal.24B Electrophysiologically, 
eft,. -I- airway epithelial eells showed no cAMP-mediated chloride response, 
however ATP induced chloride secretion was preserved.247 Baseline PDs in 
cultured murine nasal epithelial celIs were not different,247 however, in vivo 
measurement showed a more negative baseline nasal PD in CF ani mals 
cOlnpared to controls.24s In summary, these eft,. -j- mice do not develop severe 
pulmonary disease spontaneously. Contrastingly, the majority of cystic 
fibrosis patients suffer from progressive lung disease with chronic 
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pulmonary infection mainly caused by Staphylococcus aureus, Haemophilus 
influenzae, Pseudomonas aeruginosa, and Burkholderia cepacia. Animal 
models would largely facilitate the investigations into the pathogenesis of 
this CF lung disease. Therefore, studies have been performed in which CF 
mice were challenged with bacteda to incite lung infection. In one study, 
aerosols containing Staphylococcus aureus or Burkholderia cepacia showed a 
higher susceptibility in the CF mice to develop infection. 249 Other groups 
showed increased morbidity and mortality in CF mice infected by 
Pseudomonas aetuginosQ, compared to disease severity in normal animals, 
due to an excessive inflammatOlY response that fails to kill the bacteria. 250 In 
addition, the pulrnonary clearance of P. aeruginosa and the degree of 
inflammation was negatively influenced by malnutrition. 251 In an inbred 
congenie cftr knockout strain that was generated by backcrossing outbred 
cftr'nlUNC mice into a C57BL/6J background, carly onset of progressive 
pulmonruy disease develops spontaneously.252 The most prominent 
abnormalities are the ineffective inucociliruy clearance with accumulation of 
thick materiaI, dilatation of acini, and interstitial thickening of the 
parenchyrna. However, DO chronic colonization with bacterial pathogens, as 
is associated with human CF lung disease, was observed naturally in this 
mause model. 252 The administration of PseudomonQs aen~ginosa to the 
ainvays of these animais, showed similar results as the other knockout 
modeis, namely exacerbation of lung infection, iDcreased rnortality and 
impaired bacterial clearance compared to controllittermates.253 
In the pancreas of cftr-/- mice little pathological changes were seen,243,245 
although sorne blockage of pancreatie ducts was seen in a few of the cftr -1-
mice generated by Ratc1iff et a1. 244 Investigations into pancreatic composition 
of cft,. -j- mice, however, showed reduced pancreatie weight accompanied by 
reduced protein content.2S4 Levels of pancreatic enzymes, especially amylase 
and lipase, were lower compared to controllittermates. Yet, it is not certain 
whether these changes are primary to CF disease, or due to secondary 
effects of malnutrition as has been seen in malnourished rats. 2SS In addition, 
a recent study in the cAMP- and Ca2+ -mediated amylase secretion in isolated 
pancreatic acini from cftr -j- mice, showed no reduced responses compared to 
control mice.2S6 The obselvation that exocrine pancreata of CF mice show 
relatively few pathological changes compared to humans, may indicate that 
cftr is Ie ss important in maturational development and maintaining ductal 
function of the pancreas, in mice. Moreover, the pancreatic ducts contain an 
Ca2+-activated alternative secretOly pathway that may compensate for the 
lack of cftr and protects the cftr -/- mouse [rom pancreatie abnormalities.2S7 
No overt macroscopie abnormalities were seen in the reproductive tracts of 
female and male cftr -j- mice, and overall they seemed fertile. However, it is 
not certain if some of these mice may be subfertile, since incidentally 
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breeding pairs consisting of two cftr -j- mice did not produce litters within 3 
weeks af ter the eouple was formed (own unpublished obselvations). 
Subsequent to the knockout CF mouse model, murlne madels carrying the 
to.FS08 mutation have been generated. I98,258,259 These dF/elF mice showed 
redueed mortality eompared to the eftr ./. miee. PhenotypicaUy, they 
appeared less affeeted than the knoekout miee. Although some of the miee 
were observed with bowel obstruction, consequent rupture and 
peritonitis,25S,259 other mice showed anly dilated Clypts and thick mucus 
accumulation without complete intestinal obstruction. 198 The 
electrophysiological characteristics varied in the different dF mice modeis. 
While the mouse model reported by Zeiher et al259 showed no residual eAMP-
regulated chloride conductance or secretion in nasal and jejunal epithelia, in 
the mouse models generated by van Doorninck et al I9S and Colledge et al,25S 
residual cAMP-iuduced chloride conductance was detected. Moreover, in the 
van DOOl'uinck et al I9S mouse model these small, subnormal, residual cAMP-
regulated chloride responses were seen in both nasal epithelium, intestinal 
tissue, and gall bladder. This supports our obsenrations of residual chloride 
conductances in respiratOly and intestinal tissues of a number of AFS08 
homozygous CF patients (Chapters 4 and 5 & ref 260), and the 
dernonstration of cAMP-mediated chloride channels in gaIlbladder tissues of 
llF508 homozygotes. 191 
The phenotype of a mouse model for the G551D mutation, classified to eause 
defective regulation of the CFTR chloride channel in humans, appeared to 
match that of CF patients261 in that these mice express only small amounts 
of chloride channel activity and suffer from prominent but less severe 
intestinal clisease than the CF knockout mice.262 
1.14 Additional lunclions ol CFTR 
Cystic fibrosis is not solely characterlzed by alterations in the Cl- transport. 
In addition, other abnormalities exist like abnormal Na+ transport, abnormal 
regulation of outwardly-rectifying Cl- channels, and increased sulfation of 
glyeoeonjugates. Therefore, it is hypothesized that CFTR has more funetions 
than just Cl' transport, whieh is supported by the faets that CF is a single 
gene defect263 and on the basis of the putative protein structure CFTR 
belongs to the ABC transporter family that is associated with transport of 
substrates.264 However, another explanation would be that changes are 
secondary to CI- transport abnorrnality. 
One of the additional functions of CFTR that has been observed is its role in 
eAMP-regulated membrane recycling.265 In normal ceUs eAMP inhibits 
endocytosis and stimulates exocytosis, however this effect of cAMP is not 
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seen in eells lacking CFTR expression. Since membrane recycling regt.llates 
the localization of proteins on the plasma membrane, th is defect may result 
in different expression of membrane proteins with various consequential 
biochemical abnormalities. 
Another function of CFTR might be its involvement in the acidification of 
intracellular vesic1es. Certain intracellular vesic1es are acidified by a proton 
pump with Cl- following passively into the vesicle to maintain 
electroneutrality.266 If Cl- ions are unable to follow, proton pumping will be 
hampered and acidification of the vesicles disturbed. al-Awqati et al266 have 
suggested that the diminished chloride conductance of the membranes of 
these vesicles and the consequent decreased acidification might alter the 
activity of pH-sensitive enzymes, which influences the last steps of the 
biosynthesis of glycoproteins, i.e. fucosylation, sialylation and sulfation. 
Several studies have demonstrated abnormal compositions of glycoproteins 
in CF.267,268 The compositional and/or structural anomalies might influence 
protein functions, and some investigators have hypothesized on increased 
bacterial adhesion by these altered CF glycoproteins. 269 However, Seksek et 
al270 have investigated pH in the trans-Golgi and endosomal compartments, 
and showed na differences between CF and control, contradicting the 
defective acidilication hypothesis. 
Several investigators report that CFTR is not only a chloride channel, but 
able to mediate ATP permeability as wel1.271 ,272 However, other studies did 
not substantiate these observations.273-275 This issue is important to 
investigate since the nucleotide triphosphates are able to induce chloride 
conductance by interaction with apically located extracellular receptors. 
Consequently, differences in ATP release and purinergic signaling might be 
involved in CF pathogenesis.276 
1.15 Regulation of other ion channels by CFTR 
A role for CFTR has been assigned in the regulation of the ORCC. lt has been 
demonstrated that ORCC can only be activated by PKA and ATP when the 
transport function of CFTR is intact.277 Moreover, the presence of CFTR 
resulted in an increased open probability and altered channel kinetics of the 
ORCC.278 
Another regulatoly function of CFTR is demonstrated by the inhibition of the 
amiloride-sensitive epithelial Na+ channel (ENaC). In some studies, the 
stimulation of CFTR by cAMP-agonists appears to inhibit these ENaC 
channels,279 while this inhibition of sodium transport seems absent in cells 
co-expressing AF508 CFTR instead of wild-type CFTR.280 Therefore, it is 
suggested that the enhanced amiloride-sensitive Na+ conductance in CF 
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respiratory and possibly intestinal epithelia is mediated by the lack of CFTR, 
which would inhibit this Na+ transport.21 ,281 However, in another laboratOlY 
studies in nasal epithelium did not show this cAMP-sensitivety of the ENaC 
channel (Dl'. H.R. de Jonge, personal communications). 
1.16 Alternative non-CFTR Cl- secretory pathways 
The increase in intracellular cAMP that activates cAMP-dependent protein 
kinases (PKA), and the activation of PKC both induce chloride secretion by 
phosphorylation of CFTR. In normal epithelia, these processes have been 
demonstrated to activate other chloride channels as weIl. 147,150,282,283 These 
chloride channels have distinct properties from CFTR. They have an 
outwardly rectifying current-voltage relationship, with a single-channel 
conductance around 30 pS at hyperpolarizing voltages and around 70 pS at 
depolarizing voltages, and can be activated by prolonged depolarization. 
These outwardly rectitying chloride channels (ORCC) can be blocked by Cl-
channel blockers like OPC and DIOS. The halide permeability is different 
from CFTR, i.e. 1- > Br > Cl- > F-. It is not evident yet if these channe1s are 
the same channels as the volume regulated channels. 284 
Another apically located non-CFTR chloride conductance can be activated by 
a rise in the intracellular Ca2+ concentration. Ca2+-mediated chloride 
secretion was observed in human colonic epithelial celllines,285 and by other 
investigators in cultured ainvay epithelia or cells. 156,286 Anderson et aF56 also 
showed that these channels are distinct from CFTR, and that CFTR itself is 
not sensitive to activation by Ca2+. These Ca2+-dependent channels 
expressed in secretOly epithelia show a linear I-V relationship with a single-
channel conductance of 15 - 20 pS, the halide permeability sequence is I' > 
BI" > Cl- > F-, and these channels are inhibited by DIOS, OPC, and NPPB.287-
289 Anderson et aP56 detected na Ca2+ -dependent chloride secretion in 
human intestinal celllines. In parallel, Clarke et al290 demonstrated the 
presence of Ca2+ -stimulated CI- conductance in the airways, but not in 
intestinal stripped mucosa of their CF knockout and con trol mice, and 
therefore suggested a beneficial role for this Cl- secretOly pathway. In 
contrast, more recent studies on another type of CF knockout mouse, 
demonstrated Ca2+-regulated chloride secretion in the intestinal tissues of a 
subgroup of their CF mice. These CF knockout mice \Vith residual Ca2+-
dependent chloride conductance showed a relatively mild intestinal 
pathology compared to their more severely affected littermates.291 
Studies on the presence of Ca2+-mediated CI- conductance in intestinal 
biopsies from CF patients show discrepancies, in that some studies did not 
detect Ca2+-induced chloride secretory response.92,95 In contrast, our studies 
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demonstrated Ca2+ -initiated responses in CF intestinal tissue of compound 
heterozygotes,222 and in a subgroup of ó.F508 homozygotes,260 that were not 
seen in controls. This residual chloride secretion was also observed in 
intestinal celllines.292,293 
The agonists that increase intracellular calcium levels may stimulate Ca2+-
dependent chloride secretion either by direct aetion of Ca2+ on the transport 
protein, or by activating calcium/ calmoduIin-dependent protein 
kinases.289,294~296 Extracellular application of nucleotides induces the 
increased Ca2+ concentration as weIl. When interacting with purinergic 
receptors on the apical eeU membrane, these substances increase the 
phosphoinositide metabolism, thereby mobilizing intracellular Ca2+ stores 
and stimulate Ca2+-regulated chloride channels.297 
Swelling-induced chloride channels289 have been detected in secretory 
epithelia and appear to be unaffected in CF.284 
Several other chloride channels have been identified, like the chloride 
channels belonging to the CIC family of Cl- channels,298 of which function, 
localization, and impact or association with CF disease are being 
investigated, but are not clear for all of the channels identified at present. 299 
One of the CIC channels, CIC-2, has been shown to mediate regulatOly 
volume decrease.300 
Table 1.2 summarizes the different Cl- secretory pathways observed in 
human epithelia. 
The investigation of i) alternative pathways to induce chloride secretion and 
H) the presence of alternative, non-CFTR chloride channels is important 
since these entities are suggested as modifiers of the CF disease phenotype. 
Table 1 2 Regulation of 0 secretion in epilhelial argans of normol and CF tissues 
Normal CF References 
Sweot glond coil cAMP Defective 73.77.301 
Ca2+ Ca2+ 6.73.77.290 
not by PKC not by PKC 77 
Sweot glond duet cAMP defective 302-304 
Respirotary troet cAMP defective 150.156.282.286.305-307 
Ca2+ Ca2+ 286.294.296.308.310 
PKC defective 150.286.309 
Intestinol troct cAMP defective 91.92.94.95.311 
Ca2+ Ca2+ 293.312 
'91:94:260 
defective 47.92.95.311 
PKC PKC '47:94:260 
cGMP 168 
. NOTE. -In these studies. the Indlcated canductonce pothwoy IS present In CF 
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Scope of thls thesis 
Cystic fibrosis (CF) is a disease with a highly variabie phenotype even among 
patients with identical genotype for the disease causing mutations in the 
cystic fibrosis transmembrane conductance regulator (CFTR) gene. The basic 
defect that is produced by mutations in this gene, is aberrant or absent 
chloride transport in exocrine epithelial tissues. Although tremendous 
discoveries have been made in the past decades on the pathophysiology of 
the disease, substantial gaps persist in our knowiedge. The European CF 
1\vin and Sibling Study has been initiated to extend the knowledge on the 
relative impact of factors influencing CF phenotype. This thesis focuses 
predominantly on this Study, in particular on the effect of residual chloride 
membrane permeability on CF phenotype, and the importance of genetic 
background in expressing this residual chloride conductance. For this 
purpose, European monozygous and dizygous twins and siblings, 
homozygous for the most common CFTR gene les ion flFS08, were recluited 
(Chapter 3). Studying affected patient pairs is the classical method to assess 
the relative impact of genetic and environmental factors in a monogenie 
disease like cystic fibrosis. In such an approach, individuals with extreme 
phenotypes are expected to be most informative on associations between 
genotype and phenotype. Therefore, we investigated the twin and sibling 
pairs belonging to one of the following three classes: discordant pairs, 
involving one mildly affected and one severely affected sibling; concordant 
mild pairs, composed of two siblings with mild disease; concordant severe 
pairs, in which both siblings are severely affected. By investigating 
monozygous and dizygous sibling pairs homozygous for the major disease 
causing lesion, flFS08, the impact of genetics and epigenetic factors on 
disease phenotype can be assessed. 
The presence of residual chloride secretion appeared relatively variabie in 
epitheliai tissues of different CF patients. Thus, it has been detected in 
patients with diverse genotypes, like flFS08 homozygotes but also in patients 
canying stop-codon mutations. Both these CF genotypes are considered to 
result in the absence of CFTR proteins in the apical plasma membrane, 
causing the lack of chloride channel function at this site. However, the 
contrasting observation of chloride secretOly responses in these individuals, 
points to the presence of chloride conductance(s). The fact that certain stop-
codon patients also exhibited these responses, in which patients CFTR 
chloride channels can certainly not be present, suggests the existence of 
alternative, non-CFTR-mediated chloride conductance(s) in their epitheliai 
tissues. 
The objectives of this thesis are to investigate the frequency and amount of 
residual chloride secretion in intestinal tissues of CF individuals, and 
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segregate the different pathways of chloride secretion (Chapter 4). This is 
achieved by using the intestinal current measurements on rectal suction 
biopsies, which challenges chloride secretion through CFTR chloride 
channels by addition of cAMP-agonists, and activates possible alternative, 
non-CFTR chloride conductances by Ca2+-agonists. 
In addition, this thesis aims to assess the presence, frequency and origin of 
residua! chloride conductance in the nasa! epithelium by the method of 
nasa! potentia! difference measurement (Chapter 2 and 5). 
When lCM and NPD results are obtained, expression and origin of residual 
chloride secretion in intestinal tissue can be judged against expression and 
origin in the respiratory tissue (Chapter 5). Moreover, the impact of these 
electrophysiological characteristics on respective phenotypes in these organs 
can be addressed. 
A further objective of this thesis is to evaluate the influence of genetic 
background versus epigenetics on the expression of the various chloride 
conductances, by comparing the concOl"dance within monozygous twins to 
that within dizygous sibling pairs (Chapter 4 and 5). 
The association between genotypes and the expression of residual chloride 
conductance in CF patients that are not .ó.F508 homozygous, but have 
nonsense, compound heterozygous, or mild genotypes, are reported in 
Chapter 6. 
The heterogeneity of the CF phenotype is illustrated by two atypical 
presentations of CF disease in Chapter 7. 
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and 
Intestinal Current Measurement 
Chapter 2 
Electrophysiological characterization of respiratOJy and intestitwl tissues 
Electrophysiological techniques as Ussing chamber measurements on 
intestinal biopsies and nasal potential difference measurernents principally 
determine the conductance properties for sodium and chloride ions of the 
specific tissues. In early reports, typical CF patients with severe phenotypes 
diagnosed by abnormal sweat tests, presented with clearly abnormal ion 
transport characteristics in the epithelia most drastically aifected in CF.1-4 In 
these studies, the basal potential difference (PO) of the respiratory tissue and 
its reaction to amiloride, and to application of a chloride free solution were 
abnormal,1,2 while in jejunal and recta} tissues secretagogues like 
acetylcholine and prostaglandin were unable to induce chloride secretion.3-S 
Both these techniques have developed into methods that are not only used 
for diagnostic purposes,2,6-11 but are widely applied for scientific 
investigations to elucidate the relationship and mechanisms between the 
basic ion transport defect and the clinical symptoms in CF disease (Chapter 
5 & refs 12-14). 
Nasal potential difference measurement (NPD) 
The set-up to rneasure the nasal potential difference is depicted in Figure 
2.1. The potential difference across the nasal epithelium is measured by a 
catheter positioned against the inferior turbinate in the nose, with a 










against inferior turbinate 
superfusion pumps 
Figure 2.1 Set-up of the nasal potential difference measurement. 
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Bath the exploring catheter and the subcutaneous needie are connected to a 
high-impedance voltmeter by Ag/ AgCI electrodes. The exploring bridge 
consists of different PE-50 tubings to allow the independent superfusion of 
different solutions. 
Firstly, measurement of the basal potential difference across the nasal 
epithelium occurs by superfusion of the epithelium with a physiological salt 
solution Wigure 2.2a). 
a ·60 Contral ·49 
·47 
> ·40 ·35 
E ·30 
•• e 
·20 ·19 .. 
0 t t t t t NaC! Amil erfree lso ATP 








·23 ·23 ·23 
·20 
t t t t t 
0 NaCI Amil cr tree lso ATP 






·25 ·25 ·29 .. 
·20 
·20 
t t t t t 
0 NaG! Amil erfree lso ATP 
Figure 2.2 Tracings of nasal potential difference measurements for a contral person 
(a), with large responses to the U·free solution (CI-free), and isoprenaline (Iso); for a 
typical CF patient (b), with na significant responses to the U-free solution or 
isoprenaline; for a CF patient exhibiting residual U secretion (c), with a small 
response to Ihe U·free solution, but na response la isoprenaline. Note thai in these 




Thîs luminal basal PD is negative compared to the suhcutaneous reference 
electrode. Thereafter, amiloride is appJied which inhibits the Na+ transport 
by the epithelial ENaC channel and consequently malces the PD less 
negative. Chloride conductances are identified by the subsequent addition of 
a Cl~-free solution, isoprenaline, and ATP, all in the presence of runiloride. 
The Cl--free solution identifies the spontaneous chloride conductance, which 
is generated by chloride channels that are already in the opened state. In 
non-CF individuals the PD becomes more negative. With the p-adrenergic 
agonist isoprenaline, cAMP-mediated chloride channels are stimulated, and 
like the chloride free solution generates a more negative PD in non-CF 
individuals. Extracellular ATP interacts with the purinergic P2u-receptors in 
the apical membrane wUh ane of the consequences being an increased 
phosphoinositide metabolism and hence mobilization of intracellular 
calcium,12 thereby inducing alternative Ca2+-dependent chloride 
conductances. In control tissues ATP responses of variabie magnitudes were 
observed (Table 2.1). 
Table 2 1 NPO responses for CF versus controls (mean + SO) 
CF palients Range Con/rols Range 
PO or "PO PO or "PO 
(mV] n [mV] n 
Inves/igated 98 24 persons 
No cooperation 6 -
(Chronic] rhinitis 18 -
Basal PO -56.0 ± 9.8 74 -76--36 -24.4 ± 10.8 24 -47 --8 
Amiloride 27.9 ± 8.6 74 (100%) 8-53 10.0 ± 5.8 24 3-29 
Glucona/e 
-6.0 ± 2.9 22 (30%) -12 --I -15.0±9.6 24 -31 -0 (CHree) 
Isoprenaline -2.6 ± 1.3 7 (9%) -5 --I -7.8 ± 3.6 24 -17--1 
ATP -4.4 ± 2.7 55 (74%) -15 --I -0.6 ± 3.0 24 -8- 8 
NPD tracings of non-CF 
In Figure 2.2b the NPD tracing of a typical CF patient is shown. Although 
there is overlap, the basal potential difference of CF individuals is more 
negative cornpared to non-CF. While the mean basal PD of controls is around 
-25 mV, in CF the mean value lies around -55 mV (TabIe 2.1). Compared to 
controls, amiloride inhibits the PD more extensively in CF patients. The 
chloride free solution and addition of isoprenaline exert no effect in the 
severe CF condition. CF patients may present with a large ATP response 
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compared to controls, though this response varies considerably between CF 
patients. 
The NPD tracing of a CF patient with residual chloride conductance is seen 
in Figure 2.2c. This individual shows a response to isoprenaline pointing to 
the presence of chloride mernbrane conductance. Although this is not seen 
in this particular patient, some CF patients might exhibit a small response 
to isoprenaline. The mean values for the NPD responses fOf a group of CF 
patients versus contrals are depicted in Tab!e 2.1. While the mean values 
differ between CF and non-CF, some responses show overlap between the 
two graups. We have demonstrated that the diagnosis of CF can be more 
easily and reliably made by the interpretation ofthe complete set of 
responses including the basal PD, rather than on any of the individual 
responses,9 
Intestinal ClUTent measurement (lCM) 
In the intestinal current measurement, a rectal suction biopsy is mounted in 
an Ussing chamber and the voltage across the rectal tissue is clamped to 0 
mV. This enables the measurement of changes in ion currents, expressed as 
short-circuit currents (lsc) in reaction to the appIication of specific drugs. 
Af ter the stabilization of the short-circuit current, amiloride is applied to 
inhibit electrogenic, ENaC-mediated Na+ transport (Figure 2.3a), which 
reduces the short-circuit CUlTent. Thereafter, indomethacin addition inhibits 
formation of endogenous prostaglandin synthesis and reduces cAMP 
formation. In some control biopsies but not in others, a reduction in Isc is 
seen in response to indomethacin. Subsequently, carbachol is applied which 
causes chloride secretion by inducing intracellulal' calcium mobilization and 
activating pl'Otein kinase C. 8-Br-cAMP and forskolin is then used to 
stimulate the cAMP-regulated chloride secretion, which generates a 
sustained increase in Isc. The tissue is then incubated with 4,4'-
diisothiocyanostilbene-2,2'-disulfonic acid (DIDS), which inhibits non-CFTR 
chloride channels. Histamine is added 10 minutes after DIDS to exert a 
similar action to carbachol, namely ac!ivation of the Ca2+ jPKC pathway, and 
in controls histamine causes a similar transient chloride secretOly peak as 
seen in response to carbacho! (Figure 2.3a). Carbachol and histamine 
interact with muscarinic lS and Hl receptors,16 respectively, which are located 
on enterocytes. This causes increased cytosolic calcium levels, thus inducing 
chloride secretion. Both secretagogues increase intracellular Ca2+ levels by 
initiating the metabolism of phosphoinositides with the consequent 
formation ofinositol (1,4,5) triphosphate, which releases calcium from 
intracellular stores. 17-19 Some differences between the effects of carbachol 
and histamine on the inositol phosphates metabolism have been identified, 






















+ + + 





·5 Amil Indo 
+ + + 














CF: OIDS-sens. Cl' secretion + 
His! +5 
Carb 
o ~-~ • 
+ + 





Figure 2.3 Tracings of intestinol current meosurements for a con trol person (a). a 
typicol CF potient (b), a CF pat/ent with residuol Cl- secretion thot is /nsensitive 
(insens.) to DIDS (e), ond a CF pat/ent with DIDS-sens/tive (sens.) Cl- secretion (d), 
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increases in concentration of inositol (1,3,4) triphosphate and inositol 
tetrakisphosphate, tB however, in contral non-CF tissues Dur lCM studies 
show chloride secretory responses of similar magnitudes when carbachol or 
histamine are applied. This is also found when the rectal tissue is incubated 
with OIDS af ter carbachol, and subsequently histamine is added. Since in 
contral tissues DIDS-sensitive chloride conductances do not significantly 
contribute ta PD or chloride currents, the carbachol response before the 
incubation with DlOS and the histamine response aftel' the addition of DlOS, 
remain of similar magnitude (Figure 2.3a). With this knowIedge, we 
introduced this protocol in lCM measurements of CF patients. By comparing 
carbachol and histamine responses in CF tissues, and calculating the 
difference we were able ta segregate the presence of DIDS-sensitive non-
CFTR chloride conductances from DIDS-insensitive CFTR chloride channels. 
The lCM tracing of a typical CF patient is seen in Figure 2.3b. Carbachol and 
histamine cause reversed responses in the opposite direction to the 
responses seen in control tissues, while cAMP-agonists do not induce any 
response. The reversed responses upan addition of carbachol and histamine 
have been investigated by several researchers, and are most likely due to 
apical K+ efflux stimulated by carbachol and histamine, i.e. an increase in 
intracellular calcium concentration.21 
With our protocol we were able to identify CF patients with intestinal 
residuai chloride cunents (Figures 2.3c and dl. In a CF patient with DIOS-
insensitive secretion, the chloride currents induced by carbachol are also 
induced by histamine and are not inhibited by the incubation of the tissue 
with DIDS. DIDS-sensitive residual chloride conductance is recognized byan 
lCM pattern as in Figure 2.3d, with a chloride secretOly current in reaction 
to carbachol, which is inhibited by the incubation of the tissue with DIOS, 
which results in a reversed histamine response without any chloride 
secretory current. The responses to carbachol and histamine in CF 
individuals appear to consist of two components. One lumen-positive current 
that is most likely caused by the apical K+ efflux through Ca2+ -sensitive K+ 
channels,20 since this Isc response can be inhibited for about 70% by 
bariumchloride.21 The second component is a lumen-negative current, 
caused by apical chloride secretion.l°,13,14 In rCM measurements of non-CF 
individu als the apical K+ efflux component in reaction to carbachol and 
histamine is not observed (Figure 2.3a), since it is masked by the much 
larger CI- conductance which results in a great unidirectional, transient, 
lumen-negative chloride secretory response. In CF patients with a two-
directional response, e.g. the histamine response in Figure 2.3c, the net 
response is quantified by the summation of the negative reversed response 
and the positive chloride secretory response. 
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When we compare the mean values for a group of controls versus a group of 
CF individuals, we see that Done of the values of the responses to carbachol, 
cAMP, and histamine overlap between the two groups (TabIe 2.2). 
Table 2 2 lCM responses for CF versus con/rols {mean + SDi 





Investigated 98 persons 
No cooperation 6 
Technical 16 disturbance 
Carbachol ~4.60 + 7.36 76 ~35.24 - 8.43 43.9 + 18.9 103 11.9-110.2 
cAMP 3.03 + 2.90 67 0-13.28 7.1 +8.2 76 0.0-30.5 
Histamine ~4.50 + 5.48 59 ~21.84 - 5.10 38.5 + 19.0 69 8.3-80.0 
In conc1usion, when utilizing these protocols for NPD and lCM 
measurements in CF disease, significant distinction ean be made between 
the electrophysiological characteristics of the respiratory and intestinal 
tissues of non-CF versus CF individuals, and can aid and facilitate the 
diagnostic process. Moreover, since chloride concluctances of different origin 
can be segregated with these elec!rophysiological methods, lCM and NPD 
techniques can be used to further investigate the basic defect of abnormal 
CFTR-rnediated chloride transport, the irnportance of alternative non-CFTR-
dependent chloride conductances, and their influence on CF disease 
severity. 
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Abstract 
Cystic fibrosis (CF), the most common severe autosomal recessive trait 
among Caucasians, is caused by molecular lesions in the cystic fibrosis 
transmembrane conductance regulator gene (CFTR). The course of the multi-
organ disease CF is highly variabie suggesting the influence of environmental 
factors and/or modulating genes other than CFTR on the disease phenotype. 
To evaluate the cause of CF disease variability, the European CF twin and 
sibling study collected data on two clinical parameters most sensitive for 
course and prognosis of CF, i.e, wfh% (representative for the nutritional 
status) and FEVPerc (representative for the pulmonary status) for a cohort of 
277 sibling pairs, 12 pairs of dizygous twins and 29 pairs of monozygous 
twins. Of these 318 CF twin and sibpairs, 114 were reported to be 
homozygous for the most frequent CF disease causing lesion, t<.FS08, 
Intrapair discordance was assessed by the intrapair differences in wfh% and 
FEVPerc and by DELTA, a composite parameter defined by linear 
combination of wfh% and FEVPerc in order to descrlbe disc01'dance with 
respect to the overall disease severity, Monozygous twins had a significantly 
lower DELTA than dizygous twins (P ~ 0.05) indicating that CF disease 
severity is modulated by an inherited component besides the CFTR gene 
itse1f. Extreme phenotypes are considered to be more informative for the 
analysis of any quantitative trait, Thus, we aimed to quantifY disease-
severityand intrapair disc01'dance in order to select pairs with the extreme 
phenotypes DIS (discordant patient pairs), CON+ (concordant and mildly 
affected patient pairs) and CON- (concordant and severely affected patient 
pairs). The a1gorithm reliably discriminated between pairs DIS, CON+ and 
CON- among the cohort of I1F508 homozygotes. The selected pairs from these 
categories demonstrated non-overlapping properties for wfb%, FEVPerc alld 
the intrapair difference of both parameters. 
Introduction 
Cystic fibrosis (CF) is known as the most common severe autosomal recessive 
disease within the Caucasian population, exhibiting an incidence of 1 in 2500 
births,l The symptoms of the disorder are caused byan impaired function of 
exocrlne glands in many organs, but major manifestations involve the 
respirat01y and the gastrointestinal tracts. 1 The disease is caused by 
mutations in both chromosomal copies of the cystic fibrosis transmembrane 
conductance regulator (CFTRj gene.2 The course of CF is highly variabIe when 
comparing unrelated patients with identical CFTR mutation genotypes,3,4 or 
even CF siblings who carry the same CFTR alleles and share several 
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environmental factors, such as socioeconomic status, generalliving condition 
and therapeutic measures. This indicates the impact of factors other than the 
CFTR genotype on the CF disease phenotype, By studying affected patient 
pairs, the European CF 1\vin and Sibling Study pursues a classicai approach 
to address the relative impact of the CFTR gene, other inherited factors and 
environmental effects on CF disease. 
Approximately 70% of CF alleles in central European populations bear the 
same CFTR mutation '\F508,5 Consequently, half of all CF patients are 
homozygous for the same CFTR lesion which enables analysis of the disease 
severity in a group with a homogeneous mutation genotype in the major 
disease-causing gene. Oue to the prevalence of one mutation genotype in a so-
called monogenic disease that follows an autosomal recessive trait, CF is the 
onIy inherited disorder where a relatively large number of patient pairs can be 
selected who carry the same lTIutation genotype in the disease-causing gene. 
The sem'ch for disease modulating factors of CF equals an assessment of CF 
disease severity as a quantitative trait whereby the phenotype under 
investigation - tbe CF disease severity - assumes a continuous distribution. 
Under this condition, individuals with extreme phenotypes are likely to have a 
large number of functional alleles at most loci determining the quantitative 
trait and therefore, extreme phenotypes are generally considered to be most 
informative.6-9 Based on the phenotype of an individual, three categories of 
patient pairs with extreme phenotypes can be distinguished: 
coneordant/mildly affeeted patient pairs (CON+), composed of two siblings 
with mild disease, concordant/severely affeeted patient pairs (CON-), 
comprised of two severely diseased siblings and discordant pairs (DIS) 
wherein one sibling is mildly affected and the other is severely affeeted, With 
the intention to identify these most informative pairs, we aimed at a 
quantitative description of disease severity and intrapair discordanee for CF 
patients. The evaluation was based on two clinical parameters most sensitive 
to course and prognosis of CF disease, i.e. weight expressed as weight 
predicted for height (wfh%) - sueh as to assess the nutritional status of the 
CF patient - and values of fm'ced expiratory volume in Is (FEVI) expressed 
as age and gender normalised parameter - such as to assess the pulmonary 
status of the CF patient. lO As aresuit, tbe CF disease phenotype was rated 





Patients and clinical parameters 
CF patient pairs were enrolled from 158 CF clinics from 14 European 
countries. With a ane-page evaluation [orm, information on gender, CFTR 
genotype, actual weight, height and forced expiratory volume in 1 s (FEVI) and 
the zygosity status of twin pairs was enquired. From these data, tWD clinical 
parameters most sensitive to course and prognosis 10 were calculated: 
nutritional status was assessed by weight predicted for height (wfh%) on the 
basis of age and gender corrected centiIes for weight and height by Prader et 
al.". Pulmonary status was assessed by FEV1%pred which are predieted 
values referring to the non-CF population based on the data by Knudson et 
al. 12 
Among CF patients, FEV1%pred declines with age 13 (Figure 3.1b) as expected 
for this progressive lung disease. To correct for the CF speciflc age decline of 
FEV1 %pred, age eorreeted centiles for the CF population for FEV1 %pred, called 
FEVPere, were caleulated based on the European CF registty (ERCF) report of 
199614 that compiles lung function data of FEV1 %pred from 25667 CF patients 
from AustIia, Canada, Denmark, France, Gennany, Ireland, The Netherlands, 
Sweden, United Kingdom and USA. 
Consistent with data [rom other cross-sectional studies, the centiles were age-
independent for wfh% 15 (Figure 3.1a) and for FEVPere (Figure 3.1c) within the 
cohort of CF twin and sibling pairs. 
Evahwtion of mono- and dizygosity status of CF twins 
If DNA was available, the zygosity status of twin pairs was assessed to 
eonfirm the information provided by the CF center using the AmpFLSTR 
Profiler Plus"l typing kit on an AB! Prism 377 (perkin Elmer Applied 
Biosystems) 16 or by oligonucIeotide fingerprinting of simple repeats applying 
in situ gel hybridisation of Mbo! or Hinfl genomic digestsY 
Definition of composite parameters 
To assess the overall CF disease severity and the intrapair discordance, the 
two clinical parameters describing apatient's nutritional and pulmonruy 
status, i.e. wfh% and FEVPerc, were combined. Rank numbers Xi for wfh% 
and yi for FEVPerc were assigned within the complete patient cohort whereby 
a rank number of 1 delineated the most severely affected state. The disease 
severity of patient i was eharacterised by the distanee form origin (Of 0) in the 
plot of Xi versus yi (Figure 3.2). The intrapair discordanee was quantified by 
the distance behveen two data points representing hvo patients i and j of a 
palr 
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Figure 3.1 Age dependence of wfh% (a). FEVI%pred {bi and FEVPerc (cl. The solid 
line indicates the median, fhe dofted lines the inner quarfiles. The [number of 
patients) within each age closs are: <7y [3ó), 7y- /Oy [7S), IOy-12,Sy [66), 12,Sy-ISy 




within the same diagram (DELTA). Thus, disease severity and intrapair 
discordance were defined by: 
Analysis of intrapair rank number difference (IRND) distributions 
Intrapair sirnilarity of CF twins and siblings was characterised by comparison 
of the patient pair cohort to a set ofunre1ated couples. Ta assess the intrapair 
similarity of the complete cohort, the distribution of intrapair rank number 
differences (IRND) was analysed. 
The IRND distribution expected for unrelated couples was derived as follows: 
for a cohort ofn individuals, or nj2 palrs, IRNDs between land (n-I) are 
possible. The minimal IRND of m ~ I is obtained if two individuals from a 
couple occupy rank numbers (n-I) and n. (n-I) rank nu mb er combinations of 
two individuals result in an IRND of 1) but there is only one possibiIity to 
obtaln the maximal IRND ofm ~ (n-I), by occupying rank numbers land n, 
respectiveIy. In general, the probability fm for any IRND m in a cohort of n 
individuals is given by the norrnalised expression 
ll-JlI 
.f", ::: -"-1~--"'-
~.:< 1/ - 111) 





To test whether the IRND distribution observed among the CF twins and 
siblings differed from a random IRND distribution, classes of IRNDs 
j 
:L .I;" were defined whereby the boundaries were chosen as slieh that each 
class was occupied with the same probability in a random IRND distribution: 
j L j;" = eonst . The size of the classes was set to an expectancy value 
m=; 
j 
E ~ 11 • I.I~ of E ~ 20, 30 or 50 couples per class. 
m=; 
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SJbllng J. 
e ........ 
<1> ~ ~ Sibling i ..... .... 
~ / ~ DELTA (Sibpair ij) 
~ ..' ~ ./ 
~ /..' Dra (Sibling i) 
rank number wfh% 
Figure 3.2 Delinilion of composite parameters. The two clinical parameters, wfh% 
and FEVPerc, describing the patient's nutritional and puJmonary status, were 
combined as a measure of the pafient's overall disease severity, Rank numbers tor 
wfh% and for FEVPerc were assigned to all pallents. The disease severity of a patient 
was characterised as distance farm origin (Of 0) in the plot of the pallent's rank 
number tor FEVPerc versus the rank number tor wth%, The infrapair discordance was 
quantilied through the distance between two data points representing two pallents i 
and i of a pair within the same diagram (DELTA). For the set of 318 pairs, maximal 
values of Of 0 and DELTA as defined by Equations (3. I) and (3.2) are 899 and 898, 
respecllvely. 
For the analysis of the cohort of all CF twins and sibs, rank numbers were 
assigned to wfh% for 467 pairs (n ~ 934. cOJTesponding to 24 (E ~ 20), 16 (E ~ 
30) and 9 (E ~ 50) IRND classes) and to FEVPerc for 318 pairs (n~ 648, 
corresponding to 16 (E ~ 20), 11 (E ~ 30) and 7 (E ~ 50) IRND classes). Within 
the cohort of ~F508 homozygous twins and siblings, rank numbers for wfh% 
and FEVPerc were assigned to 114 pairs (n~ 228, corresponding to 6 (E ~ 20), 
4 (E ~ 30) and 2 (E ~ 50) IRND classes). Observed occupancy of IRND classes 
was compared to expectancy values by Z2 statistics,18 
Comparison of disease severity and intrapair disc01'dance 
Unless stated otherwise in the results section, all comparisons were carried 
out using the non-parametric Mann-Whitney rank test, 19 
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Table 3.1 Genotype and gender of 318 CF twin and sibling pairs 
Sibpairs Twins 
Dl MZ 
mm 75 3 14 
ff 72 2 15 
mI 130 7 0 
n on ~tlF 5081 n on~"F 508 88 3 2 
non~tlF508/"F508 94 5 12 
tlF508/M508 95 4 15 
totol: 277 12 29 
NOTE. non-óF508: all CFTR olleles ot her than .ó.F508, including CFTR olleles wilh unknown 
mutation, m: male, f: female. 










14.9 years ( 8.8 - 21.8: 6.8 - 37.2) 
14.6 years (11.0-17.9: 6.1- 3l.3) 
15.lyears (12.2-22.9:6.837.2) 
12.7years ( 8.8 17.3:6.1 30.31 
n.s. 
n.s. 
Table 3.2b Dislribution of age at day of eva/uation of 277 CF sibling pairs (median 
[inner quartiles: rangel) 
all siblings 
,IF508/"F508 
P - 0.005 
(277 pairs) 
( 95 pairs) 
Table 3.3 Home country of CF twin pairs 
Number of pairs (%) recruited 
17.2 [ 12.1 - 23.5: 5.9 - 59.1 ) 
16.9 [ 11.2 - 20.3: 6.0 - 38.1 ) 
trom: FRA GB&EIRE GER IrA OTHER 
monozygous 4 (14%) 5 (17%) 7 (24%) 7 (24%) 6 (17%) 
dizygous 2(17%) 2(17%) 3(25%) 3(25%) 2(17%) 
non~6F508/6F508 3 (18%) 4 (24%) 2 (12%) 6 (35%) 2 (12%) 
6F508/6F508 3116%) 3 (16%1 5/26%1 2/11%) 6/32%1 
NOTE. Number of pairs from FRA: France, GB&EIRE: Great Britain and Eire, GER: Germany and 
ITA: [tory, respectively, OTHER: summarizes number of pairs recruifed from The Nelherlands, 
Sweden, Poland, Auslria and Swilzerlond. 
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Resulls 
Clinical data on 318 CF twin and sibling pairs 
Data on wfh% was obtained for both patients in 467 pairs. Complete clinicai 
data, i.e. wfh% and FEVPerc, could be calculated for 318 CF patient pairs 
(Tables 3.1, 3.2b and 3.5). 114 pairs thereof were reported to be ilF508 
homozygous. FEVPerc was lower in our patient pair cohort than expected from 
the ERCF report (Tabie 3.5a and Figure 3.1c). This systematic shift rellects 
different modes of data collection and coincides with the well-known difference 
between best and average annual values of FEV1 %pred that could also be 
demonstrated by the average 8.2% difference between best and mean annual 
FEV1 %pred value for 
the patient population at the CF clinic Hannover (646 entries). The EUCFR 
registry recorded the best FEVl %pred within a two-year-period, whereas in 
our study the questionnaire asked for the most recent lung function data. 
Clinical data on monozygous and dizygous CF twins pairs 
Zygosity status could be determined or was reliably reported by the CF center 
for 41 twin pairs with Wlll% and FEVPerc avaliable (Tables 3.1, 3.2a and 3.4). 
AF508 alleIe frequency was 0.67 which is consistent with population gene tic 
data for central Europe.5 Average age of DZ twins was slightly lower than that 
of MZ twin pairs and ilF508 homozygous twins were younger at the day of 
evaluation compared to ilF508 heterozygous twins, but the differences in age 
were not significant (Tabie 3.2a). There was no bias between MZ and DZ twins 
with respect to the country of origin (Tabie 3.3). However, while ilF508 
homozygous twins were recluited from a variety of European countries, pairs 
from Italy were overrepresented among AF508 heterozygous pairs reflecting 
the lowel' AF508 fl'equency in southern European countriesS (Tabie 3.3). 
Comparing MZ and DZ twins, the groups were indistinguishable in wfh% but 
FEVPerc was significantly lower for DZ twins than for MZ twins (P ~ 0.02; 
Table 3.4a). 
Intrapair discordanee was assessed by the intrapair difference in wfh% 
(representative for the nutritional status), the intrapair difference in FEVPerc 
(representative for the pulmonary status) and DELTA (composite parameter 
describing discordance with respect ta the overall disease severity, Figure 3.2). 
Regal'ding CF twin pairs with all CFTR genotypes, MZ patient pairs had a 
significantly lower DELTA than DZ twin pairs, but intrapair differences in 
wfh% and FEVPerc were comparable for MZ and DZ twins (Tabie 3.4b). 
77 
Chapter3 
Table 3.4a Oisease manifestatian (median [inner quartiles: range)} af CF twins 
wfh% 
FEVPerc 
monozygous (58 patientsl 
98.8 [91.9 - 109.4; 72.0 - 136.7] 
49.6[30.6- 74.6; 0.5-111] 
dizvgous 124 pafienfsl 
98.7 [92.6 - 109.6; 84.2 - 125.7] 
28.4[16.0- 55.0; 0.1-114] 




monozvgous (29 pairsl dizygous (12 pairsl P 
infrapair differences in: 
wfh% 5.8[3.0- 9.3; 0.4-23.9] 6.6[ 3.8- 11.7; 0.7- 21.0] 0.48 
FEVPerc 13.8 [ 6.0 - 23.9; 0.0 - 69.8] 27.8 [ 5.6 - 49.8; 1.7 - 92.6] 0.14 
composite parameter: 
DELTA 145.1 [78.2-213.6; 17.1-366.0] 179.1 [135.6-215.3; 70.4 510.1] 0.04 
Table 3.50 Oisease manifestation (median [inner quortiles: range)} af CF siblings 
all CF siblings (277 pairs) M5081M508 [95 pairsl P 
wfh% 
FEVPerc 
100.1 [91.0-109.2 ;54.5-175.8] 98.7 [89.5 - 105.5; 54.5 - 145.2] 
34.6 [16.5- 60.6;-3.1 115 1 
0.002 
43.8[21.2 74.7;-3.0-120] < 0.0001 
Tabfe 3.5b Intrapoir discordonce (median (inner quarti/es: range)} of CF siblings 
all CF siblings (277 pairs) óF508/M508 [95 pairs] P 
infrapair difference in: 
wfh% 11.3 [ 5.7 - 18.5 ;0.1- 61.4] 10.2 [ 6.1 - 15.6 ; 0.3- 53.4] 0.21 
FEVPerc 23.4 [ 11.8 - 41.7; 0.0- 96.9] 24.1[11.9- 42.7 ; 0.0- 96.9] 0.41 
composite parameter: 
DELTA 244.8 [ 145.0 349.1 ; 8.1 771.6] 253.3 [179.0 347.9; 46.1 694.8] 0.13 
Tabfe 3.6 P values of x' test camparisons of IRNO distributions of CF twin and sibling 
pair cohorts to IRNO distributions expected for a cohort of random couples 
E - 20 
all pairs 
wfh% (647 pairs] P < 0.001 P < 0.001 P < 0.001 
FEVPerc (318 pairs] P < 0.001 P < 0.001 P < 0.001 
#508 homozygotes 
wfh% [114 pairs] 0.025 < P < 0.05 0.025 < P < 0.05 0.025 < P < 0.05 
FEVPerc (114 pairs! 0.9 < P < 0.95 0.7 < P < 0.9 0.9 < P < 0.95 




I ____ ~~ -75 
(normalîsed) 
IRND class 
Categories of !J.FS08 homozygolls CF patÎent pairs 
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Figure 3.3 Differences of inlropoir ronk number difference (IRNO) dislribufions 
comparing a cohorl of CF Iwins and siblings 10 a similarly sized cohorl of random 
couples: (a) for wfh% and pafienl pairs wilh various CFTR genolypes (467 pairs. 9 
IRND classes. 50 pairs expecfed wifhin each IRND class: E = Sa): (b) for FEVPerc and 
pafienl pairs wilh various CFTR genolypes (318 pairs, 71RND classes. 50 pairs 
expecled wilhin each IRND class: E = Sa): (c) for wfh% and (d) FEVPerc of dFS08 
homozygaus pairs {I 14 pairs. 4 IRND classes. 30 pairs expecfed wifhin each IRND 
class: E = 30}. Bars represenfing Ihe 9, 7, 4 and 4 IRND classes in (a-d) are ordered 
according 10 Ihe magnilude of Ihe IRNDs from low IRND 10 high IRND. To al/ow 
comparison of dala, Ihe scale wifhin plols (a-d) is normalised such as 10 display a 
75% deviafion from Ihe expeclancy value E wifh E=SO (a and b) and E=30 (c and dj. 
In plols (a) and (b), +75 corresponds 10 on occupafion of on IRND class by 88 poirs 
and -75 carresponds ta on occupation of on IRND cJass by /3 pairs in contrast to the 
expecled 50 pairs. Analogously, in plo Is (c) and (d) +75 corresponds 10 on 
occupafion of on IRND class wilh 52 pairs and -75 corresponds 10 on occupafion of 
an IRND cJass with 8 pairs in contrast to the expecfed 30 pairs_ 
Intrapair rank number difference distribution within a cohort of CF twins and 
siblings 
To charactetise the cohort of CF twins and sibs in terms of the intrapair 
similarity, the distribution of intrapair rank number dilferences (IRND) of the 
patient pair cohort for wfh% and FEVperc was compared to the IRND 
elistribution of a set of ranelomly assigneel couples (see Eq. 3.3). The IRND 
elistribution of the CF patient pairs eliffereel significantly from a random IRND 
elistribution (Table 3.6 anel Figure 3.3), i.e. the average IRND was significantly 
smaller in CF twin and sihpairs than in unre1ated couples. Likewise, the 
subgroup of t.F508 homozygous twins anel sibpairs was significantly more 
concordant in their IRND distribution of the nutritional parameter wfh% 
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Table 3.7a Example for two pairs with similor high DELTA. but different intrapair 
difference in OIO 
Data [ronk number] of Sibling A Data [rank number] of SibJing B 
oge wfh% FEVPerc Of 0 oge wfh% FEVPerc Of 0 
Example I 25y 119.5 [578] 1 [ 12] 578 [502] 21y 120.0 [582] 82 [526] 784 [588] 
DELTA = 514 
DiffDIO = 206 
Example 11 20y 103.1 [389] 75 [490] 625 [432] 16y 94.2[206] 1 [27] 207[115] 
DELTA = 497 
DiffDfO = 418 
NOTE. The graphic representation of disease severity and intrapairdiscordance of these two 
pairs is shown in figure 3.9J, pair 1 (examp!e I) and Figure 3.9h. pair 7 (example 11). 
Table 3.7b Example lor three concordant patient pairs with similor DELTA. but 













Data [rank number] of Sibling A Data [rank number] of Sibling B 
oge wfh% FEVPerc DfO oge wfh% FEVPerc Of 0 












NOTE. The graphic representation of diseose severify and intrapair discordance of these three 
pairs is shown in Figure 3.9d, pair' (example I), Figure 3.9m, pair 3 (example lil and Figure 
3.90, pair 5 (example lil). DELTA and Of 0: composife parameters as defined in Figure 3.2. 
oiffofO: intrapair difference in ofO. 2: Of 0: intrapair sum of DfO. Rank numbers were assigned 
fo wfh%, FEVPerc and Of 0 wifhin the cohort of 318 pafient pairs. 
(TabIe 3.6 and Figure 3.3). In contrast, the IRND distribution of FEVPerc in 
the "'F508 homozygous pairs was indistinguishable from that of randomly 
assigned couples. The ranges of intrapair differences in wfh% or FEVPerc were 
similar in the whole cohort of CF patient pairs and the to.F508 homozygous 
subgroup (TabIe 3.5b). 
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Properties of discordant CF panent pairs 
The age-independent clinical parameters wfh% and FEVPerc were linearly 
combined to define the composite parameters DfO (Eq. 3.1 and Figure 3.2) as a 
measure of the overall disease severity based on an equal weight for both, the 
anthropometric and the lung function parameter. The parameter DELTA 
defined as the absolute distance between the DfO vaIues of a twin or sibpaIr 
(Eq. 3.2) was taken as the indicator of intrapaIr difference of disease severity 
(Figure 3.2). As shown in Figure 3.4, the vaIue of DELTA did not correlate with 
the intrapaIr age difference of sibpairs. Discordant paIrs, indicated by high 
vaIues of DELTA, were observed at similar frequency in sibpaIrs with high and 
Iow age differences. 
800 
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.1:...... .,. . O~·~~~·~·~·~~~'--·_·r-----·-----r--------~ 
• 12 fa 
age difference (years] 
Figure 3.4 Composite parameter DELTA and intrapair age difference. DELTA was 
defined as indicated in Figure 3.2 based on rank numbers tor wfh% and FEVPerc to 
quantify intrapair discordonce. C/osed circJes: dizygous CF patient pairs. Open 
circies: monozygous CF twin pairs. 
For 318 patient pairs canying various CFTR genotypes, the maximum rank 
number that can be assigned to wfh% or FEVPerc values is by definition 636. 
There was no correlation behveen the intrapair rank number differences for 
wfh% and FEVPerc (data not shown): patient paIrs were observed to be 
discordant for both parameters, or only discordant for wfh%, but concordant 
for FEVPerc and vice versa. Among monozygous nvins, the highest value for the 
composite parameter DELTA was 366. Sixty-four dizygous patient pairs had 
vaIues for DELTA>366. These extremely discordant pairs could be compiled 
into three cohorts as indicated in Figure 3.5: 15 pairs \Vere concordant in \vfh% 
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Figure 3.5 Characteristics ot Ihe mosl discordanl patienl pairs. 
Wilhin this plol, 64 pairs wilh values ot DELTA ~ 366 or higher are divided inlo Ihree 
cohorls wilh Ihe tol/owing characlerislics: 
11 111 
upper left lower right upper right 
IRNDwlh% < 250 >250 > 250 
IRND FEVPerc > 250 <250 > 250 
No of pairs 15 25 24 
fhereof L\F508 homozygous 7 (47%) 7 (28%) 7 (29%) 
l<.F508 heterozygous 5 9 12 
A veroge values for: 
oge (y] 20.2 17.7 21.5 
wfh% 104 102 99 
FEVPerc 45 50 41 
DELTA 441 429 537 
Average volues for infrapair differences in: 
age (y] 2.7 2.8 2.6 
wfh% 7 28 29 
FEVPerc 71 25 67 
OIO 278 556 625 
discordant in wfh% (cohort II) and 24 pairs were discordant for both 
parameters (cohort lIl). These three phenotypes were neither discIiminated by 
the patient's absolute values for age, wfh% or FEVPerc nor by the intrapair age 
difference (legend of Figure 3.5). There was a trend towards an 
overrepresentation of .ü.FS08 homozygotes in cohort I compared with cohorts II 
and III (p~ 0.15; Fisher's exact test).20 
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The average value for DELTA was highest in cohort IJl and average values for 
intrapair difference in DfO were lower for cohort I (legend of Figure 3.5) than for 
cohort II and III. The intrapair difference in DfO (DifTDfO) differentiated pairs 
who are discordant (Il, III) and who are not discordant (I) in wlh%. Defining a 
discordant pair (category DIS) as a pair composed of one sibling with low DfO 
and one sibling with high DfO, pairs from cohort I could be distinguished from 
pairs belonging to the category DIS by taking the intrapair difference in DfO 
(DifTDfO) into account. Table 3.7a displays clinicai data from two IIF508 
homozygous patient pairs with similar high DELTA but different DifTDfO to 
illustrate their phenotypic differences. 
Propelties of concordant CF patient pairs 
For the identification of concordant pairs two characters, i.e. the pair's 
concordance and their disease severity, had to be combined in order to 
discrlminate between concordant pairs with mild phenotype and concordant 
pairs with severe phenotype. In Table 3.7b, data from three IIF508 
homozygous patient pairs representative for the phenotypes 
"concordantjmildlyaffected" (category CON+, example I), 
"concordantjmoderatelyaffectee{" (example 11) and "concordantjseverely 
affected" (categOly CON-, example III) are shown. These three pairs ail have 
similar low vaiues for DELTA and intrapair difference in DfO (DifTDfO) 
indicating their concordance. In concordant pairs, the intrapair sum of DfO 
(EDfO) is a measure of disease severity: mild: high EDfO with both siblings 
displaying wfh% and FEVPerc values above the 75!h centile (example Ij, 
moderate: intermediate EDfO with both siblings displaying wfh% and FEVPerc 
vaiues close to the 50th centile (example Il) and severe: low EDfO with both 
siblings displaying wfh% and FEVPerc vaiues below the 25th centile (example 
III) . 
Definition of rank numbers 
Based on DELTA, the intrapair sum of DfO and the intrapair difference in DfO 
(DiffDfO), five rank numbers were calculated (TabIe 3.8): DISCDELTA defined the 
pair's position in the sequence of discordant pairs whereby the discordance 
was quantified solely on the basis of DELTA. The most discordant pairs were 
recognised by low DISCoELTA. Rank numbers within the sequence of 
concordant pairs were assigned by linearly comblning a parameter describing 
the disease severity of a pair with a parameter describing the pair's 
discordance. For instance, in a diagram wherein the rank number for DELTA 
was assigned to the x-axis (whereby the rank number 1 corresponded to the 
lowest DELTA, i.e. to the most concordant pair) and the rank number for EDfO 




















Figure 3.6 Infrapair discordance (a-d) and rank numbers (e-I) for monozygous fwin 
pairs. fnfrapair differences of rank numbers are shown for wfh% (a. e) and FEVPerc (b, 
d) for monozygous .-JF508 homozygous twins (open elrc/es in a, b) and monozygous 
twins wifh ofher CFTR genofypes (open squares in e, dj. The maximal intrapair rank 
number difference of 636 is displayed for a fotolof 318 patienf pairs. 
Rank numbers (Tabie 3.8) for .-JF508 homozygous monozygous fwins obfained within 
fhe cohort of 114 dF508 homozygous patienf pairs are displayed in (e - i): (e) rank 
DISCoELTA (t) rank CON+OELTA (g) rank CON-DELTA (h) rank CON+o.HOIO (I) rank CON-O.HOIO. 
Except tor rank DISCDHTA, na significant differences were found comparing the ronk 
numbers befween fhe IS monozygous and the 99 dizygous .-JF508 homozygous 
paf/enf pairs: (e) rank DfSC DELTA; P = 0.05 (t) rank CON+ DElTA; P = 0.17 (g) rank CON-
DELTA' P = 0.07 (h) rank CON+ O'ffOIO; P = 0.29 (I) rank CON- O.HOIO: P = 0.17 
highest value for EDfO, i.e. the most mildly affeeted pair), the data set closest 
to the origin defined the most eoneordantjmildly diseased pair employing 
these criteria. Accordingly, the rank number for the distance [rom origin in 
this diagram was used to define CON+OELTA. In an analogous mannef, CON-
DELTA, CON+OillDfO and CON-OlflDfO, were defined as indicated in Table 3.8. In 
other wards, the four rank numbers for CON+OELTA, CON-DELTA, CON+DifiDfO 
and CON-oiflDfo defined a palr's position in the sequenees CON+ and CON-
wherein discordanee was defined via the composite parameter DELTA and the 
pair's position in the sequence CON+ and CON- wherein discOl'dance was 
defined via DiffDfO. 
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In Figure 3.6, rank numbers DISCO>:J.TA (Figure 3.6e), CON+OELTA (Figure 3.6fj, 
CON-OELTA (Figure 3.6g), CON+DiffDfO (Figure 3.6h) and CON-OiffDfO (Figure 3.6i) 
are graphically disp!ayed for monozygous twins. Intrapair differences of rank 
numbers for wfh% and FEVPerc were lower for ó.F508 homozygous 
monozygous twins (Figures 3.6a and b) and monozygous twins with other 
genotypes (Figures 3.6c and d) (P ~ 0.0005 for wfh% and P ~ 0.01 for 
FEVPerc). Rank numbers for DISCoELTA were significantly !ower for LlF508 
homozygous monozygous twins than for dizygous LlF508 homozygotes (P ~ 
0.05, Mann-Whitney U-test, Figure 3.6e). In contrast, rank numbers for 
CON+DELTA, CON-OELTA, CON+OilIDfO and CON-OiffDfO which were defined by a 
linear combination of a parameter describing the disease severity and a 
parameter describing the intrapair concordance, were not significantly 
different between monazygous and dizygous LlF508 homozygotes (Figures 3.6f-
i). This observation indicates that monozygous LlF508 homozygous twins 
express concordant mildly, concordant moderately and concordant severely 
affected phenotypes and consequently, rank numbers for CON+OELTA and the 
three similarly derived rank numbers did not segregate with the zygosity 
status of the patient pair. 
Categorisation of CF patient pairs 
The interrelation of the five rank numbers DISCOELTA, CON+DELTA, CON-DELTA, 
CON+OiffDfO and CON-OifIDfO enabled the discrimination of 6 different categories 
of patient pairs (Tab!e 3.9): for a discordant patient pair (category DIS, examp!e 
I in Tab!e 3.7a), a !ow rank number for DISCoELTA, but high vaiues for the other 
four rank numbers were expected. Pairs ranking low in DISCOELTA and in 
CON+DifIDfO or CON-OfflDfO were distinguishab!e from the category DIS. These 
pairs were summarized as giscordantjfoncordant mild disease (DC(l); examp!e 
II in Tab!e 3.7a) and giscordatltjfoncordant severe disease (DC(2)), respective!y. 
Concordantj mild!y affected patient pairs (category CON+, examp!e I in Tab!e 
3.7b) had !ow rank numbers for CON+OELTA and CON+DiflDfO, but high values for 
the ather three rank numbers. Analogous!y, concordantjseverely affected 
patient pairs (category CON-, examp!e III in Tab!e 3.7b) were expected ta have 
low values for CON-DELTA and CON-DilIDfO, but high vaIues for the other three 
rank numbers. Concordantjmoderately affected pairs were summarized as 
gon-giscordant (ND, examp!e II in Tab!e 3.7b). ND pairs are expected to have 
similarly low rank numbers for CON+DELTA, CON-OELTA, CON+OiffDlO and CON-
OiffDfO as by definition for each of these rank numbers intrapair concordanee 
and disease severity was weighed equally. Consequently, pairs characterised by 
definite intrapair concQl'dance but average disease severity were ranked 
comparably low in each of these sequences. Thus, the ND pairs were 
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discrirninated from pairs categorised as CON+ and CON- by their low diJference 
between the corresponding rank numbers (CON+OELTA - CON-OELTA) and(or 
(CON+OifIDfO - CON-OiffDfO). 
In order to determine the sequence of pairs within each of the categorles in an 
unambiguous manner, a pair's position within any of the sequences had to be 
described using the same aigorithm on all CF patient pairs (Figure 3.7). 
lowest of the five rank numbers: 
DISCu,. .. 
lowest of the live rank numbers: 
CON+< .. 1.T~ OR CON+"f'lJ'O 
lowesl of Ihe live rank numbers: 
CONbau OR CON"b-"U<l 
I OIS~I.T' - CON+o,f'O'O I > 20 ANC 
I CISc..au - CON,!>"D" I > 20 
I DlSCo.:,.TA - CON+o"""" 15;20 
I DlSCo:au - CON,!>=", Is. 20 
CON"o..."., - CON+o,~ > 30 ANC 
CON"baTA - CON+<>au > 30 
CON"O."<>'O - CON+tJ-""" $30 OR 
CON"l:nTA -CON+<>an $30 
CON+tJ-"<!'J - CON"o"""", > 30 ANO 
CON+calA - CON"b-a'" > 30 
CON+o,,,,,,.., - CON"of'lJ'O $ 30 OR 
CON+tatA - CON-D-lTA S. 30 
Calegory DIS wJth rank OISCt,.", 
Summarlsed as DC(I) 
Summarlsed as DC(2) 
Category CON+ wilh tank CON+oa .. 
Summarlsed as NO 
CalegoryCON-wJth rank CONt",,, 
Summarlsed as NO 
Figure 3.7 Flow chart for the assignment of 114 tlFS08 homozygous twin and sibfing 
pairs to the categories DIS. CON+. CON-. NO, De( I) and De(2) based on 5 rank 
numbers derived from composite parameters (see fable 3.8 lor delinition and text for 
detaifs). 
Categories oJ L1FS08 homozygotls CF twin and sibling pairs 
The ranking aigorithrn (Figure 3.7) was applied to 114 "F508 homozygous CF twin 
and sibling pairs. The outcome is displayed in Figures 3.8 and 3.9. As indicated in 
Figure 3.8b, 59% of the "F508 homozygous pairs were sOlted into the categories 
DIS, CON+ and CON- while the remaining 41 % were summarized in the categOlles 
with intelmediate phenotypes NO, OC(l) and OC(2). 
To identity pairs from the three categories DIS (discordant pairs), CON+ 
(concordant(mildly diseased pairs) and CON- (concordant(severely diseased 
pairs), we sorted the cohort of patient pairs as sueh that subsequently 
ranked pairs possess the qualities of the respeetive categOly in dec1ining 
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Table 3.8 Definition of rank numbers D/SC DELTA, CON+ DELTA, CON+ o:ffDfQ, CON- DELTA 
and CON- o:ffDfQ 
SEQUENCE OF DISCORDANT PAIRS: rank number derived from one parameter 
DISC DElTA rank number for DElTA 
rank number for DISC DElTA::: 1: highest DELTA;; most discordant pair 
SEQUENCES Of CONCORDANT PAIRS: rank number derived from combination of two 
parameters 
al! rank numbers are defined as disfance from origin in a plof whereby the following 




ronk number for DELTA rank number for ~DfO 
rank number for DELTA::: 1 ...- 10west DELTA ronk numberfor IDfO;;;: 1: highesl IDfO 
=> most concordant pair dasesl la origin => mildesl affecled pair dosest la origin 
ronk number for DiffDfO rank number for IDfO 
ronk number for DiffDfO oe; 1 ...-Iowesl DiffDfO rank number for IDfO ;;;: 1: highesl IDfO 
=> mosl concordant poir dosest to origin => miidesl affecled pair dosesl la origin 
CON- DELTA rank number for DELTA ronk number for IDfO 
rank number for DELTA::: 1 ...- lowest DELTA rank number for IDfO;;;: 1: lowesl ~DfO 
=> most concordant pair dosesilo origin => most severely affecled pair 
doses! to origin 
CON- ()ffD:O ronk number for DiffDfO ronk number for IDfO 
ronk number for DiffOfO ::: 1 ...- lowest DiffDfO ronk number for IDfO;;;: 1: lowesl IDfO 
=> mosl concordonl pair dosesl la origin => most severely affecled pair 
dosesl la origin 
NOTE. DELTA and Of 0: composite parameters as defined in figure 3.2. DiffDfO: intrapoir 
difference in DfO. ~DfO: infropair sum of DfO. 
fashion: the most discordant pair (defined by rank 1 within the category DIS) 
is followed by the second most discordant pair (defined by rank 2 within the 
categOly DIS) and so forth. In a likewise manner, ranking of pairs within the 
categories CON+ and CON- was intended. This gradient is visible in the clinical 
data for the patient pair cohOltS defmed in Figure 3.8c: DiscOl'dance decreased 
with increasing rank numbel' in the categOly DIS. This was obselved with 
respect to DELTA as weil as the intrapair differences in wlh% and FEVPerc 
(Figures 3.8d, e and fj. In the categolies CON+ and CON-, DELTA and the 
intrapair difference in FEVPerc raised with increasing rank number (Figures 
3.8d and f). Intrapair differences for wfh% were lower within the categories 
CON+ and CON- than within the category DIS. The average disease severity of 
pairs from the categOly DIS was intennediate compared to patient pairs ranked 




























Figure 3.8 Oisease severi/y and in/rapair discordance ol 114 .JF508 homozygous twin 
and sibling pairs assigned to the categories DIS, CON+, CON-, NO, OC{I) and 0C(2). 
(a) Layou/ lor (b-I) and proposed relation ol/he three extreme pheno/ypes DIS, 
CON+ and CON- to the in/ermediate pheno/ypes NO, Ocr 1) and 0C(2). (b) 
Occupancy ol/he ca/egories whereby 100% represents the total number ol 114 
&508 homozygous CF twin and sibling pairs. (c) Oelinifion ol cohorts with decreasing 
ronk numbers in the category and number of pairs per cohort. Monozygous fwins are 
indica/ed by '. (d-I) Intrapair discordance as defined by average values within /he 
cohorls lor DELTA (d), inlrapair difference ol wlh% (e) and in/rapair difference ol 
FEVPerc (I). (g-I) Oisease severily as delined by average values wi/hin the cohorls lor 
the in/rapair sum 01010 (g). wlh% (h) and FEVPerc (I). 
The dissimilar, non-overlapping character of patient pairs from the categories 
CON+ and CON- is evident from the dissimilar values of the average intrapalr 
sum in DfO, wfh% and FEVPerc (Figures 3.8g, hand ij. Analogously, these 
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observations are visible in Figure 3.9 wherein rank numbers for wfh% and 
FEVPerc far all 114 AF508 hamazygOlls twin and sibling pairs are depicted in a 
plot employing the same axes assignment as for definition of the composite 
parameters DELTA and Of 0 (Figure 3.2). CON- pairs are faund in the lower left 
area of tbat diagram as intended due to their low Of 0 (Figures 3.9a, b and c) 
while CON+ pairs are located in the upper right area of the diagram indicating 
their high Of 0 (Figures 3.9d, e and 1). Bath COhOl'!S of concordant pairs occupy 
distinct, non-overlapping areas within the diagram whereby patients from pairs 
summarized as ND are located in the space between the two extreme 
concordant phenotypes (Figures 3.9m and nl. 
Adjacent to the cohorts CON+(IIl) (Figure 3.91) and CON-(IIl) (Figure 3.9c), more 
discordant pairs with high Of 0 respective low Of 0 are summarized as DC(I) 
(Figure 3.91) and DC(2) (Figure 3.9k). In most ofthe pairs from tbe category DIS 
(Figures 3.9g, h, i and j), the sibling with the better phenotype is characterised 
by the belter wfh% together with the belter FEVPerc as indicated by a positive 
slope of the line connecting both data points of a discordant pair. In contrast, 
pairs summarized as DC(I) or DC(2) are observed to be concordant in wfh% as 
well as discordant in FEVPerc or discordant in wfh% albeit concordant in 
FEVPerc or the sibling witb tbe belter wfh% exhibits the lower FEVPerc. Thus, 
most data points from DC(I) and DC(2) pairs are connected by a line parailel to 
the y-axis, parallel to the x-axis or with a negative slope, respectively. 
Discussion 
The clinicai phenotype of the monogenic disease CF is characterised by a broad 
spectrum of disease severity and variation of the clinical course behveen 
patients with the same mutation genotype in the disease-causing gene CFTR.3,4 
For the multi-organ disease CF, the anthropometric parameter wfh% and the 
lung function parameter FEVI are instrumentai for the foliow-up of CF patients 
to monitor growth, development, gastrointestinal and pulmonary disease. 10 By 
studying affected patient pairs, i.e. CF twins and siblings, we have taken a 
classical approach to assess the influence of inherited versus environmental 
factors on the clinical parameters wfh% and the FEVI derived FEVPerc. 
The prominent role of tbe CFTR gene in CF is evident from tbe mode of 
inheritance of this autosomal recessively transmitted disease. 1 
The more than 800 reparted CF associated CFTR mutations have been reliably 
classified as to whether they confer exocrine pancreatic sufficiency or 
insufficiency21,22, but the association of CFTR mutation genotype with CF 
disease manifestation is less straightforward for parameters describing the 
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nutlitional status or CF pulmonary disease. The same range of disease 
manifestation is observed in wfh% and FEVPerc among ilFS08 homozygotes, 
ilF508 compound heterozygotes and patients with non-ilF508jnon-ilF508 
genotypes (Tab!e 3.5a), so that the CFTR genotype - CF phenotype assoCÎation 
becomes ambiguous. 
In order to evaluate the influence of the CFTR mutation genotype on the 
intrapair disease variability, we evaluated the intrapair rank number difference 
(!RND) distribution among CF patient pair cohorts. When the who!e cohort with 
various CFTR genotypes was analysed, the two members of a twin or sibpair 
were on the average significantly more similar in both wfh% and FEVPerc than 
unrelated patients (Tab!e 3.6 and Figure 3.3) demonstratIng the impact of 
shared CFTR genotype on the CF disease phenotype. However, among ilF508 
homozygous pairs representing a cohort nonnalised for the genotype in the 
major disease-causing gene, any deviation of the observed IRND distribution to 
the distribution expected for unre!ated coup!es cannot be based on the CFTR 
genotype. ilF508 homozygotes differed in their IRND disuibution from random 
coup!es in wfh%, but not in FEVPerc (Tab!e 3.6 and Figure 3.3). Although more 
subtle effects not evident In a hundred pairs wou!d probab!y show up with 
increasing sample size, the global picture is clear-cut: The IRNDs were 
apparently random!y disu'ibuted for FEVPerc, but significantly skewed to !ow 
numbers for wfh%. 
Figure 3.9 (see previous page) Graphical represenfation ol rank numbers lor wlh% 
and FEVPerc lor 114 &508 homozygous categorised patient pairs. Each patienf pair is 
depicfed as a set of a blaek and a white numbered data point wifhin a diagram of 
the rank number FEVPerc (y-axis) p/olfed againsf the rank number lor wlh% (x-axis) as 
defined in Figure 3.2. Bath axes ol all diagrams within this Figure are sef ta the maximol 
rank number ol 636 fhaf can be abfained lor 318 pairs. Far each pair, the data point 
closer to the origin indicated by fhe black colour carresponding fa fhe more severely 
allecfed patient. The line connecting bath data points ol a pair represenfs fhe 
eomposite parameter DELTA describing the intrap air discordance. The pairs shown in 
Figures (a) fa (n) correspond fa fhe coharfs defined in Figure 8c as is exp/ained in fhe 
two triangular diagrams at the bolfam ol this Figure. 
(a-c) 19 pairs categorised as CON- ordered by increasing rank number for CON-DELTA 
(d~f) 20 pairs eafegorised as CON+ ordered by increasing rank number for CON+OELrA 
(g-J) 28 pairs categorised as DIS ordered by increasing rank number lor DISCDELTA (k): 
11 pairs summarized as DC(2) and (I): 8 pairs summarized as DC( I) ordered in a 
sequence wifh decreasing DELTA (m). (n): 28 pairs summarized as NO ordered in a 
sequence with increasing DELTA. 
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Tabfe 3,9 Definilion of patienl paircalegories DIS, CON+, CON-, NO, DC(I) and 
DC(2) by rank number characleristics 
Cotegory DISC DElTA CON+ OHTA CON DElTA CON+ D:UDrO CON- D:ffDfO in Fig. 3.9 
CON- high high tow high low (a), (b), (c) 
CON+ high low high low high (d), (e), (I) 
ND high low low low low (mI. (n) 
DIS low high high high high (g), (h), (i), UI 
DC (I) low high high low high (I) 
DC 12) low high high h"gh lew Ikl 
NOTE. CON+: concordant/mildly otfected. CON-: concordanf/severely affected, 
ND: non-discordant (concordanf/moderafely QffectedJ. DIS: discordant pair. 
DC(l): discordant and concordant/mildly affecfed. 
DC(2): discordant and concordant/severely affected. 
Such a skew is only observed if the shared factors significantly outweigh the 
individual genetic and epigenetic factors. 
An overrepresentation of shared alleles in sibs compared to unrelated subjects 
should account for their more similar wfh% values, because anthropometry has 
astrong inherlted component.23 , 24,25 However, weight predicted for height is in 
CF influenced by eating habits and lifestyle,26,27,28 the mode of and adherence 
to a high-calorie diet,26,27,28 the adrninistration ofpancreatic enzymes and fat-
soluble vitamins to treat exocrine pancreatic insufficiency and maldigestion of 
nutrients29 and the frequency and severity of respiratOly infections.3o All 
investigated patient pairs but a few adults shared homes, family life and CF 
physician with each Dther 80 that they were exposed to the same nutIitional 
lifestyle and medica! expertise. Common medica! treatment and living 
conditions certainly contributed to the significantly lower intra- than interpair 
varianee in wfu%. The therapeutic regime aimed at the maintenance of a 
normal weight is reflected by the average values for wfh% near 100% among CF 
patients (Tables 3.4a and 3.5a & ref 15). 
As outlined above, in contrast to the nutritional status, individual rather than 
shared factors detennined the sibs' lung function. Pultnonruy disease in CF is 
characterised by a vicious cycle of infection,31,32 inappropriate host defence,31,32 
tissue disintegration and remodelling33 and irreversib1e 10ss of pulmonary 
function. 13,34,35 Although the sibpairs' airways were typically infected with the 
same bacterial strain (data not shown), the differential host response seems to 
be more important for progression of pu1monaty disease than shared 
environmental and genetic factors. The generation of immune responses by 
gene rearrangements and somatic mutation36,37,38 and the high degree of 
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polymorphism in immunorelevant loci sueh as the HLA39,40,41 are major 
reasons why siblings differ more in host defence genotypes than in any other 
categOly of expressed genotypes. 
The interrelation behveen genes determining the individual's host defenee and 
the ehallenge by immunogenic, i.e environmental, factors appears to be of 
substantial impact for the pulmonary status in CF as demonstrated by the 
obselvation that dizygous twins have a significantly lower FEVPere cOlnpared to 
monozygous twins (TabIe 3.4a): an increased susceptibility to infection is 
known for CF12 and nosocomial transmission of bacterial pathogens in CF is a 
well-known risk43 ,44 that should be similar for all hvin pairs irrespectively of 
their zygosity status. However, uvo monozygous twins are likely to possess 
equal host defence capabilities while in dizygous hvin pairs, pathogens confront 
susceptible individuals with a different genetic repertoire of host defence. 
Taken together, these findings indicate that the nutritional status in CF is 
modulated by few factors still detectable within the cohort of 114 AF508 
homozygous pairs, while the pulmonary disease in CF is modulated by 
numerous factors. Thus, it is not surprising that the four most discordant 
monozygous hvin pairs (Figure 3.6e) demonstrate intrapair differences in 
FEVPerc (Figure 3.6b), but are inconspicuous in their wfh% intrapair 
difference. On the day of evaluation, these pairs were 30, 16,9 and 9 years old. 
1'wo were pairs of male, and two were pairs of female hvins. Currently it 
remains the subject of speculation as to whether the discOl'dance in these pairs 
might reflect the influence of subtie genetic differences between monozygous 
hvins45 such as variation in the DNA methylation pattern, the result of somatic 
mutations e.g. at MHC loci or differential X-inactivation in the female pairs. 
With equal probability, twin discordance in birth weight which has been 
documented among monozygous, particularly monochorionic, hvin pairs46 
might give rise to differences in the twin's pulmonruy status, 
The comparison of intrapair discOl'dance among monozygous (MZ) and dizygous 
(DZ) twin pairs is widely accepted to disseet the influence of genetic versus 
epigenetic factors on the individual's phenotype:47,48 the hypothesis "a 
phenotypic trait is determined by inherited factors" is sustained but not proven 
by the observation of monozygous twin pairs being more concordant in the 
analysed trait than dizygous twin pairs. Within the cohort of 41 CF twins with 
known zygosity status, this applies to the parameter DELTA. The composite 
parameter describing intrapair discOl'dance based on wfh% and FEVPerc 
(Figure 3,2) was significantly lower for monozygous than for dizygous hvins 
indicating that monozygous CF twins are more concordant than dizygous CF 
twins (l'able 3.4b). However, intrapair differences for both wfh% and FEVPerc 
were comparable between monozygous and dizygous CF twins (Tabie 3.4b). As 
pulmonary funct:ion and nutritional status are clinically related,49,50 the 
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intrapair discordance of either parameter might be enhanced by the other. 
Consequently, DELTA should be more sensitive with respect to the intrapair 
differences than each of the individual parameters in itself. As aresuit, the 
concordance of monozygous twins detected by DELTA but not by wfh% and 
FEVPerc indicates the inherited component besides the CFTR mutation 
genotype that influences CF disease sevelity. The impact of inherited factors on 
CF disease is supported by the observation that DELTA is independent ofthe 
intrapair age diJference in CF siblings (Figure 3.4): The smailer the age 
difference, the more siblings have shared environmental conditions of living. 
The independenee of DELTA from intrapair age difference suggests a stronger 
impact of shared genetics than shared environmental factors on 'disease 
manifestation in CF. In other wards, the shared time of exposure to 
environmental factors and the action of the environmental factors on sibs at a 
comparabie stage of development, i.e. the extent of sharing patienfs histOly 
and state of development is less important than age-independent factors. 
Given the hypo thesis that CF disease manifestation is substantially influenced 
by genes other than CFTR, methods of reverse genetics may be applied to 
identifY the loci involved. However, the success of such an approach will be 
determined by the selection of appropriate candidates for such a study. For the 
analysis of a quantitative trait extreme phenotypes are gene rally considered to 
be more informative.6-9 Hence, a sU'ategy to identif)r these most informative 
patient pairs was developed. As the disease phenotype had to be desctibed in a 
quantitative manner, metric data was employed in order to evaluate the 
complex multi-organ disease CF. Using wfh% and FEVPerc, two clinical 
parameters most sensitive to the course and prognosis of CFiO were combined 
in order to desctibe the overall disease severity in the two major aillicted 
organs, i.e. the respiratOly and the gastrointestinal tracts. Moreover, the 
composite parameter DELTA describing the intrapair discQl'dance was 
employed in the selection procedure. As has been described in detail above, 
DELTA was more sensible with respect to the influence of the genetic 
background on CF disease severity and thus the employment of this parameter 
for patient pair selection should facilitate the identification of subjects 
informative in a genetic study. To avoid equivocal scoring, a computer-assisted 
method was executed to rank patient pairs within the categories of patient 
pairs exhibiting the phenotypes concordant mild disease (CON+), 
concordantjsevere disease (CON-) and discordant (DIS). To assure that the 
se1ected pairs represent the extremes from a continuous spectrum of 
phenotypes, no overlap of clinical characteristics comparing pairs from the 
cohorts DIS, CON+ and CON- had to be assured. As demonstrated within 
Figure 3.8, the aigOlithm employed for the ranking of the 114 "F508 
homozygous 
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pairs resulted in the identification of CON+ and CON- patient pairs with non-
overlapping wfh% and FEVPerc values. Likewise, discOl'dance in both clinical 
parameters was distinct among pairs ranked DIS compared to pairs ranked 
CON+ or CON-. In conclusion, the nF508 homozygous twin and sibling pairs 
expressed various phenotypes. Three categories of extreme phenotypes - i.e. 
DIS, CON+ and CON--and three categories with intermediate andjor 
uncommon phenotypes could be distinguished and were characterised as 
phenotypically distinct entities with respect to pulmonary function and 
nutritional state of the CF patients. 
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Abstract 
Background & Aims: Cholinergic stimulation of chloride seCl-etion is 
impaired in the intestine of cystic fibrosis (CF) patients. However, intestinal 
chloride secretion has been seen in patients carrying mild CF mutations_ The 
aim of this study was to investigate residual Cl~ seCl-etion in intestine of 
IIF508 homozygous CF patients, and examine the contribution of CFTR and 
alternative CI~ conductances. Twins and siblings with identical CFTR 
genotypes were investigated to determine impact of factors other than CFTR 
on chloride secretion. Methods: Chloride secretion in rectal tissue was 
investigated by applying Ca2+ and adenosine 3',s'-cyc1ic monophosphate 
(cAMP)-linked agonists before and aftel' the inhibition of alternative Cl-
conductances with 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DlDS). 
Results: In 73% of patients cAMP-mediated CI~ secretion was observed, while 
20% shO\ved DIDS-sensitive Ca2+-activated CI- secretion. This DIDS-sensitive 
alternative chloride conductance was only seen in CF individuals also 
responding to cAMP-agonists. Chloride secretion was more concordant 
within monozygous twins than within dizygous pairs. Conclusions: These 
results suggest the presence of CFTR-mediated Cl~ secretion in a subgroup of 
patients, implying that a portion of IIF508 CFTR can be processed in vivo 
and function as chloride channel in the apical membrane of intestinal cells_ 
Moreover, a considerable number of AFs08 homozygous patients express 
chloride conductances other than CFTR in their intestinal epithelium. 
Introduction 
Cystic fibrosis (CF) is an inherited disorder of ion transport! in exocrine 
glands that is caused by molecular lesions in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene, which encodes an 
adenosine 3',5'-cyclic monophosphate (cAMP)-regulated chloride channel 
found in the apical membrane of epithelial cells. 2 •3 The more than 800 
known CFTR mutations are classified as severe or mild alleles dependent 
upon whether they confer exocrine pancreatie insufficiency or pancreatic 
sufficiency. The most frequent CFTR mutation IIF508, a deletion of the 
phenylalanine codon at position 508, occurs in about 70% of CF alleles in 
the Caucasian population. 4 
The diagnosis of CF can be made by applying specific and sensitive 
electrophysiological methods such as the nasal potential difference 
measurementS or the intestinal CUlTent measurement (ICM),6-8 which test the 
conductance properties for sodium and chloride ions of respiratory and 
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intestinal epithelium in response to secretagogues and inhibitors. The 
chloride secretory response examined by lCM not only discriminates CF from 
non-CF, but may also reveal the presence of residual chloride secretion in 
affected individuals,s by challenging the CI- secretOly pathways with 
cholinergic and fl-adrenergic agonists. The chloride secretOly responses that 
are seen in controls when applying these agonists to the intestinal tissue, 
are impaired in tissues [rom CF individuals. 7 In a previous study, residual 
chloride secretion has been detected in patients with CF, predominantly in 
pancreatic sufficient individuals who carry mild mutations such as A4SSE. 8 
Residual chloride secretion has also been seen in biopsies from patients with 
stopcodon mutations (own unpublished data) suggesting the contribution of 
chloride channels other than CFTR. In cftr -j- knock out miee Ca2+-regulated 
chloride channels are believed to modulate the manifestations of disease in 
the affected organs.9 - 11 These alternative chloride channels also exist in 
human epithelia 12-14 and might contribute to the diversity of CF disease in 
individuals with the same CFTR genotype. Moreover, IIF508 homozygous CF 
mice present with a smal I intestinal cAMP-activated CI- secretory response 
suggesting the presence of IIF508 CFTR functioning as a chloride channel in 
the plasma membrane,15 
In this study we addressed the issue whether CF patients with the most 
common severe CFTR genotype, i.e. AFS08 homozygosity, express residual 
CI- secretion in the intestinal epithelium. In order to interpret the origin of 
this residual secretion as being either CFI'R or non-CFTR-mediated, we 
introduce an extended protocol of the Ussing chamber experiments, in which 
secretagogues and inhibitors of the chloride secretory pathways are added in 
aspecific sequence. We examined the frequency and characteristics of 
residu al chloride secretion in IIF508 homozygous CF twin and sibling pairs. 
By testing mono- and dizygous patient pairs, sharing the same homozygous 
CFTR mutation genotype, the impact of the gene tic background and 
epigenetic factors on the amount and origin of the intestinal chloride 
secretion could be evaluated. 
Malerlals and Melhods 
Subjects 
Twin and sibling pairs with cystic fibrosis with different genotypes were 
enrolled for the European Cystic Fibrosis Twin and Siblillg Study. For the 
study described here, only subjects homozygous for the CFTR gene mutation 
IIF508 were selected. We invited 72 patients belonging to a dizygous twin or 
sibling pair, and 26 patients belonging to monozygous twin pairs. Patients 
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were investigated in or near their domestic countries at selected CF core 
centers in Hannover, Innsbruck, London, Rotterdam and Verona. 
Questionnaires were filled out for all 98 patients, but rectal suction biopsies 
were only taken from 81 patients due to restrictions appointed by the local 
ethics committees, or patients not approving of the lCM procedure. 
Individuals wUh interpretabIe responses ta all secretagogues were used for 
further evaluation of intestinal chloride conductances (n = 55, see 'Results' 
section below) . These 55 patients carried the following nationalities: 4 
patients originated [rom Austria, 3 [rom Belgium, 1 [rom France, 4 from 
Great Britain, 24 from Germany, 5 from Haly, 11 from The Netherlands, 2 
from Poland and 1 from Sweden (32 femalcs, age range 4.2 - 38.8 yr, mean 
age 15.8 ± 9.4 yr; 23 males, age range 5.4 - 39.3 yr, mean age 18.1 ± 8.8 yr). 
Mono~ Of dizygosity of twins was ascertained by using the AmpFLSTR 
ProfiIer PlUST" typing lut, analyzed on the AB! Prism 377 (perkin-Elmer 
Applied Biosystems)l6 or by oligonucleotide fingerprinting of simple repeats 
applying in situ gel hybridization of Mbo! or HinJl genomic digests.'7 
Approval was obtained from the Hospital Medical Ethical Committees and 
from patients or parents by written informed consent. 
Intestitwl current measurement 
The technique of intestinal current measurement has been described 
previously.7 It measures electrogenic transport of ions across the intestinal 
epithelium as a short-circuit current (Isc). Rectal tissue was obtained with a 
suction biopsy device. The biopsies were preserved in phosphate-buffered 
saline on ice and directly mounted in adapted micro-Ussîng chambers 
(aperture 1.13 mm2).7 The tissue was perfused with Meyler buffer solution at 
37°C (composition in mmol/L: Na' 126.2; Cl' 114.3; HC03- 20.2; HP042- 0.3; 
H2P04- 0.4; Hepes 10; pH ~ 7.4) and gassed with 95% 02 and 5% C02. Basal 
transepithelial resistance of the tissue was determined by measuring the 
voltage response to pulse currents of 1 pA and applying Ohm's law. Basal Isc 
prior to voltage clamping was calculated from the basal transepithelial 
resistance and the open-circuit transepithelial potential difference. 
Subsequently, the tissue was short-circuited by voltage-c1amps during the 
course of the experiment, resulting in a zero transepithelial potential 
difference. For maintenance of cell metabolism glucose (10-2 mol/L) was 
given both mucosally and serosally. Af ter equilibration specific compounds 
(mol/L) that act on the ion conductance pathways7.8 were added to the 
mucosal (M) and/or serosal (S) bathing solutions in the following order: 
amiloride (10-4, M), indomethacin (10-5 , M+S), carbachol (l0'4, Sj, 8-bromo-
cAMP (la'" M+S) together with forskolin (10-5, Sj, 4,4'-
diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) (2.10-4, M, incubated for 
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10 minutes), and histamine (5.10-4, SJ. For determination of 
interexperimental error duplicate biopsies were analyzed in a group of 27 
participating patients. lCM experiments that encountered technical problems 
were only eva!uated in their signa! pattern prior to the disturbance. All drugs 
were obtained from Sigma Chemica! Co., St. Louis, MO. 
Principle ofthe assay: differentiation ofresidual chloride cOllductallce by DIDS 
The first compound added is amiloride, which blocks the Na+ channels and 
thereby reduces the contribution of electrogenic sodium absOl-ption to the 
Isc. 18 lndOlnethacin inhibits endogenous prostaglandin synthesis and thereby 
prevents excessive cAMP production. 19 The various conductances that 
contribute to the chloride secretory response are then analyzed by sequential 
addition of carbachol, 8-bromo-cAMP + forskolin, DIDS, and histamine. 
Carbachol initiates the cholinergic activation of chloride secretion by 
increasing the intracellullar Ca2 + concentration through stimulation of Ca2+ 
influx and mobilization of intracellular Ca2+ stores.20 This causes basolateral 
Ca2+ -dependent K+ efflux which acts as the electrogenic driving force for 
apical CI- secretion.21 Moreover, carbachol activates CFTR in the apical 
membrane by increasing the formation of diacylglycerol, thus stimulating the 
protein kinase C-dependent signaling pathway.22 A large transient chloride 
secretory response upon addition of carbachol, i.e. an increase in short-
circuit current, is characteristic for intestinal epithelium from non-CF 
subjects (Figure 4. la), and is mainly caused by CFTR-mediated chloride 
secretion.7,8,23 In contrast, tissues from patients with severe CF typically 
exhibit a transient response in the reverse direction (Figure 4.1 b), 
presumably due to apical K+ secretion,24,2S unmasked by the reduction or 
absence of Cl- secretion. A small group of CF patients shows a reversed 
response followed bya small transient change in Isc in the chloride secretory 
direction (Figure 4. Ic), or an overriding but still subnormal chloride 
secretOly response (Figure 4.1d), both indicative of the presence of a residual 
chloride conductance in the membranes of the epithelial cells'? The cAMP-
linked chloride secretion, a hallmark of CFTR,2,3 is challenged by concurrent 
addition of the agonist 8-bromo-cAMP plus the adenylate cyclase activator 
forskolin. 26 Besides CFTR, cAMP simultaneously activates the outwardly 
rectifying chloride channel, the ORCC, which is known to require functional 
CFTR for its response to the protein kinase A agonist cAMP.27 In controls, the 
addition of these two compounds causes a sustained increase in Isc (Figure 
4.1a). Subsequently, the tissue is incubated with the stilbene derivative 
DIDS,28 which has been reported to block chloride conductances other than 
CFTR, such as the cAMP-stimulated outwardly rectifying chloride channej27 
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Figure 4.1 Protocol of the lCM measurement. Tracings are given for a healthy con trol 
(a), with a large increase in Isc upon addition of carbachol and histamine 
representing apical C/' secretion. (b) Typical CF patient in whom neither carbachol. 
8·bromo·cAMP + forsko/h or histamine is able 10 evoke Cl" exchange across the 
apica/ membrane. The reversed response implies apical K+ efflux. Note not onfy the 
difference in direction of the Isc response compared fo contra!, buf a/so the 
difference in scale. (c) CF patient with residual Cl" transport that is not influenced by 
the presence of DIDS: carbachol. 8·bromo·cAMP + forskolin. and histamine evoke 
residual Cl" secretion. (d) CF patient with DIDS-sensitive residual Cl" secretion. which is 
characferized by an increase in Isc in response fo carbachol and 8-bromo-cAMP + 
forskolin, buf a decrease in Isc upon stimulation with histamine in the presence of 
DIDS. The tracings depicted are origina! recordings of individuals, who express on 
lCM paltem representative lor the subgroup of patients that all show that specific 
lCM response pattem. 
and Ca2+-activated chloride channels,29 inc1uding the hCLCAl expressed in 
enterocytes and goblet cells of the human intestine,12 and hCIC-3, recently 
identified as a calcium-calmodulin dependent kinase-activated CI- channel in 
the T84 human colonic cellline. 30 In addition to its action on ion channels 
DIDS also inhibits the apical CI'/HC03- and CI,/OH- anion exchangers31 
resulting in a decrease of mucosal-to-serosal chloride flux. However, 
cytosolic changes in pH, with possible effects on CFTR function,32 are not 
generated by the DIDS concentration used in this protocol (Busche et al., 
personal communication). In the presence of DIDS, the Ca2+-dependent 
signaling pathway is again activated, to increase chloride secretion driven by 
the transient electrogenic driving force that is generated by basolateral K+ 
efflux. Since desensitization to carbachol after the first application has been 
reported,33 carbachol is substituted by histamine.34 Since man exclusively 
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expresses Hl-receptors, but no H2-receptors in the colon,35 histamine 
induces a chloride secretOly response solely mediated by the Ca2+ / protein 
kinase C signa! transduction pathway and not by the cAMP-mediated 
pathway.34 
By comparing carbachol responses before the addition of DIDS to histamine 
responses aftel' the incubation with DIDS, three principal lCM patterns were 
observed. Typica! CF patients lacking any sort of residual chloride secretion 
showed the pattern seen in Figure 4.1 b, without any significant reaction to 
carbachol, 8-bromo-cAMP + forskolin, or histamine. Patients with DIDS-
insensitive chloride secretion, i.e. a chloride secretory response before and 
aftel' the incubation of the tissue with DIDS presented a carbachol and 
histamine pattern as in Figure 4.1c, with a cAMP-induced response as weIl. 
reversed 
b 
Cia ss I 
100 - 80% 
J\ 
resfduaf 
PUH% = _--,'="",Id-:":::':...I _ x 100 
reversed" resfduaf 
Cia ss 11 ClasslIl Class IV ClassV 
80 - 60% 60 - 40% 40 - 20% 20- 0% 
f',,-i f/ 1~ r 
Figure 4.2 Quanlitative interpretation of the Cl" secretory responses to carbachol 
and histamine. (a) Sketch of a Cl" secretory response. A baseline is assigned to the 
response (dotted line) on the basis of two linear segments on the recording, one 
before and one af ter the secre/ary response (segments be/ween crosses). With 
respect to this baseline the heights of the reversed and residual responses are 
determined (between dashed lines). The amount of residual CI- conduclance (.dl".o) 
is calculated as percentage of the total response, by dividing the height of the peak 
in the chloride secretory direction by the height of the total response. This is the peak 
up height percentage (PUH%). (b) On the bosis of the residual CI- secrelion expressed 
in PUH%, carbachal and histamine responses are categarized inta five classes. 
Experimental exampfes of fracings are shown far each class. For comparisan, the 
carbachol and histamine responses of the CF palients presented in Figure 4.1 are 
thus classified as: Figure 4.1 b: carbachol closs V, histamine class V; Figure 4. Ic: 
carbachol class /I, histamine class /I; Figure 4.1 d: carbachol closs I, histamine class V. 
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DIDS-sensitive chloride secretion was characterized by an lCM pattern as in 
Figure 4.1d, showing a chloride secretory response upan addition of 8-
bromo-cAMP + forskolin and carbachol, but not upon the addition of 
histamine. 
fnte/pretation of fCM pat/ems 
Chloride secretOly responses to 8-bromo-cAMP + forskolin are typically 
sustained, unidirectional responses, and were expressed in IlAfcm2, 
Ta interpret the Ca2+-dependent Cl- secretory responses quantitatively, the 
transient responses to carbachol and histamine were analyzed with the 
computer program INTEG (Joachim Greipel, MHH). This program assigned a 
baseline to eaeh response, which was calculated [rom 2 linear segments on 
the tracing, one prior to and one after the response, by applying a third-
order polynomial spline function (Figure 4.2a). The changes in !sc in response 
to carbachol and histamine in CF patients and most likely also in controls, 
seem to be the net result of two opposite CUlTents: one component that 
causes a decrease in Isc representing apical K+ effiux (Figures 4.1a, c and d, 
downward peaks) and another component increasing the Isc indicating apical 
Cl- secretion (Figures 4.1a, c and d, upward peaks).7 Hence, the scoring of 
the responses has to involve bath camponents, which was calculated in the 
following way. The height (maximal ion flow) and area (total ion flow) below 
and above the baseline were computed and expressed as percentages of the 
total response (Figure 4.2a). Calculations with height percentages anel area 
percentages resulted in the same classifications with comparabie 
interexperimental error. For condse presentation, only height percentages 
are presented. The maximal ion flow in the Cl- secretory direction (AIsc,cI) was 
taken as a measure for residual chloride conductance and calculated as the 
height of the response in the residual direction divided by the total height of 
the response, the peak up height percentage (PUH%) (Figure 4.2a). The 
PUH% expresses the magnitude of the net response of the tissue into the CI-
secretor:'y direction in response to Ca2 +-linked agonists. The obtained 
carbachol and histamine responses were divided into five classes on the 
basis of this PUH% (Figure 4.2b). The residual chloride secretion "'h.CI, was 
only considered significant if it concerned class I, II or lil. In rectal tissue 
specimens of 61 controls the measured carbachol responses were similar to 
the corresponding histamine responses (43.3 ± 17.6 flA/cm2 and 39.3 ± 19.3 
fIA/cm2 , respectively), indicating that carbachol and histamine cause CI-
secretory responses of comparable magnitudes, in the absence of major 
contributing DIDS-sensitive Cl- conductances, as is the case in con trol 
tissues.23 Consequently, the influence of DIDS on chloride secretion in CF 
patients ean be determined by eomparing the residual seeretion before the 
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addition of DIDS (carbachol response) to the residual secretion af ter the 
incubation with DIDS (histamine response). The measured DIDS influences 
in PUH% were considered significant when carbachol and histamine 
responses of a patient differed by at least two classes, i.e. when the 95% 
confidence limits of interexperimental error of PUH% (0-37%) were exceeded. 
Concordance in CI- secretion within pairs was analyzed by comparing the 
carbachol and histamine responses of the two siblings of a pair. Intrapair 
variance was only considered significant if responses varied by at least two 
classes. 
Statistical Analysis 
Statistical differences were determined via the nonparametric Mann-Whitney 
U-test or the Fisher's exact test. P-values smaller than 0.05 were considered 
significant. Data are presented as means ± SD. 
Resulls 
Chloride secretory response in CF intestine 
Of the participating patients belonging to a sibling or dizygous twin pair, 49 
responses to 8-bromo-cAMP + forskolin, 56 carbachol, and 41 histamine 
responses could be determined. Eighteen 8-bromo-cAMP + forskolin, 20 
carbachol, and 14 histamine responses from participating patients of a 
monozygous twin pair were coUected. The mean basal transepithelial 
resistance of the rectal biopsy specimens of our group of óF508 homozygous 
CF patients was 27 n.cm2 , The mean basal short-circuit cunent was 20 
~Afcm2. 
Patients of whom a response to 8-bromo-cAMP + forskolin, carbachol, and 
histamine were available were taken for further evaluation (n = 41 for sibs of 
dizygous pairs, n = 14 for sibs of monozygous twin pairs). 
The cAMP-regulated response and the Ca2+-induced responses to carbachol 
and histamine were first anaiyzed separately. Of the 55 evaluated patients of 
dizygous and monozygous pairs, 40 responded to 8-bromo-cAMP + forskolin 
(M" ~ 3.9 ± 2.9 f.Afcm2), while no cAMP-activated Cl- secretion was 
detectable in 15 individuaIs. 
The Ca2+-linked Cl- secretOly responses to carbachol and histamine were 
classified according to their PUH% as in Figure 4.3. Eleven out of 41 
carbachol responses of dizygous individuals were assigned to class I, 11 or 111 
and thus c1early demonstrated CI- secretion in the intestinal tissue, while 9 
out of 41 histamine responses were grouped as class I to III (Figure 4.3). 
Four out of 14 carbachol responses of persons of a monozygous twin pair 
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and 1 out of 14 histamine responses scored class I to III (Figure 4.3). Mann-
Whitney U-tests on PUH% of carbachol or histamine responses revealed no 
significant differences between independent measurements on separate 
biopsies of apatient. 
The influence of DIOS on chloride conductance is evaluated in Figure 4.3 by 
comparing the carbachol response of each patient to their histamine 
response. Five patients (9%) belonging to a di- or monozygous paIr exhibited 
residual CI- secretion before and aftel' DIOS (Figure 4.3, areas \Vithin black-
bordered rectangie). In one of these patients that showed significant 
carbachol and histamine responses, the chloride secretion was partly 
abolished by DIOS, and in 10 other patients (totally 20%) the presence of 
DIOS inhibited all CI- secretion (Figure 4.3, dark grayareas). 
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Figure 4.3 Clossificafion of CI- secrelory responses 10 carbachol and hislamine 
according la Ihe peak up heighl percenlages (PUH%) for 55 dF508 homozygous CF 
palienls. The carbachol (verlical/y) and hislamine (horizonlal/y) responses are 
calegorized for 41 CF individuals be/onging la a dizygous pair (.). and for 14 persons 
of a monozygous Iwin pair (.). The influence of DIDS on Ihe chloride secretion is 
indicaled os fol/ows. Upper lelt black-bordered reclangle: patienls exhibiting DJDS-
insensitive residual CF secretion, interprefed as the presence of residuof CFTR activity: 
dark grayareos: patienls expressing DIDS-sensitive residual Cl- secretion. pointing la 
the presence of alternative Cl· conduclances: light gray are as: pafients who show 
residual Cl- secretion in Ihe presence. bul nol in Ihe absence of DIDS. For 
c/arification. Ihe lCM pat/erns of Ihe Ihree CF patienls in Figure 4.1 are ossigned la 
their corresponding carbachol and histamine classes by annofation of 4.1 b, 4.1 c, 
and 4.ld referring 10 Ihe lCM pat/erns of Figures 4.lb. c and d. respeclively. 
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In 5 patients (9%) histamine, but not carbachol, caused a chloride secretory 
response (Figure 4.3, light grayareas) corresponding to c1ass I, II or 111. 
To analyze the combination of cAMP and Ca2+-mediated chloride 
conductanees within apatient, the results of the responses to cAMP + 
forskolin, carbachol, and histamine were combined (Tabie 4.1). Since the 
cAMP pathwaYJ in comparison to the Ca2+ /protein kinase C pathway, is a 
relatively poor activator of apical K+ secretion and consequently a more 
sensitive indicator for residual CFTR-mediated CI- secretion than carbachol 
or histamine,7 the response to cAMP was first assessed to divide the 
investigated individuals into patients with (n ~ 40, 73%) or without (n ~ 15, 
27%) a response to 8-bromo-cAMP + forskolin (Tabie 4.1). 
fobie 4.1 Differenliation of chloride secre!ory responses in LlF508 homozygous CF 
patien!s 
EXPERIMENIAL FINOINGS 























5 (0: 4. M: I) 
10 (0: 7. M: 3) 
24(0: 17. M: 7) 
1 (0: I.M:O) 
Not observed 
Not observed 








Type of Cl' conductance 
present 
CFTR end possible other cAMP 
regulafed channels 
CFTR and DID$-sens. allernative 
channels 
CFTR and possible ot her cAMP-
regulated channels 
CFTR and Cl- conductance 
unmasked by DIDS 
20 No residual Cl- condudance 
7 CI- conducfance unmasked by OIOS 
NOTE. 0: number of responses observed in dizygous twins or siblings. M: number of responses 
observed in monozygous twins. 
cAMP-med.: 8-bromo-cAMP mediated. Ca'2+-med.: Ca2+-mediafed. %, percentages of total 
group of 55 óF508 homozygotes. DI OS-sens.: DIOS-sensitive. 
Subsequently, the carbachol and histamine resuIts of these patients as 
evaluated in Figure 4.3 were implemented to further differentiate their CI-
secretOly patterns. The carbachol and histamine responses of 5 of the 
patients \Vith a cAMP-activated Cl- secretory response were assigned to class 
1,11 or III and thus c1early demonstrated DIDS-insensitive Ca2+-induced 
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residual CI- secretion (Tabie 4.1, upper part). One of these 5 patients also 
belonged to the group with DIDS-sensitive chloride secretion (not shown in 
Table 4.1), since the carbachol response was significantly reduced by DIDS, 
while in 10 other patients the presence of DIDS inhibited all CI- secretion 
(totally 20%). Twenty-four of the patients that exhibited a response to the 
cAMP-agonists, failed to react to carbachol or histamine. One patient with a 
cAMP-mediated chloride response presented with a histamine response, 
however showed no reaction to carbachol. In 15 of the 55 measurements no 
response to cAMP + forskolin was observed (Tabie 4.1, lower part). Eleven of 
these patients also lacked a carbachol and histamine response. Four 
individuals without a response to 8-bromo-cAMP + forskolin did show 
significant Cl- secretion upon the addition of histamine, but lacked a 
carbachol response. Experimentally, as shown in Table 4.1, a DIDS-sensitive 
chloride conductance was onIy observed in individuals who also responded 
to cAMP (P ~ 0.045, Fisher's exact test). 
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Figure 4.4 Concordance of the CI- secretory responses to carbachol and histamine 
within patient pairs. Classification of the (a) carbachol responses of sib A (vertically) 
versus sib B (horizontally) for 29 sibling and dizygous twin pairs (.) and 9 monozygous 
twin pairs ( .). (b) Classification of histamine responses for 18 dizygous pairs (0) and 5 
monozygous pairs (0). The gray are as contain all pairs that are concordant in their Cl-
secretory response, i.e. sib A and B do not differ more than fwo classes in their 
carbachol, respecfively histamine responses. 
The concordance in 8-bromo-cAMP + forskolin, carbachol, and histamine 
responses within the dizygous and monozygous pairs was evaluated for 
those pairs of which the specific response could be determined for both 
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siblings. Responses to 8-bromo-cAMP + forskolin for both sibling A and B 
were obtained for 15 pairs belonging to dizygous pairs and for 5 monozygous 
twin pairs. Six of the 15 dizygous pairs, but none of the monozygous pairs 
were discordant with respect to the presence of a cAMP-mediated Cl-
response. Carbachol responses were obtained for 29 dizygous pairs and 9 
monozygous pairs. Eight of the 29 dizygous pairs and one of the 9 
monozygous twin pairs differed by 2 or more classes with respect to their 
carbachol responses (Figure 4.4a, concOl'dance in grayareas). Histamine 
responses for both sib A and B were obtained for 18 dizygous sibling pairs 
and 5 monozygous twins. Eight out of the 18 dizygous pairs, but none of the 
5 monozygous twins differed in their histamine response (Figure 4.4b, 
concOl'dance in grayareas). Intrapair variances for the responses to 8-
bromo-cAMP + forskolin (expressed in pA/cm2), and for the carbachol 
responses, histamine responses and DIDS influences (all expressed in 
PUH%), were caiculated by the Mann-Whitney U-test. Monozygous twin pairs 
demonstrated to be more concordant than dizygous pairs, especially for their 
cAMP-mediated responses (P < 0.001), histamine responses (P < 0.05), and 
DIDS evoked differences between carbachol and histamine responses (P < 
0.02). 
Discussion 
This study investigated the presence and frequency of chloride secretol}' 
responses in the rectal tissue of L\FS08 homozygous CF twins and siblings 
upon stimulation with cAMP and Ca2+-linked agonists, before and after the 
incubation of the tissue with DIDS. Forty (73%) of the I'!F508 homozygotes 
expressed a cAMP-stimulated chloride secretory response in their intestinal 
tissue. Since cAMP-regulated chloride conductance is indicative of CFTR, 
2,3,27 this finding suggests the presence of some active ó'F508 CFTR in the 
apical membranes of the enterocytes of these individuals. These ex vivo data 
do not concur with the current classification of the ó'F508 mutation36 drawn 
[rom heterologous expression experiments, that ó'FS08 leads to defective 
protein folding in the endoplasmic reticuIum, which prevents its processing 
and targeting to the ceU surface.37 However, recent studies on CFTR 
expression in weIl differentiated human hepatobiliary, respiratoryand 
intestinai tissues reveaied that wild-type and I'!F508 CFTR were 
indistinguishable in their maturation and immunocytochemical 
Iocalization. 13,38,39 Hence, ó'FS08 CFTR can be processed in vivo, although its 
chloride channel function in response to activation by secretagogues is 
abolished or sub norm al as is demonstrated in Dur study. The presence of 
functioning I'!F508 CFTR in intestinal cells is supported by data found in the 
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"'F508 homozygous CF mouse model, which expresses a small CI~ secretOly 
response in the intestine, upon addition of the adenylate cyclase activator 
forskolin. 15 
The observation that a selection of the patients with a cAMP~dependent CI~ 
secretory response showed na detectable Ca2+ -activated Cl- secretion, rnay be 
explained by the fact that cAMP is a more sensitive indicator for CFTR, than 
earbachol or histamine (see above).7 The lack of a Ca2+-indueed response in 
the CI~ secretory direction in these patients may thus be caused by an 
overriding K+ secretOly response in the apposite direetion, masking the Ca2 + 
activation of CFTR-mediated CI~ currents. 
A DIDS-sensitive chloride secretion was detected in 11 individuals (20%) of 
the investigated "'F508 homozygotes, pointing to the presence of alternative 
Cl- conduetances that are reported ta be DIDS-sensitive, sueh as the 
outwardly rectifying chloride channel27 or the Ca2+-activated CI~ 
channels. 12,29,30 This number of patients possessing Ca2 +-stimulated residual 
CI- secretion may even be higher, as a very small Cl~ seeretOly response may 
be overruled by a larger response due to apical K+ -efflux. DIDS-sensitive 
Ca2+-mediated residual CI- seeretion only appeared in persons possessing 
cAMP-activated chloride channels. The underlying rnechanisrn causing the 
observed co-expres sion of Ca2+ and cAMP-dependent chloride channels is 
presently not yet understood and has to be elucidated by further 
experitnents. 
It has been suggested from studies on CF mice9 ,IO that the expres sion of an 
alternative chloride channel may compensate for defective or absent CFTR 
which attenuates the disease phenotype of organs. Our number of 11 cases 
with alternative, DIDS-sensitive CI- secretion is toa low to provide a definitive 
answer as to whether the findings in the animal model can be extrapolated 
to man. However, in our cohort we did not observe a straightforward 
correlation between the presence of residual chloride secretion and a milder 
phenotype, when compared to the group that lacked any form of residual 
chloride secretion (data not shown). The divergent expression patterns of the 
members of the CLCA gene family in mouse and man, being global in 
mause ll and tissue-specific in man,12,14 may partially account for this lack of 
a clear-eut association between the detection of an alternative chloride 
conductance and clinical status. 
In a few patients (Tabie 4.1, 1 with and 4 without cAMP-activated secretion) 
a chloride secretOly response in the range of class I ta III was uncovered 
af ter preincubation with DIDS. This might be explained by the blockage of 
apical anion exchangers by DIDS,31 probably unmasldng a DIDS-insensitive 
serosal-to-mucosal chloride flux resulting in a larger histamine response 
compared to the carbachol response. 
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To summarize the chloride secretory data, the investigated L'1F508 
homozygous CF inc1ivic1uals c1emonstrated impaired chloride secretory 
responses, however 40 out of 55 expressed resic1ual chloride conductance 
mediated by CFTR, with additional alternative chloride conductance in 11 of 
these 40 patients. Though all CF patients showed impalred Ca2 '-mediated 
chloride secretion comparec1 to controls, some nFS08 homozygotes exhibited 
a subnormal carbachol response. This subnormal CI- secretion c1ic1 in no 
case exceed 30% of the mean L'1Isc,Cl response to carbachol seen in non-CF 
patients. However, this c1egree of Ca2+ -activated residual chloride secretion 
was previously only described for pancreas sufficient patients with CF who 
carry at least one mild CFTR mutation.8 
The investigation of mono- and dizygous t.F508 homozygous pairs is the 
adequate approach to dissect the relative impact of environmental factors, 
residual chloride channel activity and other genetic factors on c1isease 
phenotype. Monozygous twins proved to be more concordant in their 
patterns of residual chloride conc1uctance than c1izygous pairs. These 
findings imply that the gene tic predisposition is more important for the 
expres sion of residual chloride secretion in the intestine than epigenetic 
factors. 
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Ta investigate impact of chloride secretion by residual activity of the cystic 
fibrasis transmembrane conduclance regulator (CFTR) and/or by alternative 
chloride channels on disease manifestation in respiratory and intestinal 
tracts, we determined chloride secretOly patterns in ó.F508 homozygous 
twins and siblings with cystic fibrosis (CF). We investigated most informative 
pairs that were either concordant for a mild or severe phenotype, or 
discordant in phenotype. In the majority of patients cAMP- and/or Ca2 '-
regulated chloride conductance was detected, i.e. 84% and 73% of patients 
exhibited chloride conductance in the ainvays and intestine, respectively. 
Our finding of cAMP~mediated chloride conductance suggests that in vivo, at 
least some nF508 CFTR can reach the plasma membrane and effect chloride 
secretion. In respirator)' tissue, the expression of basal CFTR-mediated 
chloride conductance demonstrated by 30% of nF508 homozygotes, and the 
response to a cAMP-agonist seen in 9% of patients, were identified as 
positive predictors for milder CF disease. In intestinal tissue 4,4'-
diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS}-insensitive CI- secretion, 
indicative of functional CFTR channels, segregated with milder phenotype 
whereas DIDS-sensitive chloride secretion was mainly observed in more 
severely affected patients. The more concordant chloride secretory patterns 
within monozygous twins compared to dizygous pairs imply, that genes other 
than nF508 CFTR significantly influence the manifestation of the basic 
defect. 
Introducflon 
Cystic fibrosis (CF) is the most common lethal autosomal recessive disease 
in the Caucasian population, with highly variabie manifestations in the 
pulmonary, gastrointestinal, hepatobiliruy and urogenital tracts. 1 It is 
caused by mutations in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene, which encodes a cAMP-regulated chloride channel,2·3 
that is located in the apical membrane of exocrine epithelia. The deletion of a 
phenylalanine residue at position 508 (nF508) is the most frequent of more 
than 900 known CFTR mutations and accounts worldwide for about 70% of 
all CF alleles. 4 •s 
The heterageneity of cystic fibrasis disease is partly explained by the braad 
spechum of different mutations. CFTR gene nlutations have been categorized 
by their resulting phenotype into six classes6 whereby nF508 CFTR has been 
assigned to class lIJ which indicates the protein fails to reach the eeU 
membrane to function as a chloride ehannel. This classifieation was based 
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on earlier experiments done in heterologous model systems and 
immunocytochemistry of patients' sweat glands, where deviant CFTR 
expression was found in AFS08 cells.7 ,B Since clinical presentation varies 
significantly between patients with the same CFTR genotype and between 
various affected organs within CF patients, it is evident that more factors 
than the CFTR genotype are involved in determining CF disease severity. In 
cftr -/- knockout mice, an alternative Ca2+-regulated chloride conductance 
was detected in the airways and pancreas and was suggested to ameliorate 
CF lung disease and protect the tissue from the absence of CFTR-mediated 
CI- conductance.9 In addition, Ca2+-activated chloride currents were observed 
in intestinal tissue of cftr-/- knockout mice with prolonged survival. lO 
The variabIe electrophysiological characteristics in human t-F508 CF 
respiratory and intestinal tissue, i.e. the different degrees of residual chloride 
secretion observed,1l-13 might be explained by these alternative Ca2 +-
regulated chloride channels. 14- 16 Furthermore, recent immunocytochemical 
studies on intestinal, respiratory and hepatobiliary epithelia of t-F508 
homozygous CF patients revealed that t-F508 CFTR may display apical 
distribution as is seen in con trol tissues, demonstrating that at least a 
portion of t-F508 CFTR can be targeted to the plasma membraneY·18 Hence, 
it is important to clarif'y whether this t-F508 CFTR is competent to transport 
chloride across epithelial membranes in vivo. 
In this study, we investigated the basic chloride secretory defect in CF twins 
and siblings homozygous for the t-F508 CFTR gene mutation in the most 
severely affected tissues in CF, the respiratOly and intestinal tracts. We 
determined the bioelectrical properties of these tissues with the nasal 
potential difference measurement (NPD) and the intestinal current 
measurement (lCM), respectively. These methods assess the cAMP and Ca2'-
induced chloride secretory pathways by adding specific secretagogues and 
inhibitors, via which the presence ofCFTR andjor alternative chloride 
conductances can be determined. By comparing the electrophysiological 
results to the phenotype in the specific tissues, the impact of residual 
chloride permeability on organ function could be analyzed. 
The investigation of AFS08 homozygous twins and siblings is the classical 
approach to analyze a monogenic disease like CF and differentiate the 
relative importance of the lnajor disease causing lesion and other genetic 
and epigenetic factors. 19,20 The disease causing mutation and the intragenic 
haplotype are standardized and the variation in genetic background is either 
reduced (dizygous pairs) 01' eliminated (monozygous twins). Thus, the 
inJluence of gene tic background and epigenetic factors on the genotype-
phenotype corre1ation could be examined more profoundly than in a cohort 





The investigated ö.F508 homozygous patient pairs were recruited from a set 
of 114 CF monozygous and dizygous pairs enrolled for the European Cystic 
Fibrosis Twin and Sibling Study. Out of these 228 "F508 homozygous 
patients, we invited 43 pairs and 4 triplets, i.e. 98 patients. Clinical 
assessrnent, as weIl as NPD and lCM measurements were carried out at CF 
clinics in Hannover (20 pairs), Innsbruck (6 pairs), London (5 pairs), 
Rotterdam (12 pairs) and Verona (4 pairs). Mono- or dizygosity of twins was 
ascertained by using the AmpFLSTR ProfiIer PIUS™ typing kit, analyzed on 
the AB! Prism 377 (perkin-Elmer Applied Biosystems)21 or by oligonucleotide 
fingerprinting of simple repeats applying in situ gel hybridization of Mbolor 
Hinfl genomic digests.22 Twelve ofthe 47 pairs were monozygous twin pairs. 
Clinicai data of the complete cohort of patients invited to participate in this 
studyare provided in Table 5.1. Patients were not experiencing an episode of 
allergie bronchopulmonary aspergillosis or taldng any systemic 
cOlticosteroids on the day of investigation, either of which could influence 
the performed measurements. In one pair liver disease was determined, and 
3 patients all belonging to different pairs were treated with insulin for 
diabetes mellitus. All participating patients were pancreatic insufficient as 
was ascertained by the stool elastase test. Performed examinations were 
approved by the medical ethics committees of the local hospitals and by 
patients or parents by written informed consent. 
Toble 5.1 Median {inner quarliles: range] for clinical data of the recruited 43 pairs 
and 4 triplets In ~ 98 LlFS08 homozygous patients] 
dizygous pairs 
(n ::: 74 individualsl 
age [y) 13.8 [I 1.0 - 20.3; 5.4 - 39.3) 
wfh% 99.3 [91.2- 106.4; 74.7 - 133.2) 
fEVPerc 39.6 [16.0- 68.5; 0.0- 100.0) 
infrapair difference in : 
age [y) 2.6 [ 1.8 - 3.8; 0.0 - 15.6) 
wfh% 10.1 [5.8-15.0;0.4- 29.4) 
fEVPerc 30.3 [ I 1.8 - 54.6; 0.5 - 100.0) 
Assessrnellt of clinical phellotype 
monozygous pairs 
(n ::: 24 individualsJ 
12.1 [10.0-20.6; 8.8- 31.6[ 
91.5 [88.8-98.4; 78.9- 122.1) 
50.9 [20.5 - 78.4; 4. I - 92.0) 
3.2 [ 1.5- 8.1;0.0- 18.3) 
15.1 [11.0-26.6;2.8-52.7) 
In order to select the most extreme phenotypes of 114 patient pairs, the 
overall disease severity and intrapair discordance were quantified, as 
reported.23 I3riefly, apatient's nutritional status was characterized by the 
122 
Chlolide conductance, genetic background Qnd CF phenotype 
anthropometric parameter weight expressed as percentage of predicted 
weight for height (wfh%) using the data published by Prader et al24 . The 
pulmonary status was assessed by the forced expiratOly volume in Is 
(FEVI), expressed as predicted values (FEV1%pred) based on the formula by 
Knudson et al.25 FEVI %pred declines with age as expected for progressive 
lung disease in CF.26 Therefore, we employed age-specific percentiles for 
FEVI %pred (FEVPerc), calculated from the CF population data base 
published in the report of the European CF Registry,27 to correct for the age-
decline in FEVI %pred in our cohort (Chapter 3). Thus, wfh% and FEVPerc, 
two age-independent parameters most sensitive for course and prognasis, 
were evaluated to characterize CF disease severity in the two major afflicted 
organs in CF, i.e. the gastrointestinal and the respiratory tracts. Far ranking 
and selection of a patient pair composed of siblings i and j, the patienfs 
disease severity (Of 0, distance form origin) and the pair's intrapair 
discordance (DELTA) were dcfined from the rank numbers for wfh% (x;.j) and 
FEVPerc (y;.j) as defined by Equations 3.1 anel 3.2. 
These two terms describe the patient's disease severity Of 0 as a distance 
from the origin in the plot of Xi versus yi and the pair's intrapair discOl'dance 
DELTA as the distance between two data points representing the two siblings 
of the pair in the respective plot (Figure 3.2). 
A computer-assisted algorithm was employed to identify patient pairs 
composeel of two siblings with equally high wfh% and equally high FEVPerc 
(concordant/mildly affected; CON+), pairs consisting of two siblings with 
equally low wfh% and equally low FEVPerc (concordant/ severely affected; 
CON-) and patient palrs compriseel of one sibling with high wfh% and high 
FEVPerc and one sibling with low wfh% and low FEVPerc (discordant pairs; 
DIS). Other palrs were discriminated from these extreme phenotypes by the 
ranking algorithm, and excluded from the analyses describeel in this report. 
Nasal potential differenee 
The method of stuelying NPD has been adapted from a methoel deseribed 
previously,28 and measures Cl- and Na+ conductances as a potential 
differenee. In short, the referenee bridge was eonneeted to a small needIe (25 
gauge) inserted into the subcutaneous space of the forearm, which is iso-
electric with the submucosal space of the nasal epithelium, and was filled 
with saline solution. The exploring bridge was formed bya PE-90 tube 
positioned against the nasal turbinate to apply the different perfusion 
solutions. Both the reference bridge and the exploring catheter were 
connected to a high input resistance voltmeter via 4% agar-salt bridges and 
Ag/ AgCl electrodes. Transepithelial eleetric potential difference 
n1easurements were performed by positioning the exploring catheter under 
the inferior nasal turbinate using an otoscope to visualize the epitheliurn. 
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The basal PO was measured during perfusion of the nasal catheter 
(1.7mL/min) with a salt solution, and was found to be lumen-negative with 
respect to the submucosal reference electrode. The salt solution consisted of 
(mmol/L): NaCI (120), Na-gluconate (25), K-gluconate (5), NaH,PO .. (0.4), 
Na,HP04 (2.4). On the inferior turbinate, the spot with the maximal (most 
negative), stabie baseline PO was selected. This baseline PO demonstrated to 
be considerably more negative in CF patients than in non-CF individuals 
(Figure 5.1). At this site nasal potential differences were measured in 
response to superfusion with solutions of different ion compositions, or 
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Figure 5. 1 Nasal potential differenee measured upon superfusion of fhe nasal 
epithelium with amiloride (A mil). a solution in whieh chloride is substituted by 
glueonate (CJ--free), isoprenaline (Iso), and ATP(ATP). Registrations are given for (a) 
non·CF control. (b) CF patient without a gluconate or isoprenaline response. but with 
a response to ATP, (e) CF patient exhibiting residual chloride eonducfanee evoked 
by Cr-tree sofution and isoprenaline. 
First, the catheter was perfused with amiloride (lD·4), a blocker of epithelial 
Na+ channels (ENaC), thereby inhibiting the PO by eliminating the 
contribution of electrogenic sodium absorption.29 Ta determine the basal Cl-
conductance, chloride was substituted by gluconate in the solution 
containing amiloride. In con trol persons this causes a hyperpolarisation 
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(increased negativity) of the epithelium since it creates an increased driving 
force for Cl- diffusion toward the airway lumen. Subsequently, the beta-
adrenergic agonist isoprenaline (10-4) was added to the Cl--free solution 
containing amiloride, which induces cAMP-dependent chloride conductance 
and evaluates the presence of CFTR.'8 For the last perfusate, ATP (10-3) was 
added to the Cl--free solution containing amiloride and isoprenaline. ATP 
binds to purinergic receptors on the luminal surface, and byactivating 
phospholipase C and increasing intracellular Ca2 + it triggers the Ca2+-
mediated Cl- secretory pathway.3o All perfusion solutions were adjusted to 
pH 7.4. Superfusion of the nasal epithelium with the different perfusates 
was continued until a steady state was reached, or for at least 3 minutes. In 
eaeh patient nasal potential difference measurements were performed in left 
and right nostri!. The NPD tracing of the nostril with the highest Cl-
secretory responses, i.e. with the largest eapacity to transport chloride, was 
assesseel for the evaluations and calculations perfOl'med in this study. 
Tracings of patients with chronic rhinitis or a eold on the day of investigation 
were disearded from further evaluation. 
Intestinal CUlTent measurement in rectal biopsies 
The method used to study lCM has been elescribed previously.ll.12.31 It 
determines Na+ anel CI- fluxes in the intestinal epithelium as a change in 
short-circuit current (ö,Isc), Freshly obtained rectal suction biopsies were 
mounted in adapted micro-Ussing chambers with an aperture of 1.2 mm.31 
The tissue was perfused with Meyler buffer solution at 37°C (composition in 
mmoijL: Na+ 126.2; Cl' 114.3; HC03- 20.2; HP04'- 0.3; H,P04- 0.4; Hepes 
10; pH = 7.4) anel gassed with 95% 0, and 5% CO,. Basal transepithelial 
resistance was determined by the voltage response to pulse currents of 1 pA 
and applying Ohm's law. Basal Isc prior to voltage clamping was calculated 
from the basal transepithelial resistance and the open-circuit transepithelial 
potential difference. Subsequently, the tissue was short-circuited by voltage-
clamps for the course of the experiment. For cell metabolism glucose (10-2 
moljL) was given both mucosally and serosally. After equilibration, 
pharmaceuticals (moljL) were aeleled in a standardized order to the mucosal 
(M) andjor serosal (S) side: a) amiloriele (10-4, M)'9;b) indomethacin (10'5, 
M+S), to reduce basal Cl- secretion by inhibiting the endogenous 
prostaglandin formation3'; c) carbachol (10'4, Sj, to initiate the cholinergic 
Ca'+-linked Cl- secretion33; el) forskolin (10-5, M+Sj34 together with 8-bromo-
cAMP (10'3, M+S), to open cAMP-depenelent Cl- channels, like CFTR and the 
ORCC35; e) 4,4'-diisothiocyanatostilbene-2,2'-elisulfonic acid (DIDS, 2.10-4, 
M), to inhibit DIDS-sensitive CI- transporters like the Ca'+ -elependent Cl' 
channels and the ORCC14,15,35; f) histamine (5.10-4, SJ, to reactivate the Ca2+-
dependent chloride secretory pathway.36 Two rectal biopsies were obtained 
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for all patients participating in the intestinal current measurements. The 
lCM tracing belonging to the biopsy with the highest chloride secretory 
responses was inc1uded in the performed computations. All drugs for NPD 
and lCM measurements were obtained from Sigma Chemical Co., St. Louis, 
MO, USA. 
Intelpretation of lCM patterns 
By using the above mentioned lCM protocol, at least six different lCM 
patterns could be observed in tracings from CF individuals (Figure 5.2). To 
quantify the CI- secretory responses to carbachol and histamine the net 
change in !sc was defined as the sum of the negative downward peak below 
baseline, and the positive upward peak above baseline in the chloride 
secretory direction. A net negative response points to no or Httle residual CI-
secretion, while a net positive change in Isc indicates high residual CI-
secretion. The influence of DIDS on chloride secretion was determined by 
comparing the net chloride secretory response to carbachol before the 
addition of DIDS, to the net chloride secretory response to histamine aftel' 
the incubation with DIOS." Figure 5.2a shows the lCM tracing of a typica! 
CF patient lacking any type of residua! chloride secretion. Carbachol and 
histamine peaks are in the reverse direction to control, which is interpreted 
as apical K+ secretion37 unmasked in the absence of CI- secretion. These 
patients lack responsiveness to cAMP~analogues as weil. CF patients with 
different degrees of DIDS~insensitive residu al chloride secretion are depicted 
in Figures 5.2b, c and d. The presence of small amounts of DIDS~insensitive 
chloride secretion is only detected by 8-bromo-cAMP + forskolin (Figure 
5.2b), since this is a more sensitive indicator for cAMP~mediated chloride 
secretion than carbachol or histamine. 11,12 In tissues with higher degrees of 
chloride conductance carbachol and histamine evoke chloride secretory 
responses as weIl, ranging from responses that are composed of a peak in 
the reversed direction followed by a small change in Isc in the chloride 
secretory direction (Figure 5.2c), to responses that consist purely of a 
subnorma! chloride secretory peak (Figure 5.2d). DIOS-sensitive residual 
chloride secretion was characterized by an lCM pattern as in Figure 5.2e or 
f, with a component in the chloride secretory direction in response to 
carbachol, whieh is not recurring in the histamine response since it is 
inhibited by the presence of DIOS. 
Statistical analysis 
The statistical analyses of our re su lts were performed using the Mann~ 
Whitney U~test, t~test for grouped pairs, Fisher's exact test, F test, or 
Spearman~test. P values smaller or equal to 0.05 were considered 
statistically significant. 
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Figure 5.2 Sketches of lCM response patterns observed in &508 homozygous CF 
patients, upon the addition of carbachol (C). 8-bromo-cAMP + forskolin (cA), DIDS 
(0), and histamine (H). A down word, reversed peak upon addition of carbachol or 
histamine is indicative of K+ efflux, while on upward peak corresponds fa chloride 
secre/ion. (a) No response in the chloride secretory direction to any of /he applied 
compounds. (b) cAMP-mediated residual chloride secretion only evoked by cAMP + 
forskolin. (c-d) DIDS-insensitive residual chloride secretion in the presence of 0 cAMP 
response. (e-f) DIDS-sensitive residuol chloride secretion in the presence of 0 cAMP 
response. 
Results 
According to the ranking algorithm on wfh% and FEVPerc, 29 of the 47 
l'lF508 homozygous CF sibling pairs were categorized into one of the extreme 
phenotypes DIS, CON+ and CON- (see Methods section). Due to various 
reasons, electrophysiological data from NPD and/or lCM measurements were 
not obtained for all of these 29 pairs. Local medical ethical committees of 
some centers did not allow lCM measurements in minors, or prohibited a 
second lCM investigation if the first attempt had failed. Additionally, a 




Table 5.2 Mean [range} for clinical data of pairs ronked DIS. CON+ and CON- for 
whieh NPD data was obtained for bath siblinqs 
CON+ 
(6 pairs) 











19.9{ 7.&- 38.8{ 
95.4{74.7-122.81 
41.7{ 4.1-100.01 
oge{y{ 1.9{ 0.0- 5.51 2.1{0.0- 5.51 2.7{0.0- 5.5{ 
wfh% 13.0{ 0.4-27.71 5.I{1.4-12.1{ 15.5{3.3- 29.41 
FEVPerc 21.4fl1.3-34.8J 11.9fO.5-21.81 50.8[3.2-100.01 
DIS DIS 
mild/y severely 
affec/ed sfb offecfed sfb 






NOTE. The resulfs obtaÎned by NPD tor fhese pairs are disployed in Fîgures 5.30 and b. 
Table5.3 Mean [range} for clinical data of pairs ranked DIS, CON+ and CON- for 
whieh lCM data was obtained for at least one of bath siblinqs 
CON+ 
(5 pairs) 





t J J pairs) 
13.0{ 7.2- 20.51 
90.4{77.5-109.31 
36.6{ 4.1- 92.01 
DIS 
(9 pairs) 
20.0{ 7.6- 39.31 
95.3{74.7-122.81 
43.8 { 4.1-100.01 
oge{y{ 1.9 { 0.0- 5.51 1.4{0.0- 5.51 2.8{0.0- 5.5{ 
Y~h% 10.3{ 0.4-18.3{ 7.3{0.0-23.81 14.7{3.2- 29.41 
FEVPerc 19.2111.0-34.81 17.2[0.5-52.61 52.313.2-100.01 
DIS DIS 
mildly severely 
affecled sfb offecfed sfb 





20.5{ 4.1- 41.11 
NOTE. The re5ults obfained by lCM for these pairs are displayed in Figures 5.4 and 5.5. 
Finally, NPD tracings of patients with respiratory inflammation were not 
included in the analysis, and lCM responses to carbachol or histamine that 
were not interpretable owing to technical irregularities during the 
experiment, e.g. air in the connecting bridges or electrical disturbances, were 
discarded [rom further evaluations. Thus, we did not obtain 
electrophysiological data for all of the 29 pairs who were assigned to one of 
the extreme phenotypes DIS, CON+, or CON-. Ta avoid the loss of data 
points we first evaluated NPD and lCM results independently and used all 
valid data for interpretations. Tables 5.2 and 5.3 summarize absolute values 
and intrapair differences of age, wfh% and FEVPerc in pairs with valid NPD 
tracings obtained for both siblings (Tabie 5.2), and for the pairs of which 
valid lCM tracings were obtained for at least one of the two siblings (Tabie 
5.3). 
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NasaZ potentiaZ difference 
In our group of "'F508 homozygous patients with a mean age of 16.3 ± 8.5 
years (range 4.2 - 39.3 yrs), the absolute age or the intrapair difference in 
age, as weIl as the gender of individuals was not associated with different 
outcome in NPD measurements. Hence, differential NPD responses could not 
be ascribed to age or sex. 
The basal PO measured in 57 individuaIs belonging to dizygous sibling pairs 
was -56.0 ± 10.1 mV and the decrease in PD in response to amiloride was 
28.0 ± 8.9 mV (Tabie 5.4). In 17 patients belonging to monozygous twin pairs 
the basal PO was -57.0 ± 8.8 mV, while the amiloride response was 27.4 ± 
7.9 mV. Eighteen individuaIs belonging to a dizygous sibling pair exhibited 
small amounts of basal CI- conductance measured by the superfusion with a 
CI--free solution (Tabie 5.4), while 5 persons demonstrated CI- conductance 
initiated by the addition of isoprenaline, and 45 patients reacted to the 
addition of ATP. The PD of individuals of monozygous twin pairs increased in 
response to superfusion with Cl--free solution in 4 patients, while increases 
were seen in 2 individuals when isoprenaline was added, and in 10 persons 
upon addition of ATP. 
The distribution of PO responses was independent of zygosity status (Tabie 
5.4). 
To assess the correlation between the basic defect and the phenotype in the 
respiratory tissue, NPD results measured within the 3 subgroups of extreme 
phenotypes, discordant (DIS), concordant mild (CON+), and concordant 
severe (CON-), were compared to the FEVI %predicted percentiles. 
The lung functions of 8 discordant sib pairs were plotted against their 
responses to superfusion with CI--free solution (Figure 5.3a). The sibs with 
the better lung function parameters demonstrated significantly higher (more 
negative) gluconate responses than their paired siblings (t-test for grouped 
pairs, P < 0.05) and, moreover, also possessed the better weight for height 
parameter of the two siblings (data not shown). When the lung function of 
patients belonging to CON+ and CON- pairs was plotted agalnst their 
gluconate responses all persons (except one) with a gluconate response, i.e. 
increased negativity, appeared to belong to concordant mild pairs (Figure 
5.3b). The presence of this CI- secretOly response upon addition of gluconate 
was significantly associated with the concordant mild (CON+) phenotype 
(Fisher's exact test, P ~ 0.036). Only one patient belonging to a CON- pair 
showed a gluconate response. Similarly, responses to isoprenaline were not 
observed in severely affected patients, i.e. patients of CON- pairs or the 
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Figure 5.3 (a) FEV, %predicted percentiIe versus the change in NPO upon addition of 
a U-free so/ution (g/uconate substituted for eh/aride) for 8 pairs that were discordant 
for the FEVPerc parameter. /ndividua/ sibs are indicated by triang/es, sib pairs are 
connected by a line. The sib with the higher (more negative) response to g/uconate 
within a pair, was a/sa the sib with the higher /ung funcfion (P < 0.05, Student's t test 
for grouped pairs). (b) FEVPerc versus the g/uconate response for 6 pairs who were 
ranked as concordantjmild/y affected pairs (CON+, .) and 6 pairs who were ranked 
as concordanf/severe/y affected pairs (CON-, 0). A hyperpo/arisation of the PO in 
response to gfuconate, pointing to the presence of chloride conductance, 
segregated with the CON+ pairs (P = 0.00 1. Fisher's exact test). 
Potients in Fig. 5.3a DIS CON+ CON 
pairs, dizygous 7 
Qairs monoz',iQous I 
data points: 16 EJ6 
Patients in Fig. 5.3b DIS CON+ CON-
pairs, dizygous 4 5 
Qairs, monoz',iQous 2 1 
data points: 12 12 "24 
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The hyperpolarisation (increased negativity) of PD seen in 55 of the 74 
patients in response to perfusion of the nasal epithelium with ATP did not 
show any associations with lung function. 
The substantiation of the observed associations between NPD values and 
phenotype was given by the following results. For each pair, the NPD values 
of the individual sibs of a pair were added, corresponding to PDsibA + PDsibB 
in the case of the basal PD, and f,PDsibA + f,PDsibB for the responses to the 
different solutions applied to the nasal epithelium (TabIe 5.5). Summations 
calculated for the concordant mild pairs, were balanced against those of the 
concordant severe pairs (TabIe 5.5). The intrapalr summations for the basal 
PDs of the concordant mild sibs were less negative than those in the 
concordant severe couples (-101.7 ± 18.2 vs -114.8 ± 12.9), however this was 
not significant (Mann-Whitney U-test, P < 0.10, Table 5.5). The f,PDsibA + 
ilPDsibB values for the gluconate responses were significantly more negative 
for the concordant mild pairs (P < 0.05), whiIe f,PDsibA + f,PDsibB values for 
the amiloride and ATP responses were not different between concordant mild 
and concordant severe pairs. The .ó.PDsibA + .ó.PDsibB values for the 
isoprenaline responses within CON+ and CON- pairs were not significantly 
different, most likely due to the lack of a response in most investigated 
individuals and the smaIl magnitude of responses in patients who did 
respond to isoprenaline. However, ilPDsibA + APDsibB for isoprenaline was 
negative in the concordant mild couples (-1.3 ± 2.4) and positive in the 
concordant severe couples (0.5 ± 0.8, also see above: no chloride 
conductance induced by isoprenaline in siblings of CON- pairs). 
To analyze the intrapair concordance in NPD values of monozygous pairs 
versus dizygous pairs, intrapair differences \Vere calculated byabsolute 
values I PDsibA - PDsibBI for the basal PD, and by I L\PDsibA - f,PDsibBI for 
responses to applied substances (TabIe 5.6). Monozygous twins (5.0 ± 3.4 
mV) were more concordant than dizygous pairs (11.4 ± 8.3 mV, P < 0.05, 
Table 5.6) in baseline PD, but not any otber parameter. 
IntestinaZ CUlTent measurement 
To assess the impact of intestinal residual chloride secretion on clinical 
outcome, responses to the application of carbachol and histamine and the 
influence of DIDS on CI- secretOly responses, were compared in the CON+, 
CON- and DIS groups (Figure 5.4a). Carbachol responses within the mildly 
affected sibs, i.e. sibs belonging to CON+ pairs or the better sibs of DIS pairs, 
were not different from those in CON- pairs, or the sicker sibs of DIS pairs. 
Histamine responses, however, were less negative in the mildly affected sibs, 
which was significant when sibs of CON+ and CON- palrs were compared (P 
= 0.05, Mann-Whitney U-test, Figure 5.4b). In addition, the difference in 
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Table 5.4 Means ± SO for NPO values for the group of individuals belonging /0 
d' 'bi' Izygous or monozygous s/ mg pairs 
Dizygofes Monozygotes 
PO or "'PO n PO or "PO n 
[mV] [mV] 
Tofal investigated 72 26 
Qroup 
No pafienf 4 2 
cooperation 
(Chronic) rhinilis II 7 
Basol PO -56.0 + 10.1 57 -57.0 + 8.8 17 
Amiloride 28.0 + 8.9 57 [100% 27.4 + 7.9 17 (100%) 
Glucona!e (Cl -free) -5.9 + 2.8 18(32%) -6.3 + 3.9 4(24%) 
lsoprenaline -2.6 + 1.5 5(9%) -2.5 ± 0.7 2(12%) 
ATP -4.3 ± 2.4 45 [79%) -4.8 ± 3.9 10 (59%) 
Table 5.5 In/rapair summations for /he NPO values of sib A and sib B, calcula/ed far 
/he CON+ and CON pairs -
CON+ CON- CON+vs 
(6 pairs) (6 poirs) CON-
Mean±SD Range Mean±SD Range p-value 
PDslbA + PDsibB 
Basal PO -101.7± 18.2 -132 -79 -114.8± 12.9 -136 -100 0.07 
APDslbA + L\PDslbll 
Amiloride 53.7 ± !3.3 42 78 55.0 ± 18.3 24 78 0.35 
Glucana!e (U-free) 5.7 ± 6.0 -!2 4 -0.7 ± 2.2 5 ! 0.05 
Isoprenaline -1.3±2.4 5 I 0.5 ±0.8 0 2 0.16 
ATP -6.7 ± 2.4 II -4 -6.5 ± 4.7 -14 0 0.53 
NOTE. Compansons befween CON+ and CON- data were onalyzed by fhe Mann-Whltney U-
fest. 
Table 5.6 In/rapair differences of dizygaus and monozygous pairs for /he ob/ained 
NPO values 
Dizygous Monozygo DI vs 
pairs ~s pairs MONO 
(29 pairs) 6 pairs) 
Meon±SD Range Mean±SD Range P-value 
( PdslbA - PDslb,( 
Basal PD 11.4 ± 8.3 38-0 5.0 ± 3.4 10- I 0.D2 
("PDslbA - APdslb,( 
Amiloride 10.3 ± 8.4 34-0 6.7 ± 6.0 16-0 0.17 
Glucana!e (CI--free) 2.6± 3.2 12-0 2.8±3.1 8-0 0.33 
Isoprenaline 0.4 ± 0.8 3-0 0.7 ± 0.8 2 0 0.18 
ATP 2.6± 2.3 10 0 1.2 ± 1.9 5 0 0.06 
NOTE. Compansons between dlzygous ond monozygous data were analyzed by the Mann-
Whitney U-test. 
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carbachol and histamine responses due to the presence of DIDS was 
significantly different, both when CON+ and CON- sibs were compared (P < 
0.01) or when DIS+ and DIS- sibs were compared (P ~ 0.05, Figure 5.4c). 
Additionally, weight for height percentage was positively correlated to the 
magnitude of the DIDS influence on Cl' secretion (P ~ 0.02, Figure 5.5, 
Spearman's rank test). 
As previously reported, 12 monozygous twins were more concordant in their 
lCM patterns than the dizygous pairs, which was significant in the case of 
the cAMP-stimulated chloride secretory responses (Mann-Whitney U-test, P < 
0.001), the histamine responses (P< 0.05), and the influence ofDIDS on the 
chloride secretory responses (P < 0.025). 
Nasal patennal difference and intestitwZ cunent measurement 
To assess differences andj or similarities in the presence and magnitude of 
residual CI- secretion between respiratory and intestinal tissues, the NPD 
results were compared to the lCM results. The presence of a gluconate 
response did not segregate with the presence of a chloride secretOly 
component in the carbachol andj or histamine response, and there were no 
significant correlations between the amplitude of the gluconate response 
versus the amplitudes of the carbachol and histamine responses (Figures 
5.6a and b). However, in this preselected cohort of extreme phenotypes, the 
presence of a gluconate response in the respiratOly tissue and a positive 
DIDS influence in the intestinal tissue segregated with milder phenotype 
(Fisher's exact test, P ~ 0.01). Moreover, the magnitude of the gluconate 
response related to the magnitude of the DlDS influence on CI- secretion 
(Spearman's rank test, reaching the limit of significance, Figure 5.6c). 
DIscussion 
The observation that disease manifestations in cystic fibrosis are highly 
heterogeneous even in patients with the same CFTR mutation genotype 
indicates that factors other than the CFTR gene itself contribute to the 
course of CF disease. The approach of the European CF Twin and Sibling 
Study of investigating mono- and dizygous LlF508 homozygous pairs with the 
extreme CF phenotypes, is the optimal scenario to investigate the relative 
impact of environmental factors and/or inherited factors besides the CFTR 
gene, that influence the CF phenotype. 19,20,38-40 CF twins and siblings share 
many environmental factors that are major determinants of CF disease 
severity, e.g. the physician, therapeutic regime, living conditions, and the 
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Figure 5.4 (see previous page) Net /'e responses to earbaehol and histamine and the 
inl/uenee of 0/05 on the chloride seeretory response. given for the whole group (aJ/). 
and for the sibs belonging to CON+, CON-. or DIS pairs. For the CON+ and CON-
pairs, individuals were eounted when only one sib of a pair had a data en try, while 
the mean of both sibs was incJuded when both sibs had a data entry. For the DIS 
pairs, data are eompared between the cJinieaJ/y better (015+) and worse (015-) 
siblings. Comparison of mildly and severely affecled sibs and pairs was performed by 
Mann Whitney rank tests, as shown in the foJ/owing Tabie: 
lCM Mildlyollecled Severelyaffected P-value ~arameter sibs and ~airs n sibs and~airs n 
Carbachol CON+ 5 CON- la ns 
Histamine CON+ 5 CON- la 0.05 
olDS influence CON+ 5 CON- 9 0.001 < P < 0.01 
Carbadlol DIS+ 9 DIS- 8 ns 
Histamine DIS+ 5 DIS- 8 0.177 
DrOS influence DIS+ 5 DIS- 8 0.047 
Carbachol CON+ & DIS+ 14 CON- & DIS- 18 0.025 < P < 0.05 
Histamine CON+ & DIS+ JO CON- & DIS- 18 0.01 < P < 0.025 
Dl OS influence CON+ & DIS+ JO CON- & DIS- J7 0.001 < P < om 
By investigating nF508 homozygotes the major disease causing lesion of the 
CFTR gene was standardized. Apart from their identical CFTR mutation 
genotype, and an identical region around the CFTR gene locus, dizygous 
twins and siblings share on the average half of their genes, which reduces 
differences in genetic background. The intrapair variation among 
monozygous twins, who are genetically identical for their entire genome, can 
be used to delineate the influence of the environment on a trait by 
comparing the intrapair variability among monozygous pairs to that of 
dizygous pairs. 
In this study we tested the hypothesis whether the basic defect in CF, which 
presents itself as aberrant chloride conductance properties, is predictive for 
the clinical outcome in CF, and if the manifestation of the basic defect is 
substantially determined by inherited factors apart from the CFTR gene. 
Therefore, we investigated the bioelectrical properties of the respiratOly and 
intestinal epithelium that normally express CFTR, by applying the nasal 
potential difference measurement and intestinal current measurement, 
respectively. The influence of residual chloride secretion on clinical CF 
phenotype in the specific organs was evaluated by determining the presence 
and origin of residual chloride conductance in subgroups of nF508 
homozygous CF twin and sib pairs with disparate manifestation of CF 
disease. These individuals with the most extreme clinical parameters are 
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Figure 5.5 Weight lor height %predicted plotled against the inlluence ol DIDS on the 
chloride secretory response. calculated as the difference between the carbachol 
response belare the incubation ol the tissue with DIDS. and the histamine response in 
the presence ol DIDS. Values are plotted lor sibs ol CON+ pairs (.). CON- pairs (o). 
and the mildly aflected (DIS+. ~ ) and severely affected (DIS-. ll) sibs ol DIS pairs. All 
CON+ and DIS+ siblings but one. exhibited either just a small negative or even a 
positive influence ol DIDS. meaning that DIDS did not inhibit chloride secretion in 
these individuals. In contrast. DIDS inhibited the chloride secretory response in the 
CON- and DIS- sibs. which resulted in a negative DIDS influence (P ~ 0.03. Fisher's 
exact test). Moreover. weight lor height %predicted correlated with the DIDS 
influence (P < 0.025. Spearman test). 
Polienls in fig. 5.5 DIS CON+ CON 
pairs, dizygous 5 1 2 
pairs, monozygous 2 
individuals, dizygous 2 3 4 
individuals, monoli90us 1 1 1 
data points: 13 6 13 L32 
Potienfs in Fig. 5.60 DIS CON+ CON· 
pairs, dizygous 4 2 3 
pairs, monozygous 1 1 I 
individuals, dizygous 4 2 3 
individuals monozygous 3 
dato points: 14 8 14 '36 
Palienls in Fig. 5.6b DIS CON+ CON~ 
pairs, dizygous 3 3 
pairs. monozygous 1 
individuals, dizygous 3 4 3 
individuals, monOliQOUS 1 I 1 
dala points: 10 5 12 '27 
Palienls in Fig. 5.6c DIS CON+ CON 
pairs, dizygous 3 2 
pairs, monozygous 1 
individuals, dizygous 3 4 3 
individuals, monoI)"Qous I I 1 
data points: 10 5 10 ~25 
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Figure 5.6 Chloride conductance in respira10ry tissue measured by the gluconate 
response, compared ta chloride secretion in intestinol tissue. Values are given for 
individuals belonging to CON+ (.) and CON· (0) pairs, and lor DIS+ sibs (.) and DIS-
sibs ("'j, The gluconate response measured in NPD plotted versus the chloride 
secretory response measured in lCM, upon the addition ol (a) carbachol or (b) 
histamine, and (c) versus the influence on chloride secretion exerted by DIDS, Whi/e 
the gluconate response did not corre/ate with carbachol or histamine responses, the 
magnitude of the gluconate response was associated with the magnitude of the 
DIDS influence (rs ~ 0.31, n.s, trend, 0,05 < a (rs) < 0.1 j, A negative gluconate response 
pointing to chloride conductance in combination with a positive DIDS influence 
segregated with the CON+ and DIS+ sibs (P ~ 0,01, Fisher's exact testj, 
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This report and Dur earlier reports on intestinal chloride secretions,1l,12 
demonstrate that many of the LlF508 homozygous CF individuals express 
same residual chloride channel activity in bath respiratOly and intestinal 
tract. In those patients with apparent cAMP-mediated chloride secretion, Le. 
an isoprenaline response andj or a DIDS-insensitive chloride secretory 
response, the molecular entity is most Iikely CFTR, indicating the presence 
of functional LlF508 CF'TR in the apical membranes of the epithelial cells in 
these afgans. On the basis of studies in heterologous expression systems,7,8 
the LlF508 CFTR gene mutation is considered as a processing defect by 
reduced glycosylation and consequent misfolding of the CF'TR protein, which 
prevents the protein ta reach the plasma membrane and retains it in the 
endoplasmie reticulum. However, the expression of AFS08 CFTR in vivo 
might be different. Irnmunohistochemical studies performed on airway, 
intestinal and hepatobilimy tissues,17,18,41,42 demonstrated ~F508 CFTR 
localization in the plasma membrane. Moreover, functional assays on 
transfected cells,43 in mice,44,4s and on human tissue specimens18 have 
shown that nF508 CF'TR is capable of transporting chloride in response to 
cAMP-agonists. Oul' in vivo and ex vivo studies show that respiratOly and 
intestinal tissues from ~F508 CFTR homozygous individuals are competent 
to respond to agonists of the cAMP-dependent chloride secretory pathway, 
which is the hallmark of CFTR-mediated chloride transport. 2•3 Nonetheless, 
the magnitude of this detected chloride permeability is insufficient to prevent 
manifestation of CF disease. 
The results of our study demonstrate a segregation of better lung function 
with less anomalous bioelectrical properties of the nasal epithelium in the 
investigated LlF508 homozygotes. The respiratory epithelium of healthier CF 
patients appears to be less CI--impermeable (Figm'es 5.3a and b). Moreover, 
the presence of basal chloride conductance and the capacity to secrete 
chloride in response to a cAMP-agonist, determined by perfusion of the nasal 
epithelium with a Cl--free solution and isoprenaline, respectivelYJ were only 
present in mildly affected patients (TabIe 5.4 and Figure 5.3). This suggests 
that the expres sion of basal chloride conductance andf or residual cAMP-
mediated chloride secretion has a beneficial influence on respiratOly tissue 
function, most likely by increasing the hydration of the viscous ainvay 
surface mucus and increasing its clearance from the respiratory tract. These 
data in ~F508 homozygous twins and sibs substantiate the findings in an 
earlier study in CF individuals with different CFTR mutation genotypes in 
whom residual chloride secretion provided a better indication of lung 
function than genotype. 13 In contrast, the chloride conductance in the 
amiloride-pretreated nasal epithelium that is mediated by apical purinergic 
receptors and a subsequent increase of intracellular Ca2+,30 was not 
associated with a better preservation of tissue function (P ~ 0.53, Table 5.5). 
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Similarly, the Na+ absorption as inferred from the amiloride response was 
not related to CF disease severity. 
In our group of investigated AFS08 homozygous individuals, the activation of 
Cl~ conductance by isoprenaline was not different in females and males, 
which has been reported for CF adults.46 This might be due to the large 
number of non-responders to isoprenaline in our investigations, as expected 
in a CF cohort of öF508 homozygotes representative for all ages. 28 
Although residual chloride secretion only presented in the subgroup of 
individuals with better respiratOly function, few patients without chloride 
conductance possessed a relatively good lung function (above the 50th 
percentiIe, Figure 5.3b). This indicates that the presence of residual chloride 
secretion is not the only determinant of respiratOly function, and evidently 
additional factors unrelated to the basic ion transport defect are involved in 
CF airway performance. 
In summa!}', only the expres sion of basal Cl- conductance and the response 
to isoprenaline were predictive for disease outcome in our cohort of AFS08 
homozygous sib and twin pairs. 
In the intestinal tissue, the CFTR-related DIDS-insensitive chloride secretion 
was predominantly seen in the mildly affected patients (Figures 5.4 and 5.5). 
Whereas the Ca2 +-dependent CI- secretion in respiratory tissue showed no 
association with outcome, the DIDS-sensitive Ca2 +-dependent chloride 
transport pathway was more frequently observed in severely affected AFS08 
homozygotes. This data is supported bya study of the bilialy tract which 
detected the highest levels of Ca2 '-dependent chloride currents in the most 
dedifferentiated tissue samples. IB Hence, either this alternative CI-
conductance is not beneficial per se, or it is only up-regulated in the absence 
of CFTR-activity to compensate for the lack of CFTR-mediated Cl- transport. 
The latter condition of Ca2 + -activated Cl- channel function has been 
demonstrated to be beneficial for tissue function in cft,. -j- knockout mice, 
which lack cAMP-induced chloride currents. lO 
Although all subjects were homozygous for the same CFTR mutation, CF was 
found to be heterogeneous even at the level of the basic celluiar defect, 
which should reflect the closest link with the underlying genetic lesion. 
However, the consistent phenotype of CFTR expression in respiratOly and 
intestinal traets of a öF508 homozygous CF patient (Figure 5.5), suggests 
that within one person similar corrective mechanisms lead to maturation, 
processing and residual funetion of öF508 CFTR in the major affected organs 
in cystic fibrosis disease. Furthermore, monozygous twins proved to be 
significantly more concordant in the electrophysiological proper ties of their 
epithelium than dizygous palrs, especially in the intestinal traet. These 
findings imply that the genetic predisposition is important for the expression 
of residual chloride secretion. 
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We conc1ude that the ability to secrete chloride in t.F508 homozygous 
patients in the organs mainly involved in the course of CF disease is 
predictive for CF phenotype. Basal chloride conductance andj or a cAMP-
mediated response in the ainvays together with DIDS-insensitive residual 
chloride secretion in the intestine were associated with a positive outcome in 
t.F508 homozygous CF individuals. Thus, although homozygosity for the 
major disease-causing les ion was not predictive for disease manifestation 
and showed a large range of disease severity, the expression of the basic 
defect was associated with clinical outcome. Clinicians are encouraged not 
only ta use the sweat test, which is non-informative for outcome among 
t.F508 homozygous patients, but also to apply the NPD and lCM as 
predictive measures for disease and prognosis and - possibly in the future -
for stratification of clinical trials and treatment of CF disease. 
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Knowledge about genotype/phenotype cOlTelations for cystic fibrosis (CF)-
causing CFTR mutations other than tlFS08 is scarce due to the low incidence 
of homozygous index cases. This study reports on the rnanifestations of CF 
in homozygotes for the ffiissense mutation E92K, the stop mutations R553X, 
R1162X, the splice mutations 1898+3 A-G, 3849+lOkb C-T, the novel 
deletions CFTRdele2, CFTRdele2,3(21kb) and in carriers for the complex 
alleles "'F508-R553Q and "'F508-VI2121. The basic defect was assessed by 
sweat test, nasal potential difference and intestinal current measurement. 
Residual CFTR activity was necessary to confer lawer sweat e1ectrolyte 
concentrations or exocrine pancreatie sufficiency. Irrespective of the 
underlying genotype each patient exhibited sorne chloride conductance in 
the airways and/ or in the intestine which was identified by the differential 
response to cAMP and DlDS as being caused by CFTR or at least two other 
chloride conductances. The expression of alternative chloride channels sueh 
as the calcium activatable or the outwardly rectifying chloride channels may 
partially compensate defective CFTR and modulate the manifestation of 
respiratory and gastrointestinal disease in CF. 
Introduction 
Cystic fibrosis (CF) is a disease of all exocrine glands and is caused by 
mutations in the S;;ystic Eibrosis Iransmembrane Conductanee Regulator 
(CFTR) gene.' CFTR localized in the apical membrane of epithelial cells is a 
multifunctional protein which confers cAMP-activatable chloride ion 
transport and regulates the activity of numerous other transport systems. 
More than 800 CF-causing lesions have been identified (Cystic Fibrosis 
Genetic Analysis Consortium, 1999, pers. commun.), ofwhich the major 
mutation ~F508 accounts worldwide for 70% of disease alleles. 2 
Naturally occurring mutations are a guide to dissecting the features of a 
gene product. The phenotypes of most CFTR mutations other than ,.,F508 
have been investigated in hetero10gous expression systems rather than by in 
vivo or ex vivo analysis of patients( material, because al most all patients with 
CF are either homozygous for ~F508 or compound heterozygous for two 
different CFTR mutations. Reagents and methads are not available to 
differentiate the two mutant CFTR proteins in most compound heterozygotes 
but, even at the transcriptionallevel, the investigation of compound 
heterozygous individuals does not provide unequivocal information about the 
phenotype of a particular mutation in vivo, because stability and processing 
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of mRNAs transcribed from the two CFTR alleles does not occur 
independently from each other.3 
This report describes the clinical manifestation and the basic defect of 
individuals with CF who are homozygous for non-AF508 CFTR mutations. 
These rare index cases were considered to be most informative in order to 
address the complex issue of genotypejphenotype correlations, in particular 
the association between CFTR mutation and defective chloride transport, the 
abnormality which hallmarks affected patients' tissues. 4 -6 The apriori most 
severe and mildest CF-causing mutations are overrepresented in the cohort. 
Expression of functional CFTR was expected to vary between zero in patients 
who harbour two CFTR null alleles, and significant amounts ofwild type 
CFTR in patients who are homozygous for mild splice-site mutations. The 
patients' defective chloride transport across the apical membrane of 
epithelial cells was measured by physiological assays employed when 
diagnosing CF, i.e. the Gibson-Cooke pilocarpine iontophoresis sweat test,? 
the nasal potential difference (NPD}8 and intestinal current measurements 
(ICM).9.10 The investigation of the basic defect in the individuaIs with 
complex alleles or rare homozygous CFTR genotypes uncovered multiple 
origins of apical chloride conductance in the affected epi th elia in vivo, such 
as residual CFTR activity or the expres sion of alternative cAMP- or Ca2+-
activated transport systems. 
Palienls and Melhods 
Subjects 
The index cases were selected from CF centers in the Czech Republic, 
Germany and Italy. The recruîted patients are either homozygous for a non-
.6.F508 CFTR mutation or carry a second sequence variation on one AF508 
CFTR alleie. Complete records since age at diagnosis were available for all 
participants of the study and each patient has been regularly seen byat 
least one of the authors. 
Informed consent was obtained from all patients and in the case of patients 
younger than 18 yeal's of age from at least one parental guide. The study 
was approved by the ethics committee of the Medizinische Hochschule 
Hannover. 
The clinical examination at the day of assessment followed the guidelines 
defined at the workshop "Genotypejphenotype correlations in cystic fibrosis" 
held in Hannover, March 5-6, 1994. 11 The standardized questionnaire and 
examination form include family anamnesis, patient's history and the acute 
anamnesis (symptoms, CUlTent treatment, problems and complications 
during the last year), a physical examination, documentation of meconium 
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ileus, meconium ileus equivalent, hepatobiliary disease, diabetes mellitus, 
fertility, other diseases, anthropomehy (height, weight and the derived 
parameters ,body mass index" ,centiles for height and weight' and ,weight for 
height percentage', stage of puberty and onset of menarche if applicabIe), 
determination of pancreatic elastase in stool as an index for the exocrine 
pancreatie status, a lung function test (flow-volume curve, foreed vital 
capacity FVC and fOl·ced expiratory volume in 1 s FEVI given in %predicted 
according to Knudson et al 12), bacteriology of sputum or deep throat swab, 
serum IgG and IgE and the specific IgG titer against outer membrane protein 
F of Pseudomonas aelllginosa. Relative anti-oprF titers < 1 are considered to 
be negative, positive titers are differentiated inta three grades: 1-8, slight; 8-
20, moderate; >20 strong humoral response to P. aeruginosa antigen. 
Mulation analysis at the CFTR locus 
A cascade approach was taken to identify CFTR mutations in genomic DNA 
from nuclear blood cells. Whenever possible, K-EOTA blood samples were 
taken from the patient and the parents. First, frequent CFTR mutations were 
directlO' tested bO' established PCR-based protocols.!3.!4 Next, the 27 exons of 
the CFTR gene together with their flanking intron regions were amplified 
separately by PCR15. Sequence variations were sought by single strand 
conformation polO'morphism (SSCP) analO'sis of restricted PCR product or 
denaturing gradient gel electrophoresis (OGGE).!S.!6 All non-LlF508 
mutations detected by direct testing or anomalous migration behaviour in 
SSCP or DG GE were confirmed bO' direct genomic sequencing of the 
respective exon. 13 ,14 Finally, specimens which were refractory to 
amplification by PCR in exons 2 andj or 3 were scanned for genomic 
rearrangements by Southern hybridization with PCR generated genomic 
probes encompassing the respective exon and flanking intron sequences. 15 
Hybridization was performed with 5xSSC containing 1 % blocking reagent 
(Boehringer Mannheim), 6% (w/v) sos and 100 ftg/ml fish sperm DNA 
(Boehringer Mannheim). 
Nasal potential differellce 
The technique of measuring NPO was adapted from the protocol bO' KnowIes 
et al. B Access to the subcutaneous space was obtained bya needie filled with 
NaCl solution inserted subcutaneously into the forearm. The lower nasal 
turbinate was superfused with a polO'ethO'lene tube (PE-50) connected via 
sO'ringes to the various superfusing solutions. Both the needIe and the PE-50 
tubing were connected to a high-impedance voltmeter via Ag/ AgCl electrodes 
and agar/saline-filled salt bridges. BO' using an otoscope the tube was 
positioned against the lower nasal turbinate. The basal PD was measured by 
superfusing NaCl buffer A (120 mM NaCl, 25 mM NaGluconate, 0.4 mM 
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NaH,P04, 2.4 mM Na,HP04) over the nasal mucosa. Subsequently, the Na' 
diffusion potential was blocked with 0.1 mM amiloride in buffer A. Then the 
chloride conductanee of the airway epithelium was determined by generating 
a CI- diffusion potential, whereby the nasal mueosa was superfused with 
chloride free buffer B (145 mM NaGluconate, 0.4 mM NaH,P04, 2.4 mM 
Na2HP04, 0.1 mM amiloride). Finally the responsiveness ofthe nasal mucosa 
to 0.1 mM isoprenaline in buffer B, which typically activates CFTR chloride 
channels, was tested. 
Intestinal cun-ent measurement 
Within five minutes of being obtained fresh rectal suction biopsies were 
mounted in a rnicro-Ussing charnber9 . Patential difference across the tissue 
was measured through KC1-agar bridges which connected the bathing 
solutions ta rnatched calomel electrodes. Calomel electrodes ,vere eannected 
to a voltage-damp amplifier whieh recorded signals from two Ussing 
chambers in parallel in the apen or short circuited condition. The tissue was 
incubated at all times at 37"C with Meyler-buffer solution (126.2 mM Na', 
114.3 mM Cl-, 20.2 mM HC03', 0.3 mM HP04", 0.4 mM H,P04', 10 mM 
Hepes, pH 7.4 gassed with 95% 0, - 5% CO,) and successive supplements. 
After stabilization of the basal CUlTent in the presence of 10 mM glucose for 
10 to 20 min, 0.1 mM amiloride was added to the mucosal side to block 
sodium channels. 17 Thereafter 10 !!M indomethacin was applied to both the 
mucasal and serosal sides in order to stop the ftu-ther synthesis of 
prostaglandins such as PGE2.!8 Subsequently, 0.1 mM carbachol was added 
to the serasal side which provokes the opening of basolateral potassium 
channels and thereby generates the driving force far the apical secretion of 
chloride and, in smaller amaunts, potassium ions I9,20. Colonic tissue 
responds to carbachol with a singular transient response and then becomes 
desensitized to further action of carbacha1.21 Hence, the second chloride 
secretOly response is evoked with histamine instead of earbachol (see 
below).'2 Next, 10 MM forskolin + 1 mM 8-bromo-cylic adenosine 
monophosphate (cAMP) were added to both serosal and mucosal sides to 
raise the intracellular cAMP cancentration. Then the tissue was incubated 
with 0.2 mM 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (OIDS). DIOS 
is lmown to inhibit the human intestinal Ca2 + -activated chloride channel 
hCACLl,23 the outwardly rectifying chloride channel ORCC,24 a basolateral 
chloridejbicarbonate exchanger2S and an electroneutral pH-sensitive 
chloride/butyrate exchanger in the apical membrane.25 The presence of 
DIOS-inhibitable alternative Cl- conductance was assessed by adding 0.5 
rnM histamine to the serosal side in the presence of DIDS. Interaction of 
histamine with Hl receptors evokes a transient chloride secretory response 




Identification oJ large deletions in CF patients' DNA 
Two DNA samples from Turkish patients of consanguineous descent were 
found to be refractol}' to amplification by PCR with intron-f1anking primers 
of exon 2 (patients 1 and 5) and exon 3 (patient 1) of the CFTR gene, but 
characteristic and reproducible patterns of non-CFTR by-products, which 
were sensitive to the annealing temperature, were synthesized from patients' 
and parents' DNAs upon amplification of exon 2 (Figures 6.1a,b and cl. 
Hybridization of Southern blots of HindIlI-restricted DNA with exon 2 and 3 
DNA demonstrated that patient 1 was homozygous for the out-af-frame 
deletion of exons 2 and 3 and patient 5 was homozygous for the in-frame-
deletion of exon 2 (Figures 6.1d and el. Of the more than 800 known CFTR 
mutations, just seven are large deletions of more than 1,000 hp. CFTRdele2 
is rare, but the 21 kb large CFTRdele2,3 deletion seems to be a rather 
common mutation in the Slavic CF patient population (Dörk et al., 
manuscript in preparation) . 
Clinical manifestation oJ CF in patients with homozygous non-LlF5 08 CFTR 
mutation ge'lOtypes or complex LlF5 08 alleles 
Out-af-frame deletion. The CFTRdele2,3(21kb) homozygous index case 
suffers from a severe course of gastrointestinal and pulmonruy CF disease 
with numerous complications, i.e., meconium ileus at birth, repetitive 
episodes of salt 10ss and dehydration during infancy, chronic growth 
retardation and underweight, late onset of menarche, and diabetes mellitus 
since adolescence. The Turkish parents are first-generation cousins; four of 
their six children died during infancy or early childhood. 
Stop codon mutations. The R553X26 ,27 homozygous adult German female 
(patient 2) and the R 1162X28,29 homozygous ltalian sibs 3 and 4 have typical 
CF pulmonruy and gastrointestinal disease. 
In-frame deletion. The pancreas-insufficient (PI) CFTRdele2 homozygote has 
na clinical signs of lung disease. During the lO-year follow-up the lung 
function varied between 85% and 114% predicted (median 10 1 %) for FVC 
and between 82% and 121% predicted (median 98%) for FEVI. When long-
term inhalation with B2-sympathicomimetics was initiated at the age of 16 











CFTR mRNA: 111 
EXON 1 EXON l E.XON -' EXON..j 
I ... TTCAGICTGGmGAAAGIAGM .. GGGJGAA ... 1 
CFTR 111RNA: DtlKd {/IIfttCIlt'J 
EXON I EXON -' EXON of 
I .. ·TTCAGIAGAA ... GGGIGAA .. 1 
CFTR mRNA: DilR\'2,3 (outoffralllt'J 
EXON 1 EXON .1 
.. TTCAGIGAA···1 
Figure 6.1 Analysis of the deletions CFTRdele2 and CFTRdele2,3(2Ikb). a, b. DNA 
fragments amplified by 35 cycles of PCR from DNA of index families with exon 2 
flanking intron primers {l5}. The annealing temperature was increased in soC 
increments from 45°C to 65°C (from lef! to right). Size standards: S, 100 bp-Iadder, J., 
BstEII digest of Jo DNA. Please note that the same spectrum of by-products is 
synthesized in the absence (b, Ie ft) and presence (b, right) of CFTR exon2 template. 
(b) is on enlarged version of the lower panel in (a), (c) shows the temperature profile 
of the PCR. (d) Southem blot hybridization of Hindlll digests of genomic DNA from 
index families land 5 with exon 2 and exon 3 probes. Exon 2 is part of 7.3 kb Hindlll 
fragment, exon 3 part of a 3.1 kb Hindlll fragment. (e) Predicled mRNA sequences of 
CFTRdele2 and CFTRdele2,3(21 kb} at exon junetions. 
and to FEVI of 140% predicted. The Turldsh parents of patient 5 are cousins 
who lost one of their six children by the age of 6 months because of fatal 
dehydration and electrolyte imbalance. 
Mîssense mutatîon. The E92K30 homozygous son of first -generatîon Aserian 
cousins was diagnosed beeause of repetitive episodes of severe dehydratîon 
during infaney. He has normallung function, is pancreatîc sufficient (PS), 
has a normal fat exeretion and has never received pancreatie enzymes. In 
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comparison ta most patients with CF, who benefit from regular exercise, 
physical activity rapidly leads to muscle weakness and fatigue because of 
excessive sweating and salt loss. 
Complex alleles. The compound heterozygote for ilF508-R553Q/R553X3I 
(patient 7) exhibits the uncommon combination of an age-dependent 
outcome of pilocarpine iontophoresis sweat tests with gastrointestinal and 
pulmonary symptoms since childhood. Growth retardation, cough and 
wheezing were already noted in early childhood, but CF was excluded 
because of apparently normal chloride concentrations below 50 mmol/L in 
repetitive sweat tests. By the age of diagnosis at 6.8 years the sweat chloride 
concentrations were in the borderline range between 50-70 mmol/L. Since 
adolescence highly elevated sweat chloride concentrations above 100 
mmol/L have been measured. The two adult ilF508 homozygous CF siblings 
8 and 9 carry the CFTR sequence variation V1212p2 on their matemal 
ilF508 chromosomes. In contrast to most PI ilF508 homozygotes the brother 
received na and his sister minimal pancreatie enzyme supplementation: their 
serum trypsinogen levels were 15.3 and 2.0 ng/ml respectively (PI < 10 
ng/ml). However, their elastase levels in stool of < 15 Ilgjg were in the severe 
PI range at the day of assessment (PI < 200 IIg/ g). Both patients have 
chronically harboured Pseudomonas aeruginosa in their ainvays from the 
age of 5 years. The male has moderate obstlUctive lung disease whereas his 
sister has normallung function. 
Splice-site mutations. A Kurdish married couple who are cousins passed the 
A-to-G transversion at the not-obligatorily consenred position +3 in intron 12 
of the CFTR gene to their affected daughter. CF was suspected by the age of 
4 months because of recurrent pneumonia and bronchitis and confirmed by 
elevated sweat chloride concentrations. Signs of CF puhnonruy disease are 
the intermittent detection of the typical bacterial pathogens Haemophilus 
influenzae, Staphylococcus aureus and Pseudomonas aeJ1lginosa in throat 
swabs and the presentation of slight peribronchial infiltrations in the chest 
roentgenogram. The pancreas sufficient girl shows no clinical symptoms of 
gastrointestinal disease. The cryptic splice-site mutation 3849+lOkb C-T33 in 
intron 19 was identified in homozygous state in two adult brothers of Polish 
descent. Both patients 11 and 12 are pancreas sufficient and have a normal 
body mass index. Nurnerous Gibson-Cooke sweat tests over a 10-year period 
yielded highly variabie electrolyte concentrations ofbetween 15 and IlO 
mmol/L chloride. Ainvay obstruction indicated by subnormal FEVI was 
already noted in the younger sib by the age of 10, whereas his elder bmther 
did not develop pulmonmy symptoms untillate adolescence. 
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Patient CFTR genotype sex ageot symptoms ot poncreatie MI colonizotion oge at onset peculior 
no. diagnosis diagnosis status with of P. aeruginosQ features 
P. oeruginosa colonization 
out~of-frame deletion 
1 CFTRdele2,3(21 kb)/ birth meconium ileus PI yes yes 6.5y DM 
CFTRdele2,3(21 kb) 
nonsense mutotion 
2 R553X/R553X 16mo steatorrhea PI no yes 10y 
foilure to thrive 
3 Rl 162X/R1162X 5mo malnutrition PI no yes 18.3y DM, atopy 
4 R1162X/R1162X m 18 d none PI no no atopy 
in-frame deletion 
5 CFTRdele2/ m 3mo dehydration PI no no 
CFTRdele2 
missense mvtotion 
6 E92K/E92K m 8mo salt los$ PS no yes 11 y9 ma fatigue,weak 
weck muscles muscles,salt loss 9 complex altele 0 7 "F508·R553Q / 6 Y 10 me growth retordation PS->PI no no PI+pos. ST since ~ R553X cough, wheezjng adolescence,DM 8 "F508-VI2121/ birth none (fomily PS->PI no yes 5y gallstones n 
"F508 anamnesis) 0 
" 9 "F508·VI2121/ m 6mo recurrent bronchitis P$->PI no yes 7y ~ .ó.FSOB 
splice-site mutction 
" 10 1898+3 A~G / 3mo pneumonio PS no no solt loss, 2 1898+3A-G dehydrotion 
11 3849+ 10 kb C·T / m 20 y 5 mo pneumonio PS no yes 26y6mo lung transplant S· 
3849+10 kb C-T dyspnea, hypoxemio splenomegaly ~ 
12 3849+10 kb C-T / m 11 y 2 mo bronchitis PS no yes 12y3 mo ~ 
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""" ~ Table 6.2 Clinical features ot the dav of assessment ~ 
Potient CFrR genotype oge height weight weight body stool FEVl FVC sputum serum serum anti-Po o. ,Ol 
no. (y) centile centile pred. for mass pancreatie (% pred.) (% pred.) boet. IgG IgE oprF 
height index elastase (l-lg/g) (g/l) (IU/mL) titer 
out~oMrome deletion 
1 CFTRdele2.3(21 kb)/ 17.6 3-10 <3 0.89 17.9 < 15 55 70 P. o. 23 38 10 
CFTRdele2.3(21 kb) 
nonsense mutation 
2 R553X/R553X 24.8 25-50 10-25 0.91 19.9 <15 43 70 P. o. 17 520 7 
R1162X/R1162X 23.7 50-75 3-10 0.82 17.8 15 28 52 S. o. 16 48 11 
P. o. 
4 R1162X/R1162X 14.5 > 97 75-90 0.79 17.5 15 88 85 S. a. 14 <8 7 
in-frame deletion 
5 CFTRdele2/ 16.0 <3 <3 0.96 18.6 <15 114 109 S. a. 10 <8 < 1 
CFTRdele2 
missense mutation 
6 E92K/E92K 1l.8 90 > 97 1.23 24.6 450 102 97 P. Q. 13 170 6 
complex allele 
7 LlF508-R553Q / 17.3 25 10-25 0.96 20.0 n.d. 56 70 negative 16 <8 2 
R553X 
8 t.F50BN12121 / 22.1 25-50 50-75 l.06 22.0 < 15 92 115 P. o . 12 120 3 
.ó.F50B 
9 t..F508-V12121/ 23.9 90-97 90-97 0.96 22.1 <15 55 79 P. o. 18 290 7 
t..F508 
splice-site mutation 
10 1898+3 A-G / 5.8 25-50 25-50 l.05 (15.5) > SOO negative 8 12 < 1 
1898+3A-G 
11 3849+10 kb C-T / 31.9 90 90 0.98 22.0 500 88 (lTX) 74 (lTX) P. o. 6 <8 9 
3849+ 10 kb C-T 
12 3849+ 10 kb C-T / 20.2 75-90 75-90 0.98 21.4 > 500 43 72 P. a. 15 120 9 
~49+1Q kb Ç-T 
NOTE. Sibpairs: potients 3 & 4, 8 & 9, 11 & 12: n.d., not determined. P.o.: Pseudomonos oeruginoso. S.o.: Stophylococcus oureus. 
Chloride conductanee in rare CF genotypes 
Table 6.3a Basic defect: Sweat tests and NPD measurements (mVi 
Potient CFTR genotype sweat CI- (mmolfLJ basaf PO Amil CI--free lso residuol Cl" 
no. Dal prior tests (age) conductonce 
out-of-frame deletlon 
1 CFTRdele2.3(21 kb)! 103 95 (JO mo) - 60 - 38 - 48 - 48 yes 
CFTRdele2,3(21 kb) 
nonsense mulotfon 
2 R553X/R553X 96 100 (J6 mo) - 62 - 28 - 27 -35 yes 
3 R1162X/R1162X 98 110 (2y 1mo) - 48 - 25 - 27 - 29 yes 
4 Rl 162X!R1 162X 104 112(1 mo) -39 -9 -9 -9 yes 
In-frame delel!on 
5 CFTRdele2/ 102 134 (4mo) - 45 - 15 - 16 - 17 no 
CFTRdele2 
mlssense mufolfon 
6 E92K/E92K 118 93 (8 mo) - 52 - 32 - 32 - 43 yes 
complex al/ele 
7 nF508-R553Q/ 117 40-50 (4-5y) - 46 - 16 - 13 - 13 no 
R553X 63 (6 Y 10 mo) 
8 L\F508-V12121j 86 94 (J mo) - 55 -29 - 32 - 32 yes 
nF508 
9 nF508-V121211 104 108 (6 mol - 32 - 26 - 25 -25 no 
nF508 
spllce-slle mulolfon 
10 1898+3 A-G/ 73 69 (4 mo) - 33 - 12 - 15 yes 
1898+3A-G 
11 3849+10 kb C-T/ 92 64(20y5mo) - 44 - 14 - 24 - 26 yes 
3849+1OkbC-T 49 (28y4mo) 
12 3849+ 10 k b C-T/ 20 50{11y2mo) 27 - 15 - 13 - 12 no 
3849+ 10 kb C-T 
NPO reference volues 
non-CF (n;:o 25 ) - 16±4 - 7±3 - 30.±8 
CF {n - 23} - 48±9 - 19+10 -17+10 
NOTE. Amil: amiloride. Cf·-free: CI'-free solulion. Iso: isoprenoline. OOI: day of invesfigation. 
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Table 6.3b Assessment of basic defect IA}: sweal lest and NPO ImV} 
Patient CFTR genotype sweat test NPO [mVt ~PD"",O (mVJ 
no. C!- [mmol/l) basal PO Amil Cl"-free lso residual Cl· 
OOI prior tests conduclance 
loge} 
oul-ol-frame deletIon 
I CFTRdele2.3[21 kb}/ 103 95 [10 mol - 60 - 38 -10 yes 
CFTRdele2.3[21 kb) 
nonsense mutatIon 
2 R553X/R553X 96 100 {l6mo) -62 - 28 -8 yes 
3 Rl162X/Rl162X 98 110 [2y 1mo}-48 - 25 -2 yes 
4 Rl162X/Rl162X 104 112 (I mol - 39 -9 no 
In·frome deletIon 
5 CfTRdele2/ 102 134 [4 mol - 45 - 15 no 
CFTRdele2 
mlssense mulatlon 
6 EnK/EnK 118 93 [8 mol - 52 - 32 - 11 yes 
complex ollele 
7 M508-RS53Qj 117 40-50[4-5y)-46 - 16 no 
R553X 63 [6y lOmo) 
8 ó.FS08-V121211 86 94 [1 mol - 55 - 29 -3 ves 
&508 
9 l-\F50B-V12121/ 104 108 (6 mol - 32 - 26 no 
óF508 
spllce-slfe mulallon 
10 1898+3 A-GI 73 69 [4 mol - 33 - 12 -3 ves 
1898+3A-G 
11 3849+JOkbC-TI 92 64 [20V 5 mol - 44 - 14 - 10 -2 Ves 
3849+ 10 kb C-T 49 [28V4mo) 
12 3849+10kbC-Tj 20 50{llV 2mo)-27 - 15 no 
3849+ 10 kb C-T 
NPD reference volues 
non-CF (n= 25) -16±4 - 7 ± 3 - 23±8 
CF (n =23) - 48±9 - 19 + 10 -1 +5 
However, progression of pulmonary disease was rapid and by the age of 28 
years he became termina11y i11 with global respiratOly insufficiency and Cor 
pulmonale (FEVI 0.6 L = 13% predicted). A successful double lung 
transplant re-established an almost normallife. 
CF-relevant anamnestic data and clinical features of the 12 patients are 
summarized in Tables 6.1 and 6.2. 
Assessment of basic defect 
The basic defect of chloride conductance in exocrine epithelia was evaluated 
by determination of electrolyte concentrations in pilocarpine iontophoresis 
sweat test,1 chloride permeability of upper respiratory epithelium (NPD)8 and 
ion flow in rectal suction biopsies (lCM).9 
Defective chloride reabsorption in the sweat duet was noted for all genotypes 
but óF508-R553Q and 3849+lOkb C-T which demonstrated highly variabie 
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sweat sodium and chloride concentrations on separate occasions (Tables 
6.3a and b). ilF508-R553Q was found to be associated wilh an age-
dependent increase of sweat NaCI concentration from the normaI to the 
unequivocal CF range within 15 years, whereas a substantiaI day-to-day 
variation without any age-dependent trend was observed for the two 
3849+ IOkb C-T homozygotes. 
The reduced or absent chloride permeability of the apical epilhelial 
membrane in CF leads to hyperpolarisation and an increased potential 
difference between surface and submucosa which is a factor for diagnosing 
CF by nasal potential difference (NPD).S.8 As expected for the CF condition, 
the basal NPD of all 12 patients was more negative than that of non-CF 
contrals (Tables 6.3a and b). A basal PD of -27 mV wilhin the borderline 
range between CF and non-CF was measured in one 3849+ IOkb C-T 
homozygote. A chloride diffusion potential in chloride free gluconate solution 
indicative for a residuaI chloride conductance was detectabie in seven of the 
12 patients. Three patients responded to the cAMP-activating agonist 
isoprenaline which, at least in the case of the R553X homozygote, has to be 
attributed to a chloride conductance other than CFTR. Interestingly, three of 
the four patients who are homozygous for a stop mutation or an out-of-frame 
deletion expressed an aIternative chloride conductance in their upper 
alrways as indicated by the presence of a chloride diffusion potential. All 
three sibpairs were discordant in the expression of residuaI chloride 
conductance in their airways, implying that there exists no strict association 
between CFTR genotype and chloride permeability of airways. 
Three types of chloride secretOly response could be differentiated by lCM in 
patients 3 - 12 (Tabie 6.4). Figure 6.2 compares lCM tracings of rectal 
suction biopsies of a non-CF individual \Vith those of a CF patient who 
lacked any chloride secretory response. Complete absence of chloride 
secretion was observed in the R553X and CFTRdele2,3(21kb) homozygotes. 
A DIDS-insensitive transient response to carbachol and histamine was seen 
in specimens from the homozygotes for 1898+3 A-G, 3849+ IOkb C-T, E92K 
and the carrier for the complex allele ilF508-R553Q (Figures 6.3 and 6.4). 
Patients 6, 10, 11 and 12 showed a DIDS-insensitive response to forskolin / 
8Br-cAMP. This combination of signals indicates residual CFTR activity. 
Figure 6.3 shows the originaI tracings of open and closed circuit cunent 
measurements of the biopsy from the 1898+3 A-G homozygote with the 
largest, but still CF-typical, residual chloride secretion. Second, a DIDS-
inhibitable cAMP-insensitive chloride secretory response was evoked in 
biopsies from the sibpalrs with the ilF508-VI212! and Rl162X mutations, 
respectively (patients 3, 4, 8, 9, Figure 6.4). 
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Figure 6.2 TypieallCM tracings of a non-CF praband (a) and on individual with CF 
who shows no chloride seeretory response (b. here: patient I who is homozygous for 
the out-of-frame deletion CFTRdele2.3(2Ikb)). 
Figure 6.3 lCM of reclal suetion biopsies obtained from patient la who is 
homozygous for the spliee-site alleration 1898+3 A-G. Signals were recorded as short 
circuit currents (Ieft) and open circuit currents (right. pulses of 0.5 flA far O. Is). 
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Third, a DIDS-sensitive bimodal response to cAMP jforskolin was seen in the 
lCM of the CFTRdele2 homozygote (patient 5, Figure 6.4). A DIDS-sensitive 
cAMP response was also observed in specimens from a compound 
heterozygote for the stop mutations R553X and L1059X (data not shown). In 
surnrnary, the secretagogues employed in our protocol uncovered residual 
DIDS-insensitive CFTR activity and two alternative chloride conductances in 
CF rectal tissue which are both inhibitable by DIDS, but differentially 
stimulated by cAMP. 
Discussion 
More than 800 disease-causing lesions have meanwhile been identifed in the 
CFTR gene but, since about 90% of patients with CF are either homozygous 
or compound heterozygous for the most common mutation ó.F508, our 
knowledge about the phenotype of non-ilF508 mutations is based mainly on 
the characterization of mutant CFTR transcript or protein in heterologous 
expression systems. 1,35 Data about the patients' phenotype with homozygous 
non-ilF508 CFTR genotypes is scarce and scattered in more than 30 separate 
publications (examples in refs 27, 29, 30, 33, 34). The clinical manifestation 
of CF has so far been described for 25 PI and 10 PS non-ilF508 CFTR 
mutations in ab out 100 homozygotes, but with the exception of patients with 
the PS splice-site mutations 2789+5 G-A34 or 3849+ lOkb C-T33 who were 
characterized by NPD, the basic defect was only assessed by the Gibson-
Cooke sweat test. 
In our study clinical phenotype and basic defect in sweat gland and 
respiratOly and gastrointestinal tracts were investigated for two complex 
~F508 alleles, one missense, two splice-site and two nonsense mutations 
and two novel deletions (Tables 6.1 to 6.4). A chloride diffusion potential in 
NPD and a chloride current evoked by secretagogues in lCM are indicative 
for a chloride conductance in respiratory and intestinal CF epithelium 
(Tables 6.3 and 6.4). Since the inhibitor DIDS blocks chloride conductances 
other than CFTR,23-25 a DIDS-insensitive chloride secretOly response in lCM 
was taken as a criterion for the expression of functional CFTR (TabIe 6.4). 
Residual CFTR activity was only detected in pancreas suff1cient individuals 
who car1y a missense mutant in the first ectoplasmatic domain (E92K) or 
who are capable to produce some amounts of wild-type CFTR (1898+3 A-G, 
3849+lOkb C-T).33 The PS status in CF con'esponds with about 10-20% of 
normal exocrine pancreas function.36 
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fobie 6.4 Assessment of basic defect IB): lCM meosurements 
Polient CFTR genotype Response to tnterpretotion 
no. corbachol cAMP DI OS residuol sensitivily cAMP 
(% reverse ("A/cm') + histamine Cl' toDJD$ response 
signal) (% rev. signat) cand. 
out-of-frame deletlon 
I CFTRdele2.3(21 kb)/ 100 none 100 no 
CFTRdele2.3(21 kb) 
nonsense mufallon 
2 R553X/R5S3X 100 none no 
3 R1162X/R1162X 0 none 40 yes yes no 
4 R1162X/Rl162X 4S none 90 yes yes no 
In-frame deletlon 
5 CFTRdele2/ 100 5 100 yes yes' yes 
CFTRdele2 
missense mulallon 
6 E92K/E92K 40 4 50 yes no yes 
complex allele 
7 AFS08·R553Q/ > 60 <0.5 > 60 yes no (yes) 
R553X 
8 ûF508-V121211 50 < 1 100 yes yes (yes) 
ûF508 
9 óF508-V1212l/ 0 none 80 yes yes no 
AF508 
splice-slle mulallon 
10 1898+3 A-GI 0 10 0 yes no yes 
1898+3 A-G 
11 3849+ 10 kb C-l/ 70 <I 70 yes no (yes) 
3849+ JO kb C-l 
12 3849+10kbC-TI 100 <I 100 yes no (yes) 
3849+10kbCT 
NOTE. *cAMP response sensitive to DrOS 
fobie 6.5 Potients' pottems of residuol chloride conductonce in NPD ond lCM 
lCM NPO 
Residual chloride sensilivily 10 interprefotion Residuol ct- conduclance 
conduclance cAMP OIOS ion channel yes no 
polienf number 
yes yes no CFTR 6, JO, 1 J 7.12 
yes yes yes ORCC S 
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RESIDUAL CHLORIDE CONDUCTANCE 
RESPONSE TO: 













J, 4, 9 
Figure 6.4 lCM pallerns of residual chloride conduclance for palienls 6.8. 5 and 7. 
Secrelagogues: I. amiloride: 2. indomelhacin: 3. carbachol: 4. 8Br-cAMP /forskolin: 5. 
DIDS: 6. histamine. 
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Expression of chloride conductances other than CFTR found by NPD or lCM 
did not rescue the pancreas insufficient phenotype in accordance with the 
general rule that the CFTR mutation genotype determines the exocrine 
pancreatic status, whereby carriage of at least one 'PS' CF1'R allele is 
sufficient to confer pancreatic sufficiency. 37 Severity of pulmonary disease 
was highly variabie in Dur index cases and even discordant in one sibpair, 
whieh points to the importance of environmental factors and genetic 
modifiers other than CFTR on airway disease in CF, as has been seen in 
large cohorts of LlF508 homo- and compound heterozygotes,!,35,38 
A pathological outcome of sweat test, NPD or lCM is diagnostic for most CF, 
although same day-to-day variance of sweat electrolyte concentrations has 
been observed, particularly for mild splice mutations such as 2789+5 G-A 
(data not shown) and 3849+lOkb C-T (Tables 6,3a and b), A notabie 
exception is the complex allele LlF508-R553Q. The singular index case 
LlF508-R553Q/R553X presented an atypical manifestation and course of CF 
when compared with the LlF508 homozygous and LlF508/R553X compound 
heterozygous patients at our clinic,3! She was apparently healthy during 
neonatal perlod and toddier age and developed some gastrointestinal and 
pulmonary symptoms compatible with CF during pre-school age, Sweat 
electrolyte concentrations were normal until the age of six years, and then 
over a period of ten years gradually increased into the borderline range and 
linally reached the typical CF range, The course is suggestive for an age 
dependent manifestation of the basic defect at least in the sweat glands, 
which are affected in almost all CF and do not undergo secondary 
pathological alterations, 
The recently resolved crystal structure of the evolutionarily conserved 
nucleotide binding fold of a prokmyotic ABC transporter39 suggests that 
phenylalanine 508 and arginine 553 are located in adjacent helices of the 
lirst nucleotide binding fold of CFTR. The sequence variant R553Q has been 
demonstrated in heterologous systems as rescuing the processing and 
chloride channel gating defects caused by the LlF508 mutation40 and has 
been c1assified as a disease-reverting suppressor mutation in accordance 
with the anomalous course of our index patient.35 ,4Q In vivo, however, the 
role of R553Q as providing protection from disease faded over the years, By 
the age of 17 years, when the index case presented typical clinical features of 
CF, sweat chloride concentrations were highly elevated, no chloride diffusion 
potential was detected by NPD, and the chloride secretory response in lCM 
was vely subtIe (Figure 6.4, Tables 6,3 and 6.4), 
LlF508-VI212J32 is the other complex CFTR allele which was investigated as 
to its impact on the basic defect. The male index case as weIl as a further 
live LlF508 homozygotes were selected from 228 LlF508 homozygous adults 
for comprehensive analysis of the CFTR coding sequence, because these six 
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patients were c1inically exocrine pancreatic sufficient and hence were 
suspected to cany disease-attenuating suppressor mutations. V1212I was 
the only detected complex "'F508 allele in the six patients. However, lCM 
revealed that LIF508-V12121 did not confer residual CFTR activity. F508 and 
V1212 are located in functionally divergent sites of the /irst and second 
NBF.39 Lack of physical interaction may explain why V 12121 cannot rescue 
the omission of "'F508 CFTR. The index sibpair expressed no CFTR activity, 
but another DIDS-inhibitable chloride secretOly response in their intestinal 
epithelium (Figure 6.4). The pharmacological profile is characteristic for the 
recently cloned Ca2+-activated chloride channel hCLCAI.23 
hCLCAl is exclusively expressed in intestinal mucosa23 and hence cannot 
compensate absent or defective CFTR in pancreas. In non-CF individuals 
CFTR accounts for almost all chloride secretion in colonic epithelium,l°,41 
Although hCLCAl plays only a minor role for intestinal chloride secretion 
under physiological conditions, it could attenuate the basic defect in the 
intestine of individuals with CF. 
The members of the Ca2+-mediated CI- channel (CaCC) family in man exhibit 
tissue-specific non-overlapping expres sion patterns.23 ,42 For example, the 
demonstration of a Ca2 + -sensitive chloride conductance in patients' rectal 
biopsies mayor may not be associated with residual chloride secretion in the 
airways as exhibited in the incoherent pattern of the four individuals in our 
study who showed a DIDS sensitive chloride conductance in the intestine. In 
contrast rnurine mCLCAl was detected in a variety of tissues of epithelial 
and nonepithelial origins, including exocrine secretory respiratOly and 
intestinal epithelia.43 This discordant mode of expression pattern could 
re sult in a differential role of CLCA as a modifier of disease in CF mice44 and 
patients and limits the validity of predictions of phenotype byextrapolation 
from mouse to man. 
The other DlDS-sensitive alternative chloride conductance detected by lCM 
was stimulated by cAMP. Such a response is typical for the ORCC.24 
Although no evidence for residual chloride secretion was seen by NPD, 
supranormallung function could be achieved in the index case by treattnent 
with B2 -adrenergic agonists which both activate ORCC and CFTR in non-CF 
individuals. In th is patient, who is homozygous for a large deletion, no 
residual CFfR activity was seen which demonstrates that in principle the 
basic defect caused by molecular lesions in the CFTR gene can be bypassed 
by pharmacological means if alternative ion channels are expressed. 
Stop codon mutations and large deletions are generally considered to be null 
alleles. In case of the large out-of-frame deletion45 and the R553X mutation46 
the absence of protein or strong reduction of CFTR mRNA transcript, 
respectively, have been demonstrated whereas wild-type amounts of 
transcript have been measured for Rl162X.47,48 Three of our five 
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homozygotes for a large de1etion or a nonsense mutation expressed a 
residual chloride conductanee in the respiratOly andj or gastrointestinal 
tracts. The large chloride diffusion potentials in patients land 2, who 
definitely produce no CFTR, point to the presence of other chloride channels. 
Bath patients suffer [rom severe pulmonary disease indicating that the 
alternative chloride channel cannot fully compensate for the loss of CFTR. 
On the other hand, as in CF knock-out mice,44 the absence of CFTR may 
predispose to the expression of these alternative chloride channels in sorne 
but not all patients, whieh could explain the discrepant reports in the 
literature as to whether patients with two stop mutations had milder or more 
severe pulmonaty disease than LlF50S homozygotes. 
Table 6.5 summarizes the electrophysiological findings in our cohort of 
patients with complex alleles or rat'e non-LlF50S homozygous genotypes. The 
pattern of residual chloride conductance is versatile as indicated by the 
discordant outcome in siblings and the lack of correlation between airways 
and intestine. Each patient expressed some chloride conductance in at least 
one of the two organ systems. This data underlines the inherent complexity 
of genotype-phenotype associations in monogenic CF. Missense, splice-site 
or complex mutations can give rise to substantial, but still subnormal, 
CFTR-mediated chloride conductance. This residual CFTR activity is 
necessmy to confer pancreatic sufficiency and cannot be compensated by 
other chloride channels such as CLCA, probably because they are not co-
expressed in pancreas. However, in the respiratOly and intestinal epithelia 
the basic defect of impaired apical chloride transport can be modulated by 
other chloride conductances. Their role on the disease phenotype is 
currently being evaluated in a study on AF508 homozygous twins and 
sibpairs with extreme phenotypes, i.e. a vety mild or vety severe course of 
disease. 
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Abstract 
Cystic fibrosis (CF) is considered to be a lnonogenic disease caused by 
molecular lesions within the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene that is diagnosed by elevated sweat electrolytes. We 
investigated the clinical manifestations of cystic fibrosis, CFTR genetics and 
electrophysiology in a sibpair of which the brother is treated for having CF 
while his sister is asymptomatic. The diagnosis of CF in the index patient 
was based on highly elevated sweat electrolytes in the presence of CF-related 
pulmonary symptoms. The investigation of chloride conductance in 
respiratory and intestinal tissue by nasal potential difference and intestinal 
current measurements provided no evidence for CFTR dysfunction in both 
siblings who share the same CFTR alleles. No molecular lesion was identified 
in the CFTR gene of the brother. Findings in the investigated sibpair point to 
the existence of a CF -like disease with a positive sweat test without CFTR 
being affected. Other factors influencing sodium or chloride transport are 
likely to be the cause for the symptoms in the patient described. 
Introduciion 
Cystic Fibrosis (CF) is a generalized disease of the exocrine glands affecting 
predominantly the gastrointestinal. hepatobiliary, reproductive and 
respiratory tract. 25 CF is considered to be a monogenic disease of recessive 
inheritance. Therefore, the detection of molecular lesions in both cystic 
fibrosis transmembrane conductance regulator (CFTR) alleles'2 is regarded 
as being confirmatory for the diagnosis of CF. Absent or dysfunctional CFTR 
leads to defective chloride transport across the apical membrane of epithelial 
cells25 which is the basic principle when diagnosing CF by physiological 
assays, i.e. the pilocarpine iontophoresis sweat test,9 the nasal potential 
difference (NPD)'3 and the intestinal current measurements (ICM).23.24 
We report on a patient whose clinical features, CFTR genotype and basic 
defect phenotype were contradictOly with respect to the diagnosis of CF. This 
is the first case of a CF-like disease unrelated to CFTR that could be 
substantiated by pedigree data. 
Materials and Methods 
Informed consent was obtained from the patient and his sister. This study 
was approved by the local medical ethical commitee. 
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CFTR haplotype analysis 
Inheritance of CFTR alleles was traeed in all members of the two generation 
pedigree by intragenic marker haplotype. Analysis of dimorphic markers and 
intron 8 splice site haplotype was carried out as previously described.6,7 
Polymorphic microsatellites were typed using a PCR protoco1. 17 
Mutation analysis at the CFTR locus 
Mutation analysis in the patient was performed by direct testing for frequent 
CFTR mutations as well as by single strand conformation polymorphism 
(SSCP) and sequencing analysis of co ding and flanking intron sequences as 
described elsewhere.8 ,26 Briefly, the region of interest was amplified by 
polymerase chaln reaction (PCR) in presence of [a.-33PjdATP and the 
resuIting product digested by restriction enzymes to give rise to fragments of 
150--250 bp. For each PCR product, two different restriction enzymes were 
used. SSCP samples were loaded on a high resolution gel (running 
conditions: length 40cm, 0.2--0.4 mm, 5--7.5% aClylamide:bisacrylamide 
29:1,5--10% glycerol, 5--7h 25W const at 10°C) which has been shown to 
result in a sensitivity for CFTR mutations detection of more than 90%.19 
Nasal potential difference 
The technique of measuring NPD was adapted from the protocol by Knowies 
et al. 14,22 This electrophysiological measurement is used as a diagnostic tooI 
for CF by evaluating the Na+ and Cl' potential difference across the 
epithelium of the lower nasal turbinate representative for the ainvay 
epithelium. Access to the subcutaneous space, whieh is isoeleetric 
throughout the body, was obtained bya needie fiUed with NaCI solution 
inserted subcutaneously in the forearm. The lower nasal turbinate was 
superfused with a polyethylene tube (PE-50) connected via syringes to the 
different superfusion solutions. Both the needie and the PE-50 tubing were 
connected to a high-impendance voltmeter via Ag/ AgCI electrodes and agar 
saline Wied salt bridges. The tubing was positioned on the lower nasal 
turbinate by using an otoscope. The basal PD was measured by superfusing 
a NaCI solution over the nasa! mucosa. Subsequently, 10-4 M amiloride was 
added to bloek the Na+ diffusion potential. In earlier studies amiloride was 
shown to inhibit approximately 25% of the basal PD in controls and 50--60% 
in CF patients. 2 To assess the CI- conductance of the alrway epithelium, CI-
was replaced by gluconate in the presence of amiloride which shows a Cl~ 
diffusion potential in controls but not in CF patients. 14 
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Intestinal Current Measurement 
Freshly obtained rectal suction biopsies were mounted in a micro Ussing 
chamber. After stabilisation of the basal short circuit current in the presence 
of glucose, amiloride (10-4 M) was added to the mucosal side. The 
endogenous prostaglandin synthesis, possibly linked in this tissue to cAMP-
mediated chloride secretion, was inhibited by adding indomethacin (10-5 M 
applied both sides). Thereafter, carbachol (10-4 M, added to serosal side) 
provoked in controls an inward current reflecting transcellular Cl~ transport 
from serosa to mucosa. However, CF patients demonstrate an outward 
current suggesting K+ secretion in the absence of Cl- secretion.23 Milder 
phenotypes may also demonstrate a smalt inward current, but this is 
significantly reduced from that observed in controls.24 Finally the tissue was 
incubated with 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIOS, 2.10-
4, added to mucosal side). DIOS is considered to inhibit the Ca2+ regulated 
Cl- channels.l° The presence of DIOS inhibitable alternative Cl- was assessed 
by adding histamine 5.10-4 M to the serosal side in the presence of OIDS. 
The results were expressed as the maxima} signa! evoked by the used 
secretagogues. 
Results 
Clinical and laboratory findings in the parient and his sibling 
Neonatal period and infancy of the male sibling were uneventful with no 
episodes of dehydration. Starting at the age of 6 y, he suffered from 
recurrent bronchitis, chronic cough and excessive sputum production that 
required three to [Dur courses of ora1 antibiotics per year. On the occasion of 
a severe pneumonia at age 17 he was diagnosed as having CF by a chloride 
concentration of 102 mmolf1 in the pHocarpine iontophoresis sweat test. 9 
Following diagnosis he was treated with daily inhalation of salbutamol, ara! 
n-acetylcystein and intermittent ara! antibiotics, but received no pancreatie 
enzymes or vitamin supplements. Occasionally, Staphylococcus Qureus was 
detected in routine sputum cultures. Clinical and laboratory data at two 
subsequent days of assessment are summarized in Table 7a.1. The 
investigations confirmed the pathological sweat test values and revealed a 
subnormallung function and a reduced fertility. However, no signs of 
exocrine pancreatic insufficiency or chronic inflammation of the lung were 
detected. 
The patient's sister had no signs of bronchitis, cough, increased sputum 
production or impaired pancreatic function. 
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Table 70.1 Actual clinical and laboratorv data of the siblings 
Index case 
age (years) 23 
Growth 
height (m) 1.73 
body mass index (kg/m') 26.4 
Luna function parameters 
FVC (%-predieted)o 75 % 
FEVI (%-predieted)o 72 % 
Piloearpine iontophoresis sweot test 
sweot chloride (mmolIL) 97 
Tests of exocrine pancreatic suffidency 
stool ehymotrypsin (U/g) 29 
stool pancreatie elastase (~g/g) > 500 
serum vita min A (~g/l)b 540 
serum vitamin E (mg/l)b 5.8 
Mierobiology ond inflommation parameters 
sputum baeteriology normal flora 
serum IgG (gIL) 16.0 
anti-Po aeruginosa OprF IgG titre 0.7 
Spermiogram 
volume (ml) 2.5 
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NOTE. °FVC: foreed vitol capacity. FEVI: foreed expiratory volume in I S. 
bboth probands did not receive supplementotion of fat-soluble vitamins. 
Haplotype and rnutation analysis at the CFTR locus 
Eight intragenie dimorphic6 and three polymorphic microsatellite markers l7 
were used for haplotype analysis within the family. Bath sibs shared the 
same intragenic CFTR marker haplotypes (Figure 7 a.l) indicating that the 
CFTR alleles of bath siblings are identical by descent. 
No CFTR mutation was found when all 27 CFTR exons and flanking intron 
sequences of the index patient were screened by single strand conformation 
polymorphism and sequencing analysis7,26. He is compound heterozygous 
(TG)l1T7 j(TG)lOT7 for the acceptor splice site polymorphism in intron 
8.4 ,5,7,22 
Electrophysiological findings 
Defective chloride conductanee in epithelial tissues is known to be the 
pathophysiological origin of CF." To establish a chloride transport defect in 
these patients, we repeated the sweat test and extended the evaluation by 
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figure 70.1 Pedigree of inherifance of infragenic 8-marker CFTR hap/ofypes in fhe 
index fami/y. The autoradiogram shows the separation of PCR-amplified intragenic 
microsatellite IVSI7bTA alle/es. Lanes KI. K2. K3 show unre/ated contra/ samples of 
known allele composition. 
elevated in the brother and normal in the sister. However, in more specifïc 
tests i.e. NPD and lCM which both give more insight in the electrolyte 
transport, no abnormalities could be demonstrated in both siblings (Figure 
7a.2). Although ranges of the con trol and CF responses do overlap in NPD, 
Dur index case and his sister can clearly be discriminated from CF by their 
combination of normal baseline PD and gluconate response (Figure 7 a.2a). 2 
In lCM, a Cl' secretory current was evoked by Carbachol and the CF 
condition could not be mimicked by the use of D1DS which inhibits the Ca2 ' 
activated CI- channels.'o This data suggests that CFTR mediated chloride 
conductance in the respiratory and gastrointestinal tracts in both siblings is 
normal. 
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Differential diagnosis 
The pathological sweat Na' and Cl- values can be caused not only by 
impaired chloride reabsorption as in CF, but also by defective sodium 
reabsorption. Hence we searched for clinical symptoms in the patient that 
are compatible with known sodium transport abnormalities, Le 
pseudohypoaldosteronism3 ,11,21 and Liddie disease. 1,20 Both conditions \vere 
exc1uded by findings of normal blood pressure, serum electrolytes, plasma 
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Figure7a.2 NPO vafues (a) upon superlusion with: phosphate bullered saline (PBS). 
amiforide IO'M in PBS (amiforide). C{--Iree sofution in the presence ol amiforide IO'M 
(CUree). For comparison. mean PO vafues ÎSO 0125 controls and 23 CF patients are 
plolted. lCM values (b) ol index patient and sister alter addition ol amiforide and 
carbachaf. Shart circuit currents (lSCf mean .±SD) are Qiven far the amilaride respanse 
in a graup of contrafs and CF patients. Isc responses to carbachal are given far a 
control (n~50) and a CF (n~51) group. 
Discussion 
In the case described, the elements of CF diagnosis -- clinical features, 
genetic analysis and electrophysiological measurements -- are conflicting. 
Based on anamnesis, clinical investigation and the positive sweat test, the 
diagnosis of CF was independently made by two physicians with profound 
and long-standing expertise in CF care. Whereas the clinical features and 
the pathological sweat Na' and Cl- values are compatible with mild CF, CFTR 
genetics and lCM and NPD-measurements provide no evidence for defective 
CFTR. Normally, ICMjNPD are sensitive assays for diagnosing CF, even in 
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patients with borderline sweat tests,24 but in this case the results of the 
sweat test were not sustained by the other two electrophysiological assays. 
Instead, the patient presents a CF-like disease which is apparently not 
related to defective CFTR: no disease-causing les ion was found within the 
CFTR gene, no clinical signs of disease were presented by the sister who 
inherited the same CFTR alleles as the index patient, and na sign of CFTR 
dysfunction was found in the gastrointestinal and respiratory epithelia 
predominantly affected in CF. 
We present the first case of a CF -like syndrome associated with a positive 
sweat test and mild respiratory disease which could be substantiated by 
bath genetic and electrophysiological sibpair data. Although the highly 
unlikely OCCUITence of de nova mutations in the non-coding region of the 
CFTR gene, variabie penetrance of shared sequence variation(s) andj or 
somatic mosaicism cannot be excluded, the shared genotype between 
affected and unaffected sib as weIl as the normal chloride transport 
properties in the respiratOly and gastrointestinal tracts point to the non-
existence of CFTR-caused CF in the diseased individual. The demonstrated 
defective NaCI reabsorption in the sweat duet could be due to an aberrant 
tissue-specific factor acting on CFTR or due to an anomalous sodium 
reabsorption. The established entities pseudohypoaldosteronism3 ,11,21 and 
Liddie disease 1,20 were excluded. However, perturbations of sodium transport 
of another etiology could affect electrolyte homeostasis in bath sweat glands 
and airways, the latter being a predisposition to respiratOly infection as in 
CF. 
Therefore it is tempting to speculate that individuals with clinical signs of CF 
and a positive sweat test, but no identified CFTR mutation, may suffer from 
lesions in another gene. Af ter exhaustive screening of the promotor, all exons 
and flanking intron regions for sequence va1'Îations and pulsed field gel 
electrophoresis analysis of the CF locus, three out of 350 patients in our 
panel with a positive sweat test and unequivocal clinical signs of "classical(' 
CF are still negative for an anomaly in the CFTR gene. Genetic heterogeneity 
is the mIe rather than the exception for inherited disease in man and 
correspondingly CF may also be a genetically heterogeneous disease, albeit 
loci other than CFTR should account for 1 % or less of all cases. 
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Background-The diagnosis of cystic fibrosis (CF) is based on two mutations 
in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene 
and on assays that measure the basic defect of perturbed chloride transport 
in the affected organs. However, in cases of atypical CF, not all diagnostic 
measures may be informative. We report on a pancreatic suffïcient patient 
with norm al electrolyte concentrations in sweat tests who suffers [rom severe 
pulmonary manifestations typical for CF slieh as recurrent nasal polyps, 
bronchitis, bronchiectasis, continuous cough, sputum production, ainvay 
infections, hypoxaemia and cachexia. 
Methods-To substantiate the diagnosis of CF, the CFTR gene was screened 
for mutations and the basic chloride transport was electrophysiologically 
assessed by nasal potential difference and intestinal CUlTent measurement. 
Pancreatie function was tested by stool elastase and ehymotrypsin. 
Results-Our patient showed normal elastase and chymotrypsin values. All 
sweat tests were in the normal range. Intestinal eUITent measurement 
showed normallevels of CFTR-mediated Cl- conduetanee. However, the 
baseline nasal potential differenee was pathologically elevated and there was 
subnormal CFTR CI- seeretion in the nasal epithelium. Genetie analysis of 
the CFTR gene uncovered only one disease eausing lesion, the sequence 
alteration 1898+3 A->G. 
Conc1usions-We present a patient with an atypical CF phenotype in which 
the only pres enting symptom is severe CF-like lung disease, whieh is 
substantiated by an abnormal nasal potential difference measurement. 
Genetic analysis shows that the index case is a symptomatic heterozygote 
inlplying that one disease-causing lesion in the CFTR gene may be suffïcient 
to cause CF-like Iung disease. 
IntroductIon 
Typical cystic fibrosis (CF) is caused by two lesions in the Cystic Fibrosis 
Transmembrane conductanee Regulator (CFTR) gene whieh give rise to a 
generalised exocrinopathy in respiratory, gastrointestinal, reproductive and 
hepatobiliary tracts. l The protein product of the CFTR gene is a chloride 
channel expressed in the apical membrane of epithelial eells. 2 Therefore, 
diagnostie tests that measure the chloride conductance in exocrine epithelia 
like the pilocarpine iontophoresis sweat test,3 intestinal current 
measurement (lCM)4 and nasal potential difference (NPD)4.5 show c1early 
abnormal values in typical CF cases. Atypical cases of CF have a different 
presentation of clinical features: pancreatic sufficiency, mild bronchitis, 
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nasal polyposis, congenital bilateral absence of the vas deferens (CBAVD), a 
borderline sweat test, or lCM values which point to low residual chloride 
secretion in intestinal tissue either by CFTR or an alternative chloride 
channel.7- l0 We present a case that is characterised exclusively by severe 
lung disease, whereby ot her organs typical!y involved in CF are not affected 
and fail to show a chloride transport defect. 
Melhods 
This study was approved by the meelical ethical committees of the Dutch and 
German participating hospitals. Informed consent was obtained from the 
patient elescribed. Al! chemicals were obtalned from Sigma Chemical Co., St. 
Louis, MO, USA. 
Ana/ysis of the CFl'R gene 
The promotor (-3.8 to -0.3 kb) anel coeling regions and the exon-flanking 
intron sequences of the CFTR gene were screened for mutations by single 
stranel conformation polymorphism (SSCP) analysis 11 .12 anel, in the case of 
the appearance of non-wild type banel patterns in the high resolution SSCP 
gel, by subsequent sequencing.l3 Deletions in the CFTR gene were sought for 
by repeated Southern hybridizations of rnacrorestriction blots with CFTR 
cDNA probes encoding exon 1, exons 7-24 or the second nucleotide binding 
folel (codons 1202-1422). Preparation ofunsheareel genomic DNA from fresh 
blood, complete restriction digestions with ApaI, EagI, FspI, Sall or Xhol, 
pulsed-field gel electrophoresis, blotting anel hybridization followeel protocols 
1,5,7,8 and 9 of reference 14. The intragenic CFTR haplotype was 
determineel for the sequence alterations T854T and M470V,15.16 the splice 
site polymorphism in intron 8 (TG)mTn ll.17 anel the microsatellites IVS8CA, 
IVSI7bCA,IVSI7bTA.18.19 
Nasa/ potential diffe/'e1lce 
The method of studying NPD has been adapted from the methoel elescribed 
previously.5 In short, the nasal turbinate was superfused (1.7mljmin) 
subsequently for perioels of 3 minutes with the fol!owing solutions (moljL): 1) 
saline, to measure baseline PD; 2) amiloride (10-4), to block Na+ channels; 3) 
gluconate with amiloride, to assess spontaneous CI- conductance; 4) 
isoprenaline (10-4 ) in solution 3, to evaluate the presence of CFTR and finally 
5) ATP (10-3 ) in solution 4, to open non-CFTR CI- channels. To access the 
submucosal space a smal! needie (25 gauge) was inserted into the forearm 
and filleel wilh saline. Both the neeelie and superfusion catheter were 
connected to a high input resistance voltage measuring device via salt 
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bridges and AgAgCI electrodes. The saline solution consisted of (mmoIjL): 
NaCI (120), Na-gluconate (25), K-gluconate (5), NaH2P04 (0.4), Na2HPO" (2.4). 
In the gluconate solution NaCI was replaced by Na-gluconate (145). All 
solutions were adjusted to pH 7.4. 
Intestinal current measurement on rectal biopsies 
The methad used to study lCM has been described previously.4 In short, 
freshly obtained rectal biopsies were mounted in saline solution in the 
Ussing chamber (apperture 1.2mm). Aftel' stabilizing of the basal short 
circuit current (Isd the tissue was exposed to inhibitors and secretagogues 
(moIjL) to the mucosal (M) or serosal (S) side: I) glucose (10-2, M+S); 2) 
amiloride (10-4, M); 3) indomethacin (10-5 , M+S), to inhibit basal CI- secretion 
by inhibiting the endogenous prostaglandin formation; 4) carbachol (10-4, SJ, 
a Ca2+ linked secretagogue; 5) forsIcolin (10-5 , M+S) + 8-bromo-cyclic 
adenosine monophosphate (cAMP, 10-3 , M+S), to open CI- channels by 
activation of a cAMP-dependent protein kinase and phospholylation of 
specific membrane proteins; 6) 4,4'-diisothiocyanatostilbene-2,2'-disulfonic 
acid (DIDS, 2.10-4, M), to inhibit Ca2+ dependent CI- secretion; 7) histamine 
(5.10-4, S), to reactivate the Ca2+ activated pathway. 
Resulls 
Patient history 
The 34-year aId index case is the third child of Caucasian first-generation 
cousins. The fiTst child was born preterm with meconium ileus and died at 
day 10. The second child died during infancy at 6 months and CF was 
suspected at autopsy. Our index case suffered from chronic nasal polyposis 
which led to 13 polypectomies between the age of 5 to 23 years. By the age of 
15 years she was referred to achest physician because of shortness of 
breath during sports. Clubbing, subnormallung function and decreased 
exercise toleranee were noted. The diagnosis of cystic fibrosis was proposed 
because of the typical pulmonmy manifestations, but was discarded when 
normal sweat electrolyte concentrations were measured. The differential 
diagnosis of allergy as the underlying disease was excluded by normal 
bioassay of specific IgE by skintest and normal levels of specific IgE in 
selum. Immotile cilia syndrome was excIuded by normal microscopie 
appearance of a nasal cilia biopsy. Since adolescence she was underweight 
(below 3rd percentile) and had recurrent lower airway infections. Over the 
yeru's increased sputum production and chronic cough became a clinical 
problem. A lung biopsy in 1984 showed a histological pattern consistent with 
CF: bronchiectasis with localised purulent bronchitis and surrounding 
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fibrosis. Cultures of throat swabs or sputum were often positive for 
Staphylococcus aureus (>90% of samples), but never for Pseudomonas 
aeruginosa. However, the specific anti-Po aeruginosa oprF IgG titer was 
positive, indicating that she had been exposed to P. aeruginosa. 
Bronchodilators and intermittent antibiotics were prescribed, but the patient 
generally discontinued medication aftel' a few days even during acute 
respiratOly tract infections. At the age of 23 her lung function was reduced 
(VC 1.5L ~ 48% predicted), her chest X-ray had a Chrispin-Norman score of 
20, grade 3 (range 0-38), her height was at the 25th percentiIe and weight 
below the 3rd percentile. However, pancreatic function is suffïcient as has 
been shown by normal chymotrypsin in 1986, 1992, 1995 and by normal 
stool elastase in 1995 (386 mgjg) and ultra sound ofthe pancreas. Our 
patient has never received pancreatic enzymes or vitamin supplements. 
Serum levels ofvitamins (vit. A 370 ~,gjL, vit. E 11 mgjL), bilirubin and liver 
enzymes have always been in the normal range. Moreover, the sweat 
electrolytes in repetitive pilocarpine iontophoresis sweat tests which have 
been performed since she was 11 years old, were always in the normal range 
(sweat chloride 7 to 32 mmoijL). 
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Figure 7b.1 Autoradiogram ot genomic Apal digestions probed with CFTR cDNA 
(exon 7-24). No anomalous band pattem is seen for the sample from the index case 
(Iane I). For comparison, lane 4 shows the probe-reactive fragments from a 
specimen which carries a deletion in one CFTR al/ere. Apal-cfeaved fragments were 
separated in a CHEF-DRT"" cell at 5.6 V/cm in 1% agarose gels (0.5 TBE buffer, 10°C). 
Pulse times were linearly increased in two ramps from 5-20s in 18hrs and then from 5-
90s in 20hrs. 
CFTR genetics 
Despite the familial consanguinity, the index case is heterozygous at the 
CFTR locus which is shown by the different number of (TA)n repeats 
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(n~30,34) for the microsatellite at the locus IVSI7bTA, and her 
heterozygosity for a rare CFTR mutation. She is homozygous (TG) 12T7-2-1 
for the CFTR haplotype (TG)mTn-M470V-T854T. The combination of the 
TG 12 repeat with the T7 allele and the V470 CFTR isoform are known to 
significantly decrease the amount and chloride channel activity of CFTR,16 
After all CFTR exons and flanking intron sequences and most of the 
promotor area up to -4 kb had been screened by SSCP one molecular lesion, 
the splice site consensus transition 1898+3 A->G, was identified. A 
pan creatie insufficient child with CF at Dur clinic is homozygous for this 
condition and exhibits the typical pulmonary and gastrointestinal 
rnanifestations of CF indicating that 1898+3 A->G is a CF-causing lesion. No 
anomalous bands were seen in autoradiograms of macrorestriction blots 
probed with CFTR cDNAs indicating that the two CFTR alleles of our index 
case do not carry any major genomic alteration (Figure 7b.1). 
Tabfe 7b.! Eleclrophysiological results af Ihe index case. Means ± {SDI for a conlrol 
group and a CF patien! group are given for comparison 
Nasal potential difference 







Infesfinal current measurement 
"he (in ~A/cm2) afler addition of 
amiloride 
carbachol 
histamine (after DIDS incubation) 
Diagnostic assessment 
Control Index case CF 
n=25 n=23 
-24 (11) -52 -45 (Ia) 
+10 (6) +21 +21 (9) 
-15 (Ia) -3 -I (5) 
-8 (4) -4 -2 (3) 
-I (3) 0 -I (3) 
n=50 n=51 
-8.7 (11) -4.9 -8.7(11) 
38.5 (23) 45.5 -5.3 (10) 
33.0 (26) 19.4 -5.0 (10) 
On the day of electrophysiological investigation at the age of 32 she \Vas 
undenveight, below the 3rd percentile with a body mass index of 17 kgjm2 
and her lung function was severely reduced (FEV1 0.39L~ 14% predicted, 
FVC 1.23L ~ 38% predicted). At this time, she was treated with continuous 
oxygen and showed severe dubbing. Electrophysiological measurements 
were carried out by assessing the presence of chloride conductance in her 
186 
Exclusive CF hmg disease 
airway and intestinal epithelium (Tabie 7b.l). The basal NPD found with 
saline superfusion was -52 mV (Figure 7b.2). In the presence of amiloride, 
bloeking the sodiurn condudance of nasal turbinate epithelium, the PD 
depolarized to -31 rnV, a decrease of 40%. Superfusion of gluconate in the 
presence of arniloride resulted in a net response of -3 mV, indicating a 
subnormal CI- conductance. With isoprenaline, opening CFTR CI- channels, 
only a small response of -4 mV was obtained which suggests that little CFTR 
channels are present. No ATP response, usually indicative of the presence of 
alternative CI- channels,2o was seen in the ainvay tissue. In our earlier lCM 
studies carbachol provoked a negative, reversed Isc in rectal tissue of CF 
patients, sometimes followed by a positive, residual response indicating the 
presence of residual Cl- secretion. In our index case, the lCM showed a CI-
secretory current in the normal range upon carbachol addition (Figure 7b.3). 
DIDS, which inhibits the alternative pathway of Ca2+ activated Cl- currents, 
did not influence the CI- CUlTent. This suggests the presence of normal CFTR 
mediated chloride conductance in the intestine. 
Discussion 
The clinical and diagnostic features presented by this case are conflicting in 
terms of the expression of the basic defect in different tissues. In typical CF 
defective electrolyte transport in sweat gland, intestine and airway 
epithelium is dcmonstrated by a pathological outcome of sweat test, lCM and 
NPD. In our case, however, sweat chloride concentration and ion flow in the 
intestine are normal, whereas the NPD values are abnormally high. 
Pathologically elevated NPD values have so far only been found in CF and 
not in any other lung disease with related clinical manifestations like (I.l-
antitrypsin deficiency, imrnotile cilia syndrorne or congenital 
bronchiectasis.21 As weIl as a high baseline nasal PD her gluconate and 
isoprenaline response are also in the CF range. However, they do point to the 
presence of liltle residual CFTR CI- permeability in her respiratory 
epithelium. The clinical symptoms of our index case are typical of CF lung 
disease such as progressive obstructive bronchitis and bronchiectasis, 
sputum production, pathological bacterial flora and she has been 
permanentlyon oxygen since the age of 30. This could explain her anorexic 
status, since there is no sign of malabsorption or gastrointestinal disease, as 
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Figure 7b,2 Nasal Pofenfial Oifference (PO) measuremenfs of fhe index case (.), and 
mean PO values (SO) of 25 confrols (O) and 23 CF pafienfs ("'), upon superfusion wifh 
saline solufion. amiloride {lO"M} in saline solufion. CI--free solufion wifh amiloride. 
isoprenaline (IO'M) in CI--free so/ution with amiloride, ATP {l0-3M} in CI--free so/ution 
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Figure 7b,3 Infesfinal Currenf Measurements expressed as changes in short circuit 
current (/'e) of Ihe index case (.), and mean I,e (SO) of 50 controls (O) and 51 CF 
pafienls ("'). offer addifion of amiloride, carbachol. and offer fhe fissue was exposed 
10010S. hislamine. 
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This highly discordant expression of the basic defect in different tissues is 
described here for the first time: CFTR function was unaffected in 
gastrointestinal tissue whereas in airway tissue the abnormally low Cl-
conductance can only be accounted for by defective epithelial Cl- transport. 
Other cases of CF with normal sweat test and pulmonruy problems, as 
described for patients carrying the A455E or 3849+ lOkb C->T 
mutation,?,8,22,23 can clearly be diagnosed byan abnormal lCM, even when 
little or na clinical signs of gastrointestinal involvement are evident. JO 
The CF1'R gene has been screened for disease causing lesions in all exons 
and flanking intron sequences: on one chromosome a sequence alteration in 
a donor splice site has been found (1898+3 A->G). This sequence alteration 
has first been described in a compound heterozygous pancreatic sufficient 
patient (Ferrari, et al; Cystie Fibrosis Genetic Analysis Consortium, pers. 
comm.) and has been found as weil in our clinic in a pancreatic insuffïcient 
CF patient homozygous for this condition (see above). According to CFTR 
mutation analysis and the famîly anamnesis, our index patient is a carrier 
for one CFTR mutation and hence should not express any CF symptoms. 
However, our index case carries an unfavourable combination of common 
intragenic polymorphisms. She is homozygous TG12T7 for the TGmTn 
polymorphism at the intron 8 splice acceptor site. The TGl2 repeat together 
with the T7 stretch places the branchpoint nucleotide in an unfavourable 
position for splicing leading to 30% of exon 9- CFTR transcript which are 
known to be translated in CFTR proteins that do not mature. 16,24 Moreover, 
she is homozygous for the V470 allele in exon 10. V470 CFTR proteins have 
a 1.7 fald decreased intrinsic chloride channel activity compared with M470 
CFTR proteins. 16 These predisposing polymorphisms in the intragenic 
background decrease the expression and function of CFTR. Yet, they are 
present in both rectal and nasal tissue and cannot account for the 
unimpaired function of CFTR in the intestine while nearly complete absence 
of CI- conductance in the nasal tissue was observed. However, the patient's 
consanguineous descent leads to a genome wide overrepresentation of 
homozygous genotypes. This may lead to further unfavourable combinations 
of factors modif'ying the CFTR expres sion or function in the lung. As 
gastrointestinal disease is not present, we propose that the genetic 
background predisposes to severe lung disease, caused by tissue specific 
regulatOly elements whieh lead to the loss of CFTR function exclusively in 
the respiratory epithelium. 
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Cystic fibrosis is a disease with highly variabie manifestations in the 
pulmonary, gastrointestinal, hepatobiliary and urogenital tracts,l and is 
caused by molecular lesions in the cystic fibrosis transmembrane 
conductance regulator. The heterogeneous phenotype of CF is partly 
explained by the large number of different CFTR gene mutations. 2 However, 
since clinical presentation varies significantly even behveen patients with the 
same CFTR genotype and between the affected organs within CF patients, it 
is evident that other factors than the CFTR genotype are involved in 
determining CF disease severity. These additional aspects involved in CF 
disease phenotype might consist of genetic factors outside the CFTR gene 
and/ or environmental factors. An example of influencing genetic factors is 
the expression of non-CFTR mediated chloride secretion in the affected 
epithelia of the airways3 and the intestine.4 
In this thesis, we investigated the presence of residual chloride 
conductances in CF individuals, and made a distinction between residual 
cAMP-mediated CFTR conductances andjor the presence ofCa2'-stimulated 
alternative chloride channels. These features were investigated in a pre-
selected cohort of lIF508 homozygous sib and twin pairs with highly 
concordant or highly discordant phenotypes (Chapter 3). In this group the 
major CF disease-causing lesion is standardized. By comparing results in 
the CF sib pairs who vmy in genetic background, to results in monozygous 
twins who share identical genetic background, it is possible to disseet the 
importance of gene tics and environment in the course of CF disease. 5 ,6 
Moreover, analyzing individuals with most disparate phenotypes facilitates 
the detection of determinants of this CF phenotype (Chapter 3).7.8 Therefore, 
this cohort of 6FS08 homozygous sibs and twins with most extreme disease 
manifestations is optimal to investigate influences on CF phenotype and 
compare the importance of genetic background versus epigenetic factors. 
In these CF individuals, the electrophysiological methods of intestinal 
CUlTent measurement and nasal potential difference measurement (Chapter 
2) \vere employed, to determine frequency and origin of residual chloride 
secretion in the most severely affected tissues in CF, the intestinal and 
respiratOly tracts (Chapter 4 and Sl. Moreover, the influence of the various 
chloride conductances that were detected in the respiratory and intestinal 
tracts, on the course of CF disease severity was evaluated (Chapter 5). To 
analyse the possible role of genetic factors outside the CFTR gene in the 
expression of residu al chloride conductance, CF patients homozygous for the 
most common severe CFTR genotype, i.e. LiF508, were investigated (Chapter 
5). In Chapter 6, the chloride transport in CF patients with various missense 
and nonsense mutations, and compound heterozygous genotypes was 
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studied. The NPO and lCM patterns for the chloride conductances in the 
respiratOly and intestinal tissues were investigated and were related to their 
genotype. Furthermore, CF individuaIs were described with atypical patterns 
in the NPO and lCM examinations (Chapter 7), which complicate CF 
diagnosis despite the application of these electrophysiological methods. 
Electrophysiological character/sation of respiratory and intestinal 
tissues 
The electrophysiological techniques of NP09.1O and ICMll.12 test the 
conductance properties for sodium and chloride ions of the respiratOly and 
intestinal epithelium. In clinical settings, these tests are used together with 
the Gibson and Cooke sweat test, for diagnostic purposes since they give 
distinct results between controls and CF. In the NPD measurement, the 
basal PO and the change in PO in response to Cl--free and isoprenaline 
solutions are most different between CF and control, while in the lCM the 
chloride secretory responses to carbachol and histamine are most distinct 
between the two groups (Chapter 2). The NPO and lCM methods not only 
discriminate CF from non-CF, but within the group of CF patients variabie 
responses to secretagogues and inhibitors could be observed (Chapter 4 and 
5), indicating different degrees of chloride membrane permeability. In earlier 
lCM studies, the milder CF patients such as compound heterozygous for the 
mild A455E mutation appeared to exhibit a more active chloride transport 
than the CF patients with more severe phenotypes.l3 Moreover, in these 
studies chloride conductances in response to cAMP-agonists, but also in 
response to Ca2+-inducing agonists, were detected in a minority of iJ.F508 
homozygous patients. 13 In this thesis, the NPO and lCM methods were 
effectively utilized to further evaluate the amount of chloride conductance in 
CF patients homozygous for the 111'508 CFTR gene mutation and various 
other genotypes. Moreover, by using protocols for the NPO and lCM 
measurements in which the drugs were added in aspecific sequence, 
different chloride conductance pathways could be segregated in respiratOly 
and intestinal epithelia. 
presence and or/gin of residual Cl secretion: respiratory tract 
In the investigated group of 74 81'508 homozygous CF individuaIs, we 
observed spontaneous chloride eonductance in the NPD measurement in 22 
out of 74, and 7 with chloride conductance in response to the j1-adrenergic 
agonist isoprenaline (Chapter 5). Presently known chloride conductanees 
that are stimulated by cAMP, are Ihe ORCG'4 and CFTR15. However, the 
ORCC has only been observed to react 10 slimulalion by cAMP- or PKA-
agonists in the presence of functional CFTR.l6 Therefore, the finding of 
cAMP-induced chloride currents by isoprenaline, in the epithelial eells of a 
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small number of lIF508 homozygotes suggests the presence of at least some 
active nF508 CFTR in the apical membrane. 
Responses to ATP were observed in 55 of the 74 patients. ATP is reported to 
increase intracellular calcium concentrations by initiating the 
phosphoinositide metabolism and thereby inducing Ca"-dependent chloride 
secretOly pathways.17,18,19 Additional studies in CF and contral eells have 
shown that the induction of chloride secretion by apical ATP is rather 
complex,'o,,! and might involve both the cAMP- and Ca"-mediated chloride 
conductance pathways. However, since we have already stimulated the beta-
adrenergic pathway with isoprenaline previous to the addition of ATP, the 
observed additional ATP responses will be malnly induced by the Ca"-
mediated pathway, and is likely to involve apical Ca2'-dependent Cl' 
channels. 3,4,22~24 
Presence and orlgin of residual Cl secretion: intestinal tract 
In the lCM measurements of 55 nF508 homozygous CF twins and siblings 
selected for their extreme phenotypes (Chapter 4), the application of cAMP-
agonists induced a chloride secretory response in 40 (73%) of the 55 patients 
of which interpretabie lCM tracings were obtained. This suggests that, as in 
the respiratol1' tissue, also in the intestinal tissue residual CFTR is present 
and responds to cAMP-agonists. 
Cornparison of carbachol responses registered before the addition of DIDS, to 
the histamine responses recorded after the incubation of the rectal tissue 
with DIOS, segregates OIDS-insensitive chlOlide channels like CFTR," from 
DIDS-sensitive chloride conductances, such as the outwardly rectifying 
chloride channeJ14 or the Ca2'-activated Cl' channels (CaCC).3.4.22.24 In 11 
individuals (20%) of the investigated nF508 homozygotes DIOS-sensitive 
chloride secretion was identified, indicating the presence of these alternative 
non-CFTR CI- conductances. 
The observation that DIDS-sensitive Ca2+-mediated residual Cl- secretion 
only appeared in lIF508 homozygous patients possessing residual cAMP-
activated chloride currents is not yet completely understood. As a possible 
explanation for this apparent co-expression of Ca2+-dependent chloride 
channels and lIF508 CFTR, one might postulate that a less stringent quality 
control not only causes enhanced trafficking of nF508 CFTR to the apical 
membrane, but also results in an increased expression of Ca2+ -dependent 
chloride channels. An alternative explanation, i.e. that expression of CFTR is 
directly coupled to the expression of Ca2+ -sensitive chloride channels, is 
unlikely since na DIDS-sensitive CI- current component was found in con trol 
patients (Chapter 4). 
Ta investigate whether DIDS-sensitive Ca2+-mediated currents also exist in 
tissues in which cAMP-rnediated conductances are absent, Ca2+-dependent 
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conductances should be further investigated in patients carrying two CFTR 
stopcodon mutations, and do not express any chloride conductance in 
response to cAMP-agonists. In cftr knockout mice, the expression of Ca2+-
dependent chloride channels is enhanced and was suggested to be beneficial 
for the disease phenotype.26-28 The mechanism for this overexpression of 
CaCC channels in the absence of CFTR has not been elucidated, but may 
involve enhanced transcription of genes encoding DIDS-sensitive chloride 
channels. Notably, th is overexpression was not observed in the intestinal 
tract of one of the cftl-/- knockout models,27 despite its dear overexpression 
in the respiratOly tract. 
IlFSOB CFTR 
The classifications of the different CFTR gene mutations29-3l and 
investigation of the properties of i1F508 CFTR in heterologous model systems 
categorise f'..F508 as a mutation that causes defective processing of the CFTR 
protein. The i1F508 CFTR protein is misfolded and unable to form a 
protease-resistant mature conformation causing CFTR to be retained in the 
ER. Consequently, CFTR fails to traffic to the ceU membrane and express 
chloride channel function at the correct cellular location.32,33,34 
However, the observations reported in this thesis demonstrate that a 
subgroup of i1F508 homozygous CF individuals are competent to respond to 
agonists of the cAMP-mediated chloride secretOly pathway in both 
respiratOly and intestinal tract, identified by a response to isoprenaline in 
the nasal epithelium (Chapter 5), and DlDS-insensitive chloride secretion in 
the intestinal tissue (Chapter 4 and 5). Since cAMP-sensitivity is the 
haUmark of CFTR, th is suggests that at least some functional "'F508 CFTR is 
present in the apical membranes of the epithelial ceUs in these organs and is 
capable to function as a chloride channel stimulated via the cAMP /PKA-
dependent signaling pathway. 
We suggest that the expression patterns of "'F508 CFTR in vivo might be 
different from that in heterologous expression experiments, and that in this 
subgroup of CF individuals, a portion of i1F508 CFTR is able to reach the 
plasma membrane. In support of our results, earlier studies have shown that 
i1F508 transfected ceUs exhibit chloride secretion,35 and that i1F508 mouse 
models present with a residual CFTR-like chloride conductance in the 
intestina136 and respiratory36,37 tissues. Moreover, recent studies have now 
observed cAMP-induced chloride currents in human biliary tissue specimens 
in which subnormal expression of f'..F508 CFTR was recognized.38 In 
addition, immunohistochemical studies performed on human ainvay,39,40 
intestinal41 and hepatobiliruy tissues,38 demonstrated apicallocalization of 
AF508 CFTR, in some cases indistinguishable from wild-type tissues.: l 
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In conclusion, this thesis showed by application of functional in vivo and ex 
vivo assays that respiratory and intestinal tissues [rom Dur selected group of 
ilF508 CFTR homozygous individuals are competent to respond to agonists 
of the cAMP-dependent chloride secretOly pathway, which is the haUmark of 
CFTR-mediated chloride transport. 
The addition of chemical chaperones to CF eeUs, slieh as glycero142 or 
trimethylamine-N-oxide43 have shown to increase the targeting of ilF508 
CFTR to the ceU membrane. The finding described in this thesis of residual 
cAMP-sensitive chloride conductance in 8F508 homozygotes, implies that 
overcoming the ER quality contral barrier, and enhancing 8F508 CFTR 
processing to the apical membrane in CF individuals, might be a successful 
way to overcome the typical phenotype of 8F508 homozygotes. Therefore, 
further investigations of potential approaches to increase the transport of 
mutated CFTR to the eeU membrane, is of great importance for new 
therapeutic strategies in CF. 
Alternative Ca2+-dependent chloride secretion 
The Ca2+ -dependent chloride conductance has been ohsenred to be present 
in bath normal and CF airway epithelium. 44 In intestinal tissues contrasting 
results have been obtained, varying from a complete absence of Ca2+-
dependent chloride conductances in most contrals and the majority of CF 
individuals (Chapter 4 & ref 45), to a dear Ca2+-dependent DIDS-sensitive 
component in a subclass of ilFS08 homozygotes.l2,13 The existence of such 
Ca2+-dependent chloride conductances has been verified by studies in eftr -1-
knockout mice. In the CftrmlUNC/lI!lUi\'C knockout mouse,27 alternative 
conductances were obselved in the lung and pancreas, and in the 
Cftpl!lHsclmlllsCknockout mouse,26,28 such Ca2+-dependent chloride 
conductances were obselved in the respiratory, but also in the intestinal 
trad. 
The first detection of Ca2+ -dependent chloride conductance in CF individuals 
was predominantly in mild CF phenotypes. 13 The data presented here show 
that a substantial part of our selected 8F508 homozygotes with extreme 
phenotypes also exhibit this Ca2 + -dependent chloride membrane 
permeability.12 Patients with other genotypes such as patients with double 
stopcodon mutations and certain compound heterozygotes can also exhibit 
Ca2+-dependent chloride transport (Chapter 6 & ref 9). Several molecular 
entities that might be responsible for the Ca2+-dependent chloride 
conductanee, have now been cloned and characterized. In the intestinal 
tissues of healthy individuals, hCLCAl was identified, a chloride channel 
that is stimulated by increased intracellular Ca2+ concentrations, inhibited 
by DrDS, and is only expressed in small intestine and colon, and not in any 
other human organs.4 Furtherrnore, a rnember of the CIC family of chloride 
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channels, hCIC3, was identified and c10ned in T84 cells, which is activated 
by calcium-calmodulin dependent kinase, and also sensitive to DIDS.23 In 
the human respiratary tissue, hCLCA2 is recagnized which is stimulated by 
Ca2+-ianaphares and inhibited by DIOS. This channel seems ta be expressed 
in lung, trachea and mammary tissue.3 Future experiments, like 
immunohistochemical studies, Northern blot hybridization and RT-PCRs, in 
tissue preparations of cystic fibrosis individuals should reveal whether the 
above mentioned molecular entities are expressed in the CF ceUs, and 
whether their level of expres sion is modified in CF. Comparison of these 
results with the autcame of electrophysialagical tests like the NPO and lCM 
of these same individuals, can then verify if Ca2+-dependent chloride 
conductances are indeed coinciding with the molecular presence of these 
channels. 
A different study shauld investigate the expression patterns of the CaCC 
family in the respiratory and intestinal tracts within the same individual, in 
both controls and CF patients. More insight in the expression and function 
of these Ca2+-activated chloride conductances is desirabie, because of their 
possible influence on the CF phenotype. 
Correlation with phenotype 
The expres sion of cAMP- and/or Ca2+-activated residual chloride 
conductances in individuals with cystic fibrosis disease potentially 
campensate for the lack of CFTR-mediated chloride transport and might 
ameliorate CF disease severity. Consequently, exogenous administration of 
agents that initiate these residual chloride secretOly pathways, might be a 
novel therapeutic strategy in CF disease. 
Up till now, there are no studies known that try to hyperactivate residual 
CFTR in vivo as therapy in CF disease. However, in 2 differently generated 
cftr -/- knockout mice, an alternative Ca2+ -regulated chloride conductance 
was detected in several organs and was suggested to attenuate CF disease 
and protect the tissue from the absence of CFTR-mediated CI-
conductance.26-28 Clarke et a}27 found Ca2+-activated chloride currents in 
respiratOly and pancreatic tissues in their CjtliJlIVNc/mlUNc knockout mouse 
model, and postulated that th is is the reason far the lack of lung and 
pancreatic disease in these CF mice. Rozmahel et a}26 and Wilschanski et 
a128 found Ca2+ -mediated residual chloride conductance in the intestinal and 
respiratory tissues of a subgroup of their CjtrmlHsc/mlHsc knockout mice, and 
these mice had a prolonged survival compared to their CF knockout 
littermates. As previously mentioned, alternative Ca2+-mediated chloride 
channels have also been identified in human epithelia.3,4,22~24 In ainvays 
these channels are suggested ta be activated by stimulation with 
extracellular nucleotide triphosphates,18,46 Consequently, the induction of 
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chloride secretion by extracellular nucleotides has been suggested as a 
possible new therapeutic approach for CF airway disease.47 
As described above, we demonstrated the presence of cAMP- andj or Ca"-
mediated chloride conductances in the respiratory and intestinal tracts of 
lIF508 homozygous individuals within our group of investigated CF sib and 
twin pairs. To evaluate the importance of the expression of residual CFTR 
and/ or alternative CI- conductances in these two tissues, we compared the 
phenotype of ainvays and intestine to the observed CI- conductances in 
se1ected L\FS08 homozygous twins and sibs with the most disperate 
manifestation of CF disease: i.e. concordant pairs with relatively mild CF 
disease, condordant pairs with severe CF disease, and discordant pairs 
(Chapter 3). These individuals are highly informative to investigate modifying 
factors of the CF phenotype. Thus, we could analyze if the expression of 
cAMP- and/or Ca2+-mediated CI- conductance are important modifiers of CF 
disease and if they influence the disease manifestation of CF. 
Injluence of residual chloride conductance on pulmonary phenotype 
In the group of investigated AFS08 homozygotes described in th is thesis, a 
better lung function (FEVPerc) segregated with higher chloride transport 
properties of the respiratOly epithelium, which appears to be less CI--
impermeable (FigW'es 5.3a and b). Spontaneous basal chloride conductance 
(Cl--free response) and the capacity to secrete chloride in response to a 
cAMP-agonist (isoprenaline response) were only observed in clinically better 
patients. These data suggest a beneficial function of basal chloride 
conductance and/or residual cAMP-tnediated chloride secretion for 
respiratOly tissue performance, most likely by increasing the hydration of 
the viscous airway surface mucus and increasing its clearance from the 
respiratOly tract. These data of AF508 homozygous twins and sibs 
substantiate the findings of an earlier study in CF individuals with different 
CFTR mutation genotypes in whom residual chloride secretion provided a 
better indication of lung function than genotype.48 
The chloride conductance mediated by apical purinergic receptors and a 
subsequent increase of intracellular Ca2+ (ATP response), 18,46,49 did not 
con'elate with better lung function (P ~ 0.53, Table 5.5). This does not 
support the data suggested in CF knockout mice, that Ca2+-dependent 
chloride conductances induced by ATP, results in better lung function. 26-28 
Clinical trials have already investigated the safety of addition of extracellular 
nucleotides to the respiratoly epithelium, and showed that aerosolized UTP 
improves clearance of ainvay secretions in CF individuals to the basal rate of 
healthy controls. 50•5l Subsequently, the long-term inlluence of ATP and UTP 
on lung function should be investigated, to determine if continuous 
aerolization therapy with UTP is beneficial for the CF individual. 
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As was reported previously,52 we observed an increased membrane potential 
for Na+ in respiratory tissues of CF individuals as inferred from the amiloride 
response (Chapter 2,4 and 5). However, within the cohort of CF patients the 
magnitude of this response was not related to CF disease severity 
(FEVIPere), suggesting that the magnitude of Na+ hyperabsorption does not 
influence CF symptoms in the airways. 
In conclusion, in our cohort of AFS08 homozygous sib and twin pairs the 
expres sion of basal CI- conductanee and the response to isoprenaline are 
predictive for CF disease severity as expressed by the lung function 
parameter, FEV1Perc. 
Influence of residual chloride conductance on intestinal phenotype 
In the intestinal tissue, both the cAMP- and Ca2+-dependent chloride 
currents were evaluated against the CF disease manifestation in the 
intestinal tract (weight for height %predicted). The CFTR-dependent DIOS-
insensitive chloride secretion was predominantly seen in the mildly affected 
patients (Figures 5.4, 5.5 and 5.6). In contrast to the respiratoly tissue, the 
DIDS-sensitive Ca2+-dependent CI- secretion demonstrated to con'e1ate with 
CF phenotype and was more frequently observed in the severely affected 
"'F508 homozygotes. Studies in the biliruy tract of "'F508 homozygotes gave 
similar results in that the highest levels of Ca2+-dependent chloride currents 
were detected in the most affected tissue samples.38 Hence, either this 
alternative CI- conductance is not beneficial per se, or it is up-regulated in 
the absence of CFTR-activity to compensate for the lack of CI- transport and 
tissue damage would be even worse in the absent of this chloride 
conductance, as was postulated in the case of cftr knockout n1Ïce.27,53 
To compare the basic defect and the presence of alternative chloride 
conductances in the different tissues within one individual, NPD and lCM 
patterns were compared. The presence of basal chloride conductanee (CI--
free response) in the respiratory tissue was not associated with the presence 
of a chloride secretOly component in the carbachol andjor histamine 
response in the intestinal tissue (Fisher's exact test, Spearman rank test, 
Figures 5.6a and b). However, in this selected cohort of "'F508 homozygotes 
which consists of individuals with dispru'ate phenotypes (Chapter 3), the 
presence of a gluconate response in the respiratOly tissue and a positive 
DIOS influence in the intestinal tissue segregated with milder phenotype 
(Fisher's exact test, P = 0.01). Moreover, the runount of basal chloride 
conductance detected in the respiratol)' epithelium was related to the 
magnitude of the DIDS influence on CI- secretion in the intestine: the 
expression of basal chloride conductance in the airways correlated with the 
DIDS-insensitive intestinal chloride currents, i.e. CFTR-related chloride 
conductance (Spearman test, reaching the limit of significanee, Figure S.6c). 
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Thus J these two most: affected epithelia in CF showed similar expression 
patterns of the basic defect, i.e. CFTR-related chloride conductance, 
suggesting comparabie rnaturation and processing mechanisms of the 
mutated i1F508 CFTR in these two organ systems. 
In conclusion, the identical CFTR genotype of i1F508 homozygosity was not 
predictive for the appearance of disease symptoms, since a large variety of 
disease phenotypes were observed in this group. In contrast, the expression 
of the basic defect as measured by NPD and lCM was associated with clinical 
disease manifestation, which makes this group of patients with various 
expression of the basic defect and with extreme phenotypes, highly 
informative ta search for genetic modulators outside the CFTR gene. In 
addition, these data show that the utilization of the NPD and lCM 
measurements can assist in evaluation and prognosis of disease severity 
within slieh a group of identical CFTR genotypes, in contrast ta the sweat: 
test which is similar within the group of i1F508 homozygotes. For better 
understanding of the corre1ation between expression of residual chloride 
conductance and the manifestation of disease, follow up studies of individual 
CF patients would be especially interesting in which the cAMP- and calcium-
stimulated chloride conductance patterns in the epithelia are determined in 
early disease stages and monitored over time. Although protocols for these 
particular studies will be complicated, the interaction between CFTR-
mediated chloride permeability, Ca-dependent chloride conductance, and the 
resulting phenotype can be analyzed. 
lmportance of genetic background and environmentalfactors 
The varia bie manifestation of cystic fibrosis disease even in patients with the 
same CFTR mutation genotype necessitates the investigations to determine 
the factors that cause this heterogeneity. The approach of the European CF 
1\vin and Sibling Study to investigate mono- and dizygous i1F508 
homoZJrgous pairs is especially suitable to dissect the re1ative impact of 
environmental factors, residual chloride channel activity and other genetic 
factors than the CFTR genotype on a the phenotype phenotype of a 
monogenie disease like CF. 
By comparing dizygous pairs homozygous for the same CFTR gene lTIutation, 
the disease causing lesion and the intragenic haplotype were standardized 
and the variation in genetic background reduced. The intrapair variation 
among monozygous twins, who are genetically identical for their whole 
genome, can be used to delineate the influence of the environment on a trait 
by comparing the intrapair variability among monozygous pairs to that of 
dizygous pairs. 5,6 
Thus, to unravel the importance of genetic factors versus environmental 
factors for the expres sion of residual chloride conductanee, the intrapair 
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concOl'dance of dizygous sibling pairs was compared to that within 
monozygous pairs. 
Monozygous twins proved to be more concordant in their patterns of residual 
chloride conductance than dizygous pairs. This was predominantly seen in 
the intestinal tract. The cAMP responses, histamine responses and OIOS-
sensitivity of the chloride secretOly response were all significantly more 
concordant within monozygous twins than within dizygous pairs. In the NPO 
measurement, however, only the basal PO was significantly more similar in 
monozygous pairs. Thus, genetic factors are important for the expression of 
residual chloride secretion in the intestinal tissue, and are apparently not 
obscured by possible dîfferences in epigenetic factors. Since the investigated 
CF pairs were hamazygaus far the L\F508 CFTR mutatian, these genetic 
modifiers seem ta be lacated autside the CFTR gene. The disease 
manifestation in the respiratory tract appears more dependent on 
environmental factors than genetic influences, most obviously since this 
organ is far more accessible for influences from the environment. These data 
are substantiated by many studies that failed to discover evident 
associations between a certain genotype and the pulmonological phenotype. 
One of the goals of the European CF Twin and Sibling Study is ta further 
investigate pos si bie genetic modifiers of the CF phenatype, by influencing 
disease manifestation either in the intestinal or respiratmy tract. Therefore, 
part of the study is ta perfarm a gename-wiele linkage analysis by 
microsatellite genotyping (first starting with selected canelielate genes), anel 
association studies in patients with rare haplotypes are being executed. 
Electrophysiological characterization of rare genotypes 
Apart from the group of lIF508 homozygaus individuals we investigated the 
sweat test plus NPO and lCM patterns in a group of individuals with rare 
genotypes. This group consisted of homozygotes for the missense mutation 
E92K, for the stop mutations R553X or R1162X, for the splice mutations 
1898+3 A-G or 3849+lOkb C-T, the novel deletions CFTRelele2 or 
CFTRelele2,3(2Ikb) and in compaunel heterozygotes for lIF508 together with 
the complex allele lIF508-R553Q or lIF508-V12121. Sweat tests were all in 
the pathological range except one patient homazygaus for 3849+lOkb C-T, 
who had varying sweat test results on different occasions. And the individual 
with lIF508-R553QjllF508 had a normal sweat test in early life which 
progressed to abnormal sweat chloride levels at adolescent age. 
In NPO measurements, the basal POs were all elevated in the respiratory 
tissues of these CF individuals. Chloride conductance was detected upon the 
addition of a chloride free solution in the patient homozygous for 
CFTRdele2,3(2Ikb), 1898+3 A-G and 3849+lOkb C-T, and in ane ofthe 
individuals carrying the lIF508-VI212! allele (Tabie 8.1). The 3849+IOkb C-T 
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homozygote with a chloride free response also exhibited chloride 
conductance in response to isoprenaline, and three other patients showed 
isoprenaline responses: the homozygotes for R553X, R1162X and E92K. 
Within the 3 investigated sib palrs with CF (Chapter 6), no concordance was 
observed in their expression of chloride conductance. 
The chloride secretory responses in the intestinal tissue as observed by lCM 
are depicted in Table 8.1. 
Table 8.1 Expression of Cl- conduclance in nasal and intestinal tissues of individuols 





Cl- tree lso med. sensitive 
residual residual 
I CFTRdele2.3(21 kb)/ -10 - No No 
CFTRdele2.3(21 kb) 
2 R553X/R553X - -8 No No 
3 R1162X/R1162X - -2 No Yes 
4 R1162X/R1162X - - No Yes 
5 CFTRdele2/CFTRdele2 - - Yes No 
6 E92K/E92K - -11 Yes No 
7 I1F508-R553Q/ M508 - - Yes No 
8 I1F508-V12121/ 111'508 -3 - Yes Yes 
9 I1F508-V12121/ 111'508 - - No Yes 
10 1898+3 A-G/ 1898+3 A·G -3 - Yes No 
11 3849+ IOkb C-T/3849+ IOkb C-T -10 -2 Yes No 
12 3849+lOkb C-T/3849+IOkb C-T - - Yes No 
NOTE. Patlents 3&4. 8&9. 11 & 12 are slb pairS. CI·-tree: CI·-tree solution. Iso: 
Îsoprenaline. cAMP-med. residual: cAMP-mediafed residual secretion. 
The expres sion of residual cAMP-mediated chloride transport in the 
respiratOly andJ or nasal tissue might be attributed to residual CFTR activity 
in the homozygote for the missense mutation in the first ectoplasma tic 
domain (E92K), or in the 1898+3 A-G and 3849+lOkb C-T homozygotes,54 
who are capable to produce smaIl amounts of normal CFTR mRNA. In 
addition, canying the R553Q mutation on the same aIlele as llF508 has been 
identified to revert the llF508 mutation, suggesting that CFTR-induced 
chloride secretion might also be possible in this individual. 55 In the case of 
the llF508-V1212Ij llF508 siblings CFTR activity could hypothetically also be 
possible due to mutant CFTR as we have also seen in our llF508 
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homozygous patients who also exhibited small amounts of cAMP-dependent 
chloride transport (Chapter 4 and 5). 
The lCM and NPD patterns in some of our investigated patients homozygous 
for a large deletion or stop codon mutation were remarkable. In the case of 
the homozygous Rl162X siblings, residual chloride permeability may be 
ascribed to functioning CFTR, since levels of wild-type transcript have been 
detected. However, the out-of-frame deletion (CFTRdele2,3(21kb))56 and the 
R553X stop codon mutation57 are described as null alleles that do not 
produce any CFTR. Therefore, the residual chloride conductance seen in the 
respiratory tissue of these individuals suggests the presence of alternative 
non-CFTR chloride conductances. 3,4,22-24 On the other hand, these 
alternative chloride channels are activated by calcium, which does not 
explaln the isoprenaline response in the R553X homozygote alnvay. In 
epithelial cells, there have only been identified 3 non-CFTR cAMP-dependent 
CI- channels. However, one is the ORCC which only conducts chloride in the 
presence of functioning CFTR,16 the second was found in kidney cells but is 
only expressed in the basolateral membrane, 58 and the third is the CIC-2G 
CI- channel which is expressed in intestine59 but does not contribute to the 
transepithelial chloride transport in this tissue in short-circuit current 
measurements (personal communications, Dr. H.R. de Jonge). 
Calcium dependent chloride conductance was seen in the intestinal tract of 
at least two of our investigated individuals, homozygous for Rl162X and the 
compound heterozygote "'F508-V12121/"'F508, indicated by a DlDS-sensitive 
chloride secretory response. As stated earlier, such a DIDS-sensitive chloride 
conductance in the gut has also been detected by Gruber et al. 4 
Two of the three investigated sib pairs were observed with similar chloride 
secretOly patterns in their intestinal tissues. 
The electrophysiological identification of this group of rare genotypes shows 
variabie chloride conductance patterns without a dear-cut correlation 
between residual chloride conductance expressed in respiratOly and 
intestinal tissue. Moreover, the absence of concordance in the chloride 
conductance patterns in the 3 sib pairs, especially in the respiratory tract, 
demonstrates that other factors, such as environmental and non-CFTR 
genetic factors, are important determinants for the capacity to transport 
chloride. 
In conclusion, these investigations emphasize the variabie expression of the 
basic defect in the different tissues in patients with these rare genotypes, 
and the complex relationship between genotype and phenotype in cystic 
fi brosis disease. 
Future research should be directed towards the electrophysiological 
characterization of larger groups of CF patients with different genotypes, to 
gain more insight into the capacity of these persons to express CFTR and 
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transport chloride relative to their type of gene alterations. The knowledge on 
the existence of alternative chloride channels would increase by investigating 
chloride conductance pattems in additional individuals carrying definite stop 
codon mutations in whom no CFTR mRNA levels have been identified. 
Complexities in diagnosing CF 
As was shown in this thesis, the methods of NPD and lCM give clear 
distinction between controls and CF patients homozygous for the ..ó.F508 
mutation. The i1F508 mutation is classified as severe and all i1F508 
homozygotes show clear clinical manifestation of CF. And although these 
patients show considerabie variation in the expres sion of residual chloride 
secretion in both the respiratory and intestinal tracts, these amounts of 
chloride transport are all in the CF range, i.e. different [rom the contral 
group. Moreover, all these patients exhibited pathological sweat chloride 
concentrations > 60 mrnoljL. 
However, in specific cases the diagnostic process of CF is complicated. In 
Chapter 7a, a CF patient is presented with recurrent pulmonruy infections 
and pathological sweat chloride concentrations but with pancreas 
sufficiency, who was diagnosed with CF disease at 17 years of age. However, 
in CFTR mutation analysis no gene alterations were found. The fact that the 
CFTR mutation analysis is negative does not totally exclude the possibility of 
CF. Firstly, the detection rate of mutations is around 950/0,60,61 and it is 
estimated that about 10-20% of mutations are still unknown at present. 1 
However, the intragenic CFTR marker haplotype in the index case was 
similar to that in his asymptomatic sister, making CF disease unlikely since 
there would be total disc01'dance in disease manifestation both in the sweat 
gland and the pulmonary disease. There is the possibility of a de novo 
mutation in the non-coding region of the CFTR gene, although this event and 
its consequence to establish CF disease are highly unlikely. In this 
individual both the NPD and lCM examinations showed normal chloride 
transport, excluding the diagnosis of CF. 80 in this case in which sweat test 
was positive and CFTR mutation analysis did not give any conc1usion, the 
diagnosis of CF could be excluded by the assistance of the NPD and lCM 
results. Some patients in our clinic have been observed with a borderline or 
positive sweat test, with normal lCM results and only single symptoms of CF 
disease, e.g. oligospermia or nasal polyps, in whom CF diagnosis should be 
doubted (unpublished observations). 
In another individual in whom the diagnosis was not unequivocally provided 
by the exciting diagnostic tests, we found severe pulmonary disease with 
recurrent infections, continuous cough, and nasal polyps. However, repeated 
sweat tests gave normal chloride concentrations, she is pancreas sufficient, 
and with DNA analysis only one allele showed a sequence alteration, 1898+3 
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A->G. The lCM showed normal results concordant with the absence of 
intestinal disease while NPD gave results consistent with CF disease 
supporting the clinical manifestation of severe pulmonary disease. This 
individual is of consanguineous decent which leads to increased 
homozygosity for her overall genotypes. Moreover, she is homozygous for 
TG 12T7 (intron 8) and V470 (exon 10) which cause reduced mature CFTR 
protein and decreased chloride channel activity, respectively.62 We 
hypothesize that this genetic constitution has a negative effect on the CFTR 
expression in the lung, while this genotype does not influence the expression 
in the intestine, suggesting that one mutation and very unfavourable genetic 
background can cause a CF phenotype. The possibility that this patient 
might have CF is rather unlikely, since the other allele showed no sequence 
alterations in any of the coding regions, flanking introns, or the promotor 
area up to --4 kb. Thus, it could only be an unknown polymorphism in a 
non-coding region that would cause CF. In addition, patients with normal 
sweat tests and pulmonary disease in which two CFTR mutations were 
found, always showed a subnormal lCM, which was not the case in this 
individual, rejecting the diagnosis of CF as weIl. 
These two atypical cases illustrate the importance of using various 
diagnostic tests in the diagnostic process for CF disease. The sweat test has 
been shown to give false positive results, for instanee in neonates in whom 
Na+ transport is not yet matured,63 and false negative results occur due to 
specific genotypes54 andfor in cases of mild CF.64,65 DNA mutation analysis 
confi.rms CF disease when two mutations are found, however not all 
mutations are known yet. In addition, laboratories use different methods for 
CFTR genotyping and in recent studies a rather high error percentage was 
found in identifying the alterations in the CF alleles.66 In individuals in 
whom the sweat test and the CFTR mutation analysis give inconclusive 
results, the addition of further tests is indicated. In these cases, 
electrophysiological examinations, slich as the NPD and lCM, can certainly 
aid in the diagnosis and give information on the chloride transport in the 
specific tissue and moreover, recognize or discard the CF diagnosis (Chapter 
7). Therefore, we suggest to expand the standard diagnostic process. lf CF is 
suspected, the sweat test and the CFTR mutation analysis should be 




J. Welsh MJ, Tsui L-C, Baat TF, Beaudet AL. Cystic fibrosis. In: Seriver CR, 
Beaudet AL, Sly WS, Valle D, eds. Thc metabolic and molecular basis of 
inherited disease. New York: McGraw-Hill, 1995:3799-3876. 
2. hUp:j jwmv.gdb.orgj 
3. Oruber AD, Schreur KD, Ji H-L, Fuller CM, Pauli BU. Molecular cloning and 
transmemhrane structure of hCLCA2 [rom human lung, trachea, and 
mammary gland. Am J PhysioI1999;276:CI261-CI270. 
4. Gruber AD, Elble Re, Ji H-L, Schreur KD, Fuller CM, Pauli BU. Genomic 
cloning, molecular characterization, and functional analysis of human CLCAl, 
thc first human member of thc family of Ca2+-activated Cl- channel proteins. 
Genomics 1998;54:200-214. 
5. Martin N, Boomsma D, Machin G. A twin-pronged aUack on complex traits. 
Nat Genet 1997;17:387-392. 
6. Phillips DI\V. Twin studies in medical research: can they teil us whether 
diseases are genetically determined? Lancet 1993;341:1008-1009. 
7. Risch N, Zhang H. Extreme discordant sib pairs for mapping quantitative trait 
loci in humans. Science 1995;268:1584-1589. 
8. Eaves L, Meyer J. Locating human quantitative trait loci: guidelines for the 
selection of sibling pairs for genotyping. Behav Genet 1994;24:443-455. 
9. Knowies MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: 
techniques and protocols for assessing efficacy of gene transfer in cystic 
fibrosis. Hum Gene Ther 1995;6:445-455. 
10. Bronsveld I, Bijman J, de Jonge HR, Sinaasappel M, Veeze HJ. Gluconate 
response of nasal epithelium to discriminate between CF and non-CF in case of 
high baseline nasal potential difference. Pediatr Pulmonol 1996;Suppl 13:244. 
11. Veeze HJ, Sinaasappel M, Bijman J, Bouquet J, de Jonge HR. Ion transport 
abnormalities in rectal suction biopsies from children with cystic fibrosis. 
Gastroenterology 1991;101:398-403. 
12. Bronsveld I, Mekus F, Bijman J, Ballmann M, Greipel J, Hundrieser J, Halley 
DJJ, Laabs U, Busche R, de Jonge HR, Tümmler B, Veeze HJ, and The 
European 1\vin and Sibling Study Consortium. Residual chloride secretion in 
intestinal tissue of ~F508 homozygous twins and siblings with cystic fibrosis. 
Gastroenterology 2000; 119:32-40. 
13. Veeze HJ, Halley DJJ, Bijman J, de Jongste JC, de Jonge HR, Sinaasappel M. 
Determinants of mild symptoms in cystic fibrosis patients: residual chloride 
secretion measured in rectal biopsies in relation to the genotype. J Clin Invest 
1994;93:461-466. 
14. Schwiebert EM, FIotte T, Cutting GR, Guggino WBo Both CFTR and outwardly 
rectifying chloride channels contribute to cAMP-stimulated whole eeU chloride 
currents. Am J Physiol 1994;266:CI464-C1477. 
15. Bear CE, Li C, Kartner N, Bridges RJ, Jensen TJ, Ramjeesingh M, Riordan JR. 
Purification and functional reconstitution of the cystic fibrosis transmembrane 
conductance regulator (CFTR). CellI992;68:809-818. 
16. Jovov B, Ismailov I1, Berdiev BK, Fuller CM, Sorscher EJ, Dedman JR, Kaetzel 
MA, Benos DJ. Interaction between cystic fibrosis transmembrane 
208 
Discussion Qlld future perspectives 
conductance regulator and outwardly rectified chloride channels. J Biol Chem 
1995;270:29194-29200. 
17. Brown HA, Lazarowski ER, Boucher RC, Harden TK. Evidence that UTP and 
ATP regulate phospholipase C through a common extracellular 5'-nucleotide 
receptor in human ainvay epithelial cells. Mol Pharmaco11991;40:648-655. 
18. Mason S, Paradiso AM, Boucher RC. Regulation oftransepithelial ion transport 
and intracellular calcium by extracellular adenosine triphosphate in human 
normal and cystic fibrosis ainvay epithelium. Br J Phannacol 1991; 103: 1649-
1656. 
19. Barnru'd EA, Burnstock G, Webb TE. G protein-coupled receptars for ATP and 
other nucleotides: a new receptor family. Trends Pharmacol Sci 1994;15:67-70. 
20. Stutts MJ, Fitz JG, Paradiso AM, Boucher RC. Multiple modes of regtllation of 
ainvay epithelial chloride secretion by extracellulru' ATP. Am J Physiol 
1994;267:CI442-C1451. 
21. CantielIa HF, Prat AG, Reisin IL, Ercole LB, Abraham EH, Amara JF, Gregory 
RJ, Ausiello DA. External ATP and its analogs activate the cystic fibrosis 
transmembrane conductance regulator by a cyclic AMP-independent 
mechanism. J Biol Chem 1994;269:11224-11232. 
22, Anderson MP, Sheppard DN, Berger HA, Welsh MJ. Chloride channels in the 
apical membrane of normal and cystic fibrosis ainvay and intestinal epithelia. 
Am J PhysioI1992;263:LI-Ll4. 
23. Huang P, Di A, Xie W, Johnson XD, Campbell N, Kaetzel MA, Nelson DJ. 
Molecular identification of the Ca1v[KII-activated chloride conductance: 
candidate by-pass pathway. Pediatr PulmonoI1999;SuppI19:201. 
24. \Vei L, Vankeerberghen A, Cuppens H, Eggermont J, Cassiman JJ, Droogmans 
G, Nilius B. Interaction between calcium-activated chloride channels and the 
cystic fibrosis transmembrane conductance regulator. Pflugers Arch 
1999;438:635-641. 
25. Cliff\VH, Schoumacher RA, Frizzell RA. cAMP-activated Cl channels in CFTR-
transfected cystic fibrosis pancreatic epithelial cells. Am J Physiol 
1992;262:CI154-CI160. 
26. Rozmahel R, Wilschanski M, Matin A, Plyte S, Oliver M, Auerbach W, Moore A, 
Forstner J, Durie P, Nadeau J, Bear C, Tsui L-C. Modulation of disease severity 
in cystic fibrosis transmembrane conductance regulator deficient mice by a 
secondary genetic factor. Nat Genet 1996;12:280-287. 
27. Clarke LL, Grubb BR, Yankaskas JR, Cotton CU, McKcnzie A, Boucher RC. 
Relationship of a non-cystic fibrosis transmembrane conductance regulator-
mediated chloride conductance to organ-Ievel disease in Cftr{-/ -) mÎce. Proe 
Natl Acad Sci USA 1994;91:479-483. 
28. Wilschanski MA, Rozmahel R, Beharry S, Kent G, Li C, Tsui L-C, Durie P, Bear 
CE. 111 vivo measurements of ion transport in long-living CF mice. Biochem 
Biophys Res Commun 1996;219:753-759. 
29. Tsui L-C. The spectrum of cystic fibrosis mutations. Trends Genet 1992;8:392-
398. 
30. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel 
dysfunction in cystic fibrosis. Cell 1993;73: 1251-1254. 
31. Wilschanski M, Zielen ski J, Markiewicz D, Tsui L-C, Corey M, Levison H, Durie 
PR. Corre1ation of sweat chloride concentration with classes of the cystic 
209 
Chop/er 8 
fibrosis transmembrane conductance regulator gene mutations. J Pediatr 
1995; 127:705-710. 
32. Cheng SH, Gregory RJ, Mru'shaU J, Paul S, Souza DW, White GA, O'Riordan 
CR, Smith AE. Defective intracellular transport and processing of CFTR is the 
molecular basis of most cystic fibrosis. Ce111990;63:827-834. 
33. Kartner N, Augustinas 0, Jensen TJ, Naismith AL, Riordan JR. Mislocalization 
of delta FS08 CFTR in cystic fibrosis sweat gland. Nat Genet 1992; 1 :321-327. 
34. Zhang F, Kartner N, Lukacs GL. LÏmited proteolysis as a probe for arrested 
conformational maturation of delta FS08 CFTR. Nat Shuct Biol 1998;5: 180-
183. 
35. Drumm ML, Wilkinson DJ> Smit LS, Warrell RT, Strong TV, Frizzell RA, 
Dawson De, Collins FS. Chloride conductance expressed by delta F508 and 
other mutatnt CFTRs in Xenopus oocytes. Science 1991;254: 1797-1799. 
36. van DOOl'ninck JH, French PJ, Verbeek E, Peters RHPC, Marreau H, Bijman J, 
Schalte BJ. A mause model for the cystic fibrosis lo.F508 mutation. EMBO J 
1995;14:4403-4411. 
37. Kelley TJ, Thomas K, Milgram WH, Dlumm ML. In vivo activation of the cystic 
fibrosis transmembrane conductance regulator mutant b.F508 in murine nasal 
epithelium. Proe Nat! Aead Sci USA 1997;94:2604-2608. 
38. Dray-Charier N, Paul A, Scoazec J, Veissière D, Mergey M, Capeau J, Soubrane 
0, Housset C. Expression of delta F508 cystic fibrosis transmembrane 
conductance regulator protein and related chloride transport properties in the 
galibladder epithelium from cystic fibrosis patients. HEPATOLOGY 
1999;29: 1624-1634. 
39. Dupuit F, Kälin N, Brezillon S, Hinnrasky J, Tümmler B, Puchelle E. CFTR and 
differentiation markers exprcssion in non-CF and L\F508 homozygous CF nasal 
epithelium. J Clin Invest 1995;96:1601-1611. 
40. Wci X, Eisman R, Xu J, Harsch AD, Mulberg AE, Bevins 
CL, Glick MC, Scanlin TF. Turnover of the cystic fibrosis transmembrane 
conductance regulator (CFTR): slow degradation of wild-type and lo.F508 CFTR 
in surface membrane preparations of immortalized ainvay epithelial cells. J 
CeU Physiol1996;168:373-384. 
41. Kälin N, Claass A, Sommer M. Puchelle E, Tümmler B. lo.F508 CFfR protein 
expression in tissues from patients with cystic fibrosis. J Clin Invest 
1999; 103: 1379-1389. 
42. Denning GM, Anderson MP, Amara J, Marshall J, Smith AE, Welsh MJ. 
Processing of mutant cystic fibrosis transmembrane conductancc regulator is 
temperature-sensitive. Nature 1992;358:761-764. 
43. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR. Glycerol reverses the 
misfolding phenotype of the most common cystic fibrosis mutation. J Biol 
Chem 1996;271:635-638. 
44. Boucher RC, Cheng EHC, Paradiso AM, Stutts MJ, Knovlies MR, Earp HS. 
Chloride secretory response of cystic fibrosis human ainvay epithelia. J Clin 
Invest 1989;84:1424-1431. 
45. Berschneider HM, Knowies MR, Azizkhan RG, Boucher RC, Tobey NA, Orlando 
RC, Powell D\V. Altered intestinal chloride transport in cystic fibrosis. FASEB J 
1988;2:2625-2629. 
210 
Discussion Qnd future perspectiues 
46. Knowies MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of 
chloride secretion in the airway epithelia of patients "\vith cystic fibrosis. N Engl 
J Med 1991;325:533-538. 
47. Knowies MR, Olivier KN, Hohneker KW, Robinson J, Bennett WO, Boucher RC. 
Phannacologic treatmcnt of abnormal ion transport in the airway epithelium in 
cystic fibrosis. Chest 1995; 107:71S-76S. 
48. Ho LP, Samways JM, Porteous DJ, Dorin JR, Carothers A, Greening AP, Innes 
JA. Con'elation behveen nasa! potential difference measurements genotype and 
clinical condition in patients with cystic fibrosis. Eur Respir J 1997; 10:2018-
2022. 
49. Taylor AL, Schwiebert LM, Smith JJ, ICing C, Jones JR, Sorscher EJ, 
Schwiebert EM. Epithelial P2X purinergic receptor channel expression and 
function. J Clin Invest 1999;104:875-884. 
50. Bennett WD, Olivier KN, Zeman KL, Hohneker KW, Boucher RC, Knowies MR. 
Effect ofuridine 5'-triphosphate plus amiloride on mucociliruy clearance in 
adult cystic fibrosis. Am J Respir Crit Care Med 1996;153:1796-1801. 
51. Olivier KN, Bennett WD, Hohneker K\V, Zeman KL, Edwards W, Boucher RC, 
Knowies MR. Acute safety and effects on mucociliruy clearance of aerosolized 
uridine 5'-triphosphate + / - amiloride in normal human adults. Am J Respir 
Crit Care Med 1996;154:217-223. 
52. Knowies M, Gatzy J, Boucher R. Increased bioelectric potential difference 
across respiratOly epithelia in cystic fibrosis. N Engl J Med 1981 ;305: 1489-
1495. 
53. Grubb BR, Vick RN, Boucher RC. Hyperabsorption of Na+ and raised Ca2+-
mediated Cl· secretion in nasal epithelia of CF mice. Am J Physiol 
1994;266:C 14 78-C 1483. 
54. Highsmith WE, Burch LH, Zhou Z, Olsen JC, Boat TE, Spoek A, GOlVOy JD, 
QuitteIl L, Friedman KJ, Silverman L, Boucher RC, Knowies MR. A novel 
mutation in the cystic fibrosis gene in patients with pulmonruy disease but 
normal sweat chloride concentration. N Engl J Meel 1994;331:974-980. 
55. Teem JL, Berger HA, Ostedgaard LS, Rich DP, Tsui L-C, Welsh MJ. 
Identifieation of revertants for the C)'stic fibrosis L1F508 mutation using STE6-
CFTR chimeras in yeast. CellI993;73:335-346. 
56. Dörk T, Macek Jr M, Mekus F, et al. Characterization of a novel 21-kb deletion, 
CFTRdele2,3(21kb), in the CFTR gene: a cystic fibrosis mutation of Slavic origin 
common in Central and East Europe. Hum Genet 2000;106:259-268. 
57. Will K, Reiss J, Dean M, Schlosser M, Slomski R, Sehmidtke J, Stuhrmann M. 
CFTR transcripts are undetectable in lymphocytes and respiratory epithelial 
eells of a CF patient homozygous for the nonsense mutation R553X. J Med 
Genet 1993;30:833-837. 
58. Winters CJ, Reeves WB, Andreoli TE. Cl- channels in basolateral TAL 
membranes: XIII. Heterogeneity between basolateral MTAL and CTAL Cl· 
channe1s. Kidney Int 1999;55:593-601. 
59. Stroffekova K, Kupert EY, Malinowska DH, Cuppoletti J. ldentifieation of the 
pH sensor and activation by chemical modifieation of the CIC-2G CI- channel. 
Am J Physiol 1998;275:CI113-CI123. 
211 
Cl1apter 8 
60. Dörk T, Mekus F, Schmidt K, et al. Detection of more than 50 different CFTR 
mutations in a large group of German cystic fibrosis patients. Hum Genet 
1994;94:533-542. 
61. Liechti-Gallati S, Schneider V, Neeser D, Kraemer R. 1\vo buffer PAGE system-
based SSCPjHD analysis: a general protocol for rapid and sensitive mutation 
screening in cystic fibrosis and any other human gene tic disease. Eur J Hum 
Genet 1999;7:590-598. 
62. Cuppens H, Lin \V, Jaspers M, Costes B, Teng H, Vankeerberghen A, Jorissen 
M, Droogmans G, Reynaert I, Goossens M, Nilius B, Cassiman JJ. Polyvariant 
mutant cystic fibrosis transmembrane conductance regulator genes. J Clin 
Invest 1998; 10 1 :487-496. 
63. Veeze HJ. Diagnosis ofcystic fibrosis. NethJ Med 1995;46:271-274. 
64. Veeze HJ, Gan K-H, Heijerman HOM. A cystic fibrosis mutation associated with 
mild lung disease. N Engl J Med 1995;333: 1644. 
65. Strong TV, Smit LS, Tw'pin SV, Cole JL, Hon CT, Markiewicz D, Petty TL, Craig 
M\V, Rosenow EC, Tsui L-C, Iannuzzi MC, Knowles MR, Collins FS. Cystic 
fibrosis gene mutation in two sisters with mild disease and normal sweat 
electrolyte levels. N Engl J Med 1991;325:1630-1634. 
66. Dequeker E, Cassiman JJ. Evaluation of CFTR gene mutation testing methods 
in 136 diagnostic laboratories: report of a large European external quality 




Cystic fibrosis (CF) is considered to be a monogenic disease, implicating that it is 
caused by mutations within a single gene. It is an autosomal recessive disease 
resulting from alterations in both chromosornal copies of the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene. CF is the most common severe 
autosomal recessive disease within the Caucasian population, with an approximate 
mean incidence of 1 in 2500 births in Western European countties. The incidence in 
the Netherlands has been estirnated around 1 in 3600 life births. There are over 800 
known CFTR mutations of which a deletion of the phenylalanine residue at position 
F508 ('ó'F508) is the most frequent CFTR mutation, and occurs in about 70% of CF 
alleles in the Caucasian population. The CFTR gene encodes an adenosine 3',5'-
cyclic monophosphate (cAMP)-regulated chloride channel found in the apical 
membrane of epithelial cells. The clinical symptoms in CF are caused by the 
impaired epithelial chlotide transport in many exocrine glands, but major 
manifestations involve the respiratOly and gastrointestinal tracts. Typieal CF is 
characterized by the accumulation of viscous mucus resulting in chronic 
obstructions and fibrosis of the pulmonaly tissue with cough, tachypnea and 
wheezing due to recurrent bronchopulmonary infections. The intestinal tract 
demonstrates with malabsorption and pancreatic insufficiency, which causes 
steatorrhea and failure to thrive. Sweat glands are most consistently affected in CF 
and produce sweat with elevated chloride and sodium levels. 
The abnormal chloride transport in CF can be determined byelectrophysiological 
methods such as the sweat test, the nasal potential difference measurement (NPD} 
and the intestinal current measurement (lCM), whieh test the conductance 
properties for sodium and chloride ions of sweat gland, respiratory and intestinal 
epithelium, respectively. Chapter 2 describes the methods of NPD and lCM, and 
compares the results within a group of CF individuals to that in controls. With the 
NPD the following values are dctermined: baseline PD, Naf-transport, basal Cl-
conductance, cAMP-mediated Cl- conductance and the ATP-stimulated CI-
conductance. In the lCM, a unique sequence for the addition of drugs has been 
introduced to segregate the different CI- conductances that might be present in the 
intestinal epithelium. Consecutively measured are: Na+-transport, the Ca2+ jPKC 
pathway of Cl- secretion, cAMP-dependent Cl- secretion, and finally the tissue is 
incubated with 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) to inhibit the 
alternative CI- conductances, after which the Ca2+ jPKC pathway is stimulated 
again. The response to cAMP assesses the presence of CFTR, while the Ca2+ jPKC-
mediated pathway involves both CFTR and alternative CI- conductances. By 
challenging this pathway before and af ter the incubation of the tissue with DIDS, 
sensitivity of the chloride channels to DIDS could be determined. DIDS-insensitive 
CI- secretion indicates the presence of CFTR, while DIDS-sensitive Cl- secretion 
indicates the presence of alternative Ca2+-dependent Cl- channels. 
When NPD results of CF patients are compared to controls, the Naf-transport is 
larger in CF. Moreover, the chloride free solution and addition of isoprenaline exert 
no effect in the typieal CF condition, while controls exhibit chloride conductance in 
response to these solutions. The ATP response in most CF patients is larger than in 
controls, although this response varies considerably between CF patients. 
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When we compare the mean lCM values between the CF group and controls, we see 
that none of the mean values for the responses to carbachol, cAMP, and histamine 
overlap between the two groups. 
In conclusion, when utilizing these protocols for NPD and lCM measurements in CF 
disease, significant distinction can be made behveen the electrophysiological 
characteristics of the respiratoI}' and intestinal tissues of non-CF versus CF 
individuals. Therefore, these methods can aid and facilitate the diagnostic process. 
Moreover, chloride conductances of different origin can he segregated with these 
electrophysiological methods. 
The European CF twin and siblillg study has been initiated to dissect the importance 
of genetic and environmental modifiers of CF disease. In Chapter 3, data collection 
for a cohort of 277 sibling pairs, 12 dizygous twin pairs and 29 monozygous twin 
pairs is described. Of the 318 CF hvin and sib pairs, 114 were reported to be .öFS08 
homozygous. From these 114 pairs two clinical parameters most sensitive for 
course and prognosis of CF, i.e. wfh% (representative for the nutritional status) and 
FEVPerc (representative for the pulmonruy status) were obtained. Intrapair 
discOl'dance was assessed by the intrapair differences in wfu% and FEVPerc and by 
DELTA, a composite parameter defined by linear combination of w1]},% and FEVPerc 
in order to describe discordrulce with respect to the overall disease severity. 
Monozygous twins had a significantly lower DELTA than dizygous twins (P'" 0.05) 
indicating that CF disease severity is modulated by an inherited component besides 
the CFTR gene itself. Extreme phenotypes are considered to be more informative for 
the analysis of any quantitative trait. Thus, we aimed to quantify disease-severity 
and intrapair discordance in order to select pairs with the extreme phenotypes DIS 
(discordant patient pairs), CON+ (concordant and mildly affected patient pairs) and 
CON- (concordant and severely affected patient pairs). The algorithm reliably 
discriminated between pairs DIS, CON+ and CON- among the cohort of .öF508 
homozygotes. The selected pairs from these categories demonstrated non-
overlapping properties for wfh%, FEVPerc and the intrapair difference of both 
parameters. 
Chapter 4 investigates the residual Cl- secretion in intestine of .öF508 homozygous 
CF twins and siblings, and examines the contribution of CFTR and alternative CI-
conductances to transepithelial chloride transport, by applying the lCM method. 
The expression of residual chloride conductances, either by CFTR-mediated or 
alternative chloride channels, is suggested to modify CF disease phenotype and 
compensate for the lack of CFTR-mediated chloride secretion. 
Twins and siblings with identical CF1'R genotypes are investigated to determine 
impact of factors other than CFTR on chloride secretion. A majority of .öF508 
homozygous CF patients (73%) shows cAMP-mediated Cl- secretion, while 20% 
shows DIDS-sensitive Ca2+-activated Cl- secretion. In this cohort of investigated CF 
patients, DIDS-sensitive alternative chloride conductance is onIy seen in CF 
individuals also responding to cAMP-agonists. These results suggest the presence of 
CFTR-mediated Cl- secretion in a subgroup of patients, implying that a portion of 
L\F508 CFTR can be processed in vivo and function as chloride channel in the apical 
membrane of intestinal cells. Moreover, a considerable number of .öF508 
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homozygous patients express chloride conductances other than CFTR in their 
intestinal epithelium. 
Chapter 5 analyzes the impact of chloride secretion by residual activity of CFTR 
and/or by alternative chloride channels on disease manifestation in respiratory and 
intestinal tracts, in L\F508 homozygous twins and siblings with CF. The most 
informative pairs, as selected in Chapter 3, who are either concordant for a mild or 
severe phenotype, or discordant in phenotype are analyzed. In a majority of patients 
cAMP- and/or Ca2+-regulated chloride conductance is detected, i.e. 84% and 73% of 
patients in the airways and intestine, respectively. In respiratory tissue, the 
expression of basal CFTR-mediated chloride conductance demonstrated by 30% of 
L\F508 homozygotes, and the response to a cAMP-agonist seen in 9% of patients, are 
identified as positive predictors for milder CF disease. In intestinal tissue DIDS-
insensitive Cl~ secretion, indicative of functional CFTR channels, segregates with 
milder phenotype, whereas DIDS-sensitive chloride secretion is mainly observed in 
more severely affected patients. The more concordant chloride conductance 
patterns within monozygous twins compared to dizygous pairs, especially in the 
lCM results, imply that genes other than dF508 CFTR significantly influence the 
manifestation of the basic defect. 
In Chapter 6 the expres sion ofresidual CFTR and/or alternative Cl- conductances 
is investigated in rare CF genotypes by applying the sweat test and the NPD and 
lCM methods. CF patients were analyzed, homozygous for the missense mutation 
E92K, the stop mutations R553X, R1162X, the splice mutations 1898+3 A-G, 
3849+10kb C-T, the navel deletions CFTRdele2, CFTRdele2,3(21kb) and in carriers 
for dF508-R553Q or dF508-V 12121. Residual CFTR activity was necessary to confer 
Jower sweat electrolyte concentrations or exocrine pancreatic sufficiency. All 
investigated patients exhibited same chloride conductance, either cAMP- and/or 
Ca2+-mediated, in pulmonary and/or intestinal tract. The expression ofalternative 
chloride channels such as the calcium activatable or the outwardly rectifying 
chloride channels may partially compensate for defective CFTR and modulate the 
manifestation of respiratory and gastrointestinal disease in CF. Ta determine if this 
is true in patients with these genotypes, larger groups will have to be investigated. 
In Chapter 7 the difficulties in confirming CF diagnosis are described by presenting 
two patients with atypical CF symptoms. The patient of the first case presents with 
a pathological sweat test and CF-like pulmonary disease. However, CF diagnosis 
was excluded on the basis of his normal NPD and lCM results, and the fact that he 
is canying the same CFTR alleles as his asymptomatic sister. 
The other complex patient is from consanguineous descent and presents with 
normai intestinai Cl- transport as measured by lCM, and normal sweat test values. 
In contrast, she shows severe CF-like lung disease with recurrent nasal polyps, 
bronchitis, bronchiectasis, continuous cough, sputum production, airway 
infections, hypoxaemia and cachexia. This clinical picture was substantiated by 
abnormal NPD vaiues. Genetic analysis demonstrated only one disease-causing 
lesion, 1898+3 A->G, but also homozygosity for an unfavorable combination of 
intragenie polymorphisms. In addition, her consanguineous descent leads to a 
genome wide overrepresentation of homozygous genotypes, causing further 
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unfavorable genetic background. The data of this index case suggest that one 
disease-causing lesion together with unfavorable genetic background is sufficient to 
modify CFTR expression and/or function, and cause manifestation ofsevere CF 
lung disease. 
Chapter 8 discusses the findings in this thesis and its implications for further 
research. In short, in the investigation of the I1F508 homozygous CF cohort 
described in this thesis, specific protocols are applied for the NPD and lCM 
measurements to discriminate between the presence of residual CFTR and/or 
alternative Ca2+-dependent Cl- conductances. 
Moreover, in the diagnostic process of CF the methods of NPD and lCM should be 
employed in parallel to other diagnostic procedures like the sweat test and genetic 
CFTR mutation analysis, to determine the presence of CI- conductances in the 
respiratol)' and intestinal tissues. In contrast to the sweat test, which is similar in 
most I1F508 homozygous patients, specit1c NPD and lCM results are associated with 
better disease pal'ameters and predict milder manifestation of CF disease. 
The reports in this thesis of the European CF twin and siblirlg study show that the 
investigation of twin and sib pairs homozygous for the same CFTR mutation 
genotype and with extreme disease phenotypes, creates the opportunity to dissect 
the influence of genetic and environmental modifiers of CF disease. For a better 
understanding of CF pathogenesis, it is important to further investigate these 




Cystische fibrose (CF), ofwel taaislijmziekte, is een monogenetische ziekte die 
veroorzaakt wordt door mutaties in een enkel gen. Het is de meest voorkomende 
levensbedreigende autosomaal recessieve ziekte in de Kaukasische populatie, die 
ontstaat wanneer beide chromosomen van het CF gen, de cystic fibrosis 
transmembrane conductance regulator (CFTR), aangedaan zijn. In de Kaukasische 
populatie is de gemiddelde incidentie 1 op 2500 geboortes, en in Nederland wordt 
de incidentie geschat op 1 op 3600 geboortes. Er zijn meer dan 800 mutaties 
bekend van het CFTR gen, waarvan de deletie van een fenylalanine residue op 
positie 508, LlF508, de meest frequente mutatie is die op 70% van de CF allelen 
voorkomt. Het CFTR gen codeert voor een adenosine 3',5'-cyclic monophosphate 
(cAMP)-gereguleerd chloride (CI-) kanaal, dat voorkomt in de apicale membraan van 
epitheel cellen. De klinische symptomen in CF worden veroorzaakt door het 
gestoorde chloride transport in vele exocriene organen, maar de duidelijkste 
afwijkingen treden op in de tractus respiratorius en tractus gastrointestinalis. De 
ziekte wordt gekenmerkt door de produktie van taai slijm in de longen waardoor 
obstructie en schade van het weefsel optreedt. Klinische kenmerken zijn hoesten, 
het opgeven van taai slijm, een snelle ademhaling en recidiverende 
luchtweginfecties. In het maagdarmkanaal komt de ziekte tot uiting door aantasting 
van de alvleesklier met malabsorptie en diarree. De zweetklieren produceren zweet 
met een hoog chloride en natrium (Na+) gehalte. 
Het (abnormale) chloride en natrium transport kan in de zweetklier, het 
luchtwegepitheel en in de darmen gemeten worden door respectievelijk de zweettest, 
de nasaal potentiaal meting (NPD, nasal potential difference), en de intestinal 
CUlTent measurement (lCM), met behulp van het toedienen van bepaalde stoffen die 
het iontransport stimuleren of juist remmen. Hoofdstuk 2 beschrijft de NPD en 
lCM en vergelijkt resultaten van een groep CF patiënten met een controle groep. Bij 
de NPD meting worden de volgende waarden bepaald: de basale PD, Na+ transport, 
basale CI- secretie, cAMP-gemedieerde CI- secretie, en ATP-gestimuleerde CI-
secretie. Bij de lCM methode worden gemeten: Na+ transport, de Ca2+ /PKC-
afhankelijke CI- secretie, cAMP-gestimuleerde CI- secretion, waarna het weefsel 
wordt geïncubeerd met 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) om de 
alternatieve Ca2+ -afhankelijke CI- conductances te remmen, waarna nogmaals de 
Ca2 + /PKC pathway wordt gestimuleerd. Een chloride secretie respons op cAMP 
duidt op de aanwezigheid van CFTR, tenvijl de Ca2 + /PKC pathway CFTR maar ook 
alternatieve CI- kanalen stimuleert. Door deze pathway voor en na de incubatie met 
DIDS te meten, kan aan de hand van de DIDS-gevoeligheid, het type van de CI-
kanalen bepaald worden. DIDS-ongevoelige chloride transport wijst, net als de 
cAMP respons, op de aanwezigheid van CFTR. DIDS-gevoelige CI- secretie wordt 
veroorzaakt door alternatieve Ca2 +-afhankelijke kanalen. 
Bij vergelijking van de NPD resultaten in de CF groep met die in controles, zien we 
dat het Na+ transport verhoogd is in CF. Bij het typische CF beeld zijn geen basaal 
CI- transport of een respons op cAMP aanwezig, in tegenstelling tot in controle 
personen. De ATP respons varieert aannemelijk binnen de CF groep, maar is 
meestal groter dan in controle personen. De gemiddelden voor de CI- secretie 
responsen die gemeten zijn met de lCM, zijn voor de CF groep allemaal afwijkend en 
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vertonen geen overlap met de waarden die gevonden zijn in de controle groep. 
Concluderend kunnen we zeggen dat de NPD en lCM significant onderscheid 
kunnen maken tussen de electrophysiologische kenmerken van het 
luchtwegepitheel en het darmweefse1 van CF en niet~CF personen. Daarbij kan met 
deze methoden de aanwezigheid van verschillende CI- conductanties worden 
aangetoond. 
De European CF twin and sibling study is opgezet om te onderzoeken welke 
genetische en/of omgevingsfactoren de manifestatie en het beloop van CF kunnen 
beïnvloeden. In Hoofdstuk 3 wordt het cohort van de CF paren beschreven: 277 
sibling paren (broer~broer, zus~zus, ofbroer~zus), 12 twee~eiige tweelingen, en 29 
eeneiige tweelingen. Van deze 318 paren zijn 114 paren homozygoot voor de ilFS08 
mutatie. Van deze 114 paren zijn de parameters voor de voedingstoestand (weight 
for height %predicted = wfh%) en voor de longfunctie (FEVPerc = age corrected 
centiles for FEV I %predicted) verzameld. Het verschil in ziektemanifestatie in een 
paar is bepaald door de verschillen tussen de wfh% en FEVPerc waarden binnen 
een paar te berekenen. Daarnaast is ook het vershil in DELTA binnen een paar 
gemeten. DELTA is een berekende waarde uit wfh% en FEVPerc, waardoor met één 
waarde (DELTA) het verschil in ziektemanifestatie in de longen en darmen binnen 
een paar kan worden aangegeven. Eeneiige tweelingen toonden een significant 
lagere DELTA dan twee-eiige tweelingen (P = O.05).Omdat alle onderzochte paren 
ilFS08 homozygoot zijn, geeft dit aan dat de ernst van de ziekte niet alleen door het 
CFTR gen zelf bepaald wordt, maar ook nog door een andere genetische factor. 
Wanneer men zoekt naar zulke beïnvloedende factoren, blijken paren die het meest 
verschillen in ziektemanifestatie, het meest informatief te zijn. Met een in dit 
hoofdstuk beschreven algoritme zijn de volgende paren geselecteerd om verder 
onderzoek naar modifying factors te verrichten: discordante paren (DIS), 
concordante paren die mild aangedaan zijn (CON+), en concordante paren die 
ernstig ziek zijn (CON~). Deze geselecteerde paren hebben waarden voor wfh% en 
FEVPerc die niet overlappen. Ook de intrapaar verschillen voor wfh% en FEVPerc 
van deze groepen overlappen niet. 
Hoofdstuk 4 onderzoekt met behulp van de lCM, de CI- secretie in het darmweefsel 
van ilFS08 homozygote sibling en tweeling paren. De expressie van residuele CFTR 
activiteit of de aanwezigheid van alternatieve chloride kanalen in CF patiënten zou 
mogelijk kunnen zorgen voor een minder ernstig ziektebeeld. 
Door ö.F508 homozygote paren te onderzoeken, kan onderzocht worden of andere 
factoren dan de CFTR mutatie, de aanwezigheid van chloride secretie in CF bepalen. 
Het grootste deel van de ilF508 homozygoten (73%) presenteert zich met cAMP-
gestimuleerde CI- secretie, wat suggereert dat het gemuteerde eiwit ö.F508 CFTR in 
vivo in het apicale membraan terecht komt en daar CI- kan transporteren onder 
stimulatie van cAMP. Twintig procent van de ilFS08 homozygoten vertoont DIDS~ 
gevoelige CI- secretie, wijzend op alternatieve Ca2+~atbankelijke CI- kanalen. 
In Hoofdstuk 5 wordt de groep ilFS08 homozygote sibling paren onderzocht met de 
meest verschillende ziektemallifestaties zoals geselecteerd in Hoofdstuk 3: DIS, 
CON+ en CON- paren. Gekeken wordt of de expressie van CFTR CI- kanalen of 
alternatieve Cl- kanalen in het luchtwegepitheel of het darmweefsel van deze 
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patiënten, gecorreleerd is aan de ernst van hun ziekteverschijnselen. In de 
luchtwegen van 84% en in het darmweefsel van 73% van de fiFS08 homozygoten 
werd cAMP- en/ofCa2 +-gestimuleerde CI- secretie gevonden. Bij de NPD metingen 
van de L\FS08 homozygoten toonden 30% basale CFTR-gemedieerde CI- secretie en 
9% reageerde op cAMP. Beide deze responsen zijn geassocieerd met een mildere 
manifestatie van CF. Van de responsen in het darmweefsel is het hebben van DIDS-
ongevoelige CI- secretie, i.e. CFTR, geassocieerd met een betere klinische conditie, 
tenvijl de DIDS-gevoelige Cl- secretie voornamelijk voorkomt in patiënten die 
ernstiger ziek zijn. De chloride secretie patronen, voornamelijk die van de lCM 
metingen, zijn concordanter in eeneiige tweelingen dan twee-eiige paren. Dit 
betekent dat andere genen buiten het CFTR gen een belangrijke rol spelen in de 
uiting van de ziekte. 
In Hoofdstuk 6 wordt de expressie van Cl· secretie in zweetklier, luchtwegen en 
darmweefsel van zeldzame genotypes geanalyseerd. De patiënten hadden de 
volgende genotypes: homozygoten voor de missense mutatie E92K, de stop mutatie 
R553X, de stop mutatie R1162X, de splice mutatie 1898+3 A-G, de splice mutatie 
3849+10kb C-T, de deletie CFTRdele2, de deletie CFTRdele2,3(21kb), en in carriers 
van fiFS08-R553Q of t\F508-V12121. Een minder afwijkende zweettest of een normal 
functionerende alvleesklier komt alleen voor in patiënten met residuele CFTR 
activiteit. Al de onderzochte patiënten presenteerden zich met cAMP- en/ofCa2+-
gemedieerde Cl· secretie in de luchtwegen en/ of het maagdarmkanaal. Mogelijk 
spelen deze chloride conductanties een rol in het ziekteproces van CF. Echter, om 
dat bij patiënten met deze genotypes uit te verifiëren, zullen in de toekomst grotere 
groepen onderzocht moeten worden. 
In Hoofdstuk 7 komen de diagnostische problemen aan de orde die optreden bij 
patiënten die zich met atypische symptomen presenteren. De patiënt uit de eerste 
casus heeft een pathologische zweettest en CF -achtige longklachten. Echter, de 
diagnose CF is uitgesloten op basis van normale NPD en lCM resultaten, en het feit 
dat hij dezelfde CFTR allelen draagt als zijn asymptomatische zus. 
De tweede atypische patiënt, is de dochter van een eerste graads neef en nicht. Zij 
vertoont normaal CI- transport in haar darmweefsel, en heeft een normale zweettest. 
Daarentegen presenteert zij zich met ernstige CF -gelijkende longaandoeningen: 
nasaal poliepen, bronchitis, bronchiectasis, hoesten, sputum productie, 
luchtweginfecties, hypoxemie en cachexie. Daarbij vallen haar NPD waarden in het 
CF-gebied. Genetische analyse toonde één mutatie, 1898+3 A->G, maar ook 
homozygotie voor CFTR polymorfismen die de expressie van wild-type CFTR kunnen 
verminderen. Bovendien heeft zij door haar consanguine ouders een 
overrepresentatie van homozygote genotypes. De presentatie van deze patiënt 
impliceert dat het hebben van één CFTR mutatie samen met een zwakke genetische 
achtergrond, voldoende zijn om de expressie van CFTR nadelig te beïnvloeden, 
waardoor CF zich kan manifesteren. 
Hoofdstuk 8 bespreekt de bevindingen die in deze dissertatie worden beschreven 
met de mogelijke ven'olgonderzoeken. In het kort: bij de NPD en lCM metingen van 
het cohort fiF508 homozygoten worden specifieke protocollen gebruikt voor de 
toediening van de pharmaca, zodat onderscheid gemaakt kan worden tussen 
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residuele CFTR secretie, of de aanwezigheid van alternatieve Ca2 +-gestimuleerde Cl~ 
kanalen. 
In het diagnostische process van CF moeten de NPD en lCM metingen naast de 
zweettest en de genetische mutatie analyse worden uitgevoerd, om de aanwezigheid 
van CI- conductanties in het luchtwegepitheel en het darmweefsel te bepalen. In 
tegenstelling tot de zweettest, die in wam-de niet veel verschilt binnen een groep 
ilFS08 homozygoten, zijn specifieke uitkomsten van de NPD and lCM metingen 
gerelateerd aan betere klinische parameters en een mildere manifestatie van CF. 
De resultaten in deze dissertatie over de European CF twin and sibling study tonen 
aan dat het onderzoeken van CF sibling paren en tweelingen, homozygoot voor 
hetzelfde CFTR genotype, de mogelijkheid biedt om de invloed van genetische en 
omgevingsfactoren op het ziekte beloop te bepalen. Voor een betel' begrip van de 
pathogenese van CF, is het belangrijk verder onderzoek te verrichten naar de 
potentiële modifiers van de manifestatie van CF. 
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